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2 Abbreviations 
ADC antibody-drug-conjugates 
AU absorbance unit 
CD circular dichroism 
cDNA complementary deoxyribonucleic acid 
CDR complementary determining region 
CPP cell penetrating peptide 
cCPP cyclic cell penetrating peptides 
CuAAC cupper catalyzed alkyne azide cycloaddition 
Cy3 cyanine 3 
DCM dichloromethane 
DIPEA N,N-diisopropylethylamine 
DMEM Dulbecco modified eagle medium 
DMF dimethylforamide 
DMSO dimethylsulfoxide 
dNTP deoxynucleoside triphosphate 
DTT dithiotreitol 
eGFP enhanced green fluorescent protein 
FACS fluorescence activated cell sorting 
Fmoc- fluorenylmethyloxycarbonyl 
FRET Förster resonance energy transfer 
GST glutathione-S-transferase 
HA hemagglutinin 
HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV human immunodeficiency virus 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrometry 
HTRF homogeneous time resolved fluorescence 
IC50 inhibitory concentration  
IEDDA inverse electron demand diels-alder  
kDa kilodalton 
LRMS low resolution mass spectrometry 
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m/z mass over charge 
MALDI-TOF matrix assisted laser 
MeCN acetonitrile 
MesNa methanethiolate 
mRNA messenger ribonucleic acid 
MWCO mass weight cut off 
NHS N-hydroxysuccinimide  
Ni-NTA nickel – nitrilotriacetic acid 
NMM N-methylmorpholine 
OD600 optical density at 600 nm 
PBS phosphate bufferes saline 
PCR polymerase chain reaction 
PEG polyethylene glycol 
PG protecting group 
PLI protein – ligand interaction 
PPI protein – protein interaction 
PTM posttranslational modification 
quant.  quantitative 
RCM ring closing metathesis 
RP reverse phase 
SA sialic acid 
SDS sodium dodecyl sulfate 
SEC size exclusion chromatography  
shRNA short hairpin ribonucleic acid 
SPAAC strain – promoted alkyne azide cycloaddition 
SPANC strain – promoted azide nitrone cycloaddition 
SPPS solid phase peptide synthesis 
TAMRA Carboxytetramethylrhodamine 
TFA trifluoroacetic acid 
THF tetrahydrofurane 
TIS triisopropylsilane 
UPLC ultra performance liquid chromatography  
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3 Abstract  
3.1 English  
 
Synthetic peptides are a unique and versatile class of biomolecules. Due to their complex 
structure they can bind targets in a highly specific manner and furthermore exhibit unique 
biological active properties. Even though they are complex in structure, they are 
straightforward synthetically accessible, due to many advances made in the field of peptide 
synthesis throughout the last decades. Concerning functional peptides the discovery of cell 
penetrating peptide (CPP) sequences derived from full-length proteins highlighted the great 
potential to transfer peptidic properties to any cargo by using bioconjugation methods that 
can link both entities. This thesis evolves around the many different aspects, in which 
biological active peptides can be used, from specific binders to cell penetration tags. 
Furthermore, the site specific and chemoselective conjugation of an unprotected peptide to 
a functional scaffold has been addressed throughout this thesis.  
In the first project the synthesis of a peptide – polymer – nanoparticle was shown to yield a 
highly potent virus entry blocker. Here, a viral-membrane-protein binding peptide was 
displayed multiply on a polymeric nanoparticle via a chemoselective reaction, upon which 
its binding affinity and therefore antiviral activity could be enhanced drastically throughout 
the multivalent effect. This project highlighted the synthesis of a highly potent and target-
specific inhibitor by the use of bioactive peptides and their convenient synthesis.  
In the second project the conjugation of unprotected peptides to a functional scaffold was 
addressed. Here a novel bioconjugation technique was developed for the covalent linkage 
between an unprotected azido-containing peptide and a thiol-bearing biomolecule. The 
connecting linker herein used, was an alkyne-phosphonite, which proofed to be highly 
versatile. The electron rich alkyne-phosphonite was first reacted in a Staudinger 
phosphonite reaction with the unprotected azido-peptide yielding an alkyne-
phosphonamidate-peptide. In this phosphonamidate the alkyne is turned to be electron 
poor, making a selective thiol addition to the alkyne possible. This reaction cascade was 
probed for tagging eGFP with cyclic cell penetrating peptides (cCPP) and their in vitro 
application in HeLa cells was assessed. Here, we could verify that upon covalent 
conjugation of eGFP with the peptidic tag via this new bioconjugation technique, the full-
length eGFP protein was rapidly transduced into the cytosol of cells. 
This novel Staudinger induced thiol addition reaction was further used in a third project, in 
which a certain biologic function was induced by macrocyclizing synthetic peptides 
intramolecularly. Here CPPs were macrocyclized by conjugating azido and sulfhydryl 
functionality in the peptide structure throughout an alkene-phosphonite. Thereby, the 
Abstract 
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remarkable transduction properties of cCPPs were induced and could be verified by in vitro 
studies. In the same fashion a peptide taken out of a protein structure was stabilized in its 
native α-helix, upon which the peptide is able to pose as remarkable protein-protein-
interaction (PPI) inhibitor.  
In the fourth project a different chemoselective reaction was explored to conjugate cCPPs 
to eGFP. Here carboxylic acids in the protein structure were esterified successfully utilizing 
a diazo moiety, which was either directly incorporated into the cCPP or the cCPP was 
conjugated to an alkyne-diazo tag, post-esterification on protein level. The ester linkage was 
hypothesized to be cleaved inside cells upon cellular transduction to give the native protein, 
but unfortunately this could not be quantified or verified, due to an inherent toxicity 
observed for the conjugation product when applied on HeLa cells.  
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3.2 Deutsch 
 
Synthetische Peptide bilden eine einzigartige und vielseitige Klasse von Biomolekülen. 
Aufgrund ihrer komplexen Struktur sind sie in der Lage hochspezifisch an Zielmoleküle zu 
binden und können darüber hinaus biologisch aktive Eigenschaften aufweisen. Obwohl sie 
in ihrer Struktur komplex sind, können sie durch die Fortschritte, die auf dem Gebiet der 
Peptidsynthese in den letzten Jahrzehnten erzielt wurden einfach synthetisiert werden. Im 
Bezug auf biologisch aktive Peptide zeigte zum Beispiel die Entdeckung von 
zellpenetrierenden Peptidsequenzen, die aus nativen Proteinen abgeleitet wurden, dass 
bestimmte Proteineigenschaften in ihrer reduzierten peptidischen Struktur, durch die 
Verwendung von Biokonjugationsverfahren auf Cargos übertragen werden können. In dieser 
Dissertation wurden verschiedenen Anwendungen, für die biologisch aktive Peptide 
verwendet werden können, zum Beispiel in Form spezifischer Binder bis hin zu zellulären 
Aufnahme-Markern untersucht. In Zuge dessen wurde in dieser Arbeit die ortsspezifische 
und chemoselektive Konjugation ungeschützter Peptide an funktionelle Gerüstmoleküle 
betrachtet. 
Im ersten Projekt wurde gezeigt, dass multivalente Peptid – Polymer – Nanopartikel 
synthetisiert und als hochpotente Viruseintrittsblocker eingesetzt werden können. Ein Virus-
Membranprotein bindendes Peptid wurde durch eine chemoselektive Reaktion multivalent 
an einen polymeren Nanopartikel konjugiert. Dadurch konnten dessen Bindungsaffinität und 
damit auch das antivirale Potential über einen multivalenten Effekt drastisch gesteigert 
werden. Dieses Projekt zeigt die erfolgreiche Synthese eines hochpotenten Virus-Inhibitors 
auf Grundlage eines spezifisch bindenden Peptids welches einfach und schnell synthetisiert 
werden kann. 
Im zweiten Projekt wurde eine Methode zur Konjugation eines ungeschützten Peptids an ein 
funktionelles Protein untersucht. Konkret wurde eine neuartige Biokonjugationstechnik für 
die Konjugation zwischen einem ungeschützten Azido-Peptid und einem Thiol-tragenden 
Biomolekül entwickelt. Der hier verwendete Linker ist ein Alkinphosphonit, welches sich als 
vielseitiges Molekül erwiesen hat. Das elektronenreiche Alkinphosphonit wurde zunächst in 
einer Staudinger-Phosphonit-Reaktion mit einem ungeschützten Azido-Peptid zu einem 
Alkin-Phosphonamidat-Peptid umgesetzt. Im entstandenen Phosphonamidat ist das Alkin 
elektronenarm und lässt so eine selektive Thioladdition zu. Diese Reaktionskaskade wurde 
zur Markierung von eGFP mit zyklischen zellpenetrierenden Peptiden (cCPP) verwendet. Die 
cCPP vermittelte Transduktion des markierten eGFP konnte anschließend in HeLa-Zellen 
beobachtet werden. 
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Die Staudinger-induzierte Thiol Additionsreaktion wurde in einem dritten Projekt als 
intramolekulare Makrozyklisierungsstrategie angewendet. Durch die intramolekulare 
Verbrückung einer Peptidstruktur, sollte eine biologische Funktion im Peptid erzeugt 
werden. Konkret wurde ein CPP durch Konjugation von Azido- und Sulfhydrylfunktionen in 
der Peptid Struktur makrozyklisiert, wodurch die Transduktionseigenschaften des CPP 
verstärkt und auch in in-vitro Studien verifiziert werden konnten. Auf die gleiche Weise 
konnte ein kurzes Peptid, das aus einer Proteinstruktur abgeleitet wurde in seiner nativen α-
Helix, stabilisiert werden und somit als Protein-Protein-Interaktion (PPI) Inhibitor fungieren. 
Im vierten Projekt wurde eine weitere chemoselektive Reaktion angewendet, um cCPPs an 
eGFP zu konjugieren. Hierbei konnten Carbonsäuren in der Proteinstruktur erfolgreich mit 
einer Diazoeinheit verestert werden. Die Diazogruppe wurde entweder direkt in die cCPP 
Struktur integriert oder als Alkin-Diazo-Linker mit dem eGFP verestert, sodass anschließend 
ein Azido-cCPP über CuAAC an diesen Alkinlinker im Protein konjugiert werden konnte.  
Die Grundidee war, dass die Esterbindung nach der Transduktion im Cytosol durch 
Esterasen gespalten und so das native Protein nach der Aufnahme in der Zelle vorliegt. Auf 
Grund der inhärenten Toxizität gegenüber HeLa Zellen, die für diese Konjugationsprodukte 
beobachtet wurden, konnte dies jedoch weder verifiziert noch quantifiziert werden. 
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4 Introduction 
4.1 Motivation 
 
Proteins are the main players in biological processes and are covering a huge number of 
different functions inside and outside cells.1 There are structural proteins, maintaining cell 
shape and composing structural elements in connecting tissues. Enzymes catalyze 
chemical reactions and further play an essential role in signal transduction and cell 
regulation.2 Proteins are also involved in metabolic pathways and the regulation of disease 
processes. Furthermore cell signaling is controlled e.g. by proteins in form of receptors, ion 
channels or anchoring structures on cellular membranes. Proteins can also accomplish 
transportation of certain molecules and are even moving along surfaces.  
The underlying main characteristic of their numerous functions is their ability to bind in a 
specific and highly affine manner to other proteins, biomolecules or even small molecules.3 
The recognition of its binding partner is a result of the protein structure itself. The diversity 
of the different amino acid side chain functionalities are resulting in hydrogen binding, 
electrostatic and hydrophobic interaction, which form the protein’s 3D structural features 
that allow for a precise recognition of two binding partners like lock and key. Because they 
are involved in these many regulatory processes, the structural features of protein-protein 
interaction (PPI) and protein-ligand interaction (PLI) sites are highly interesting to 
researchers. Understanding the binding or function in structural detail allows the remodeling 
and usage of those core motifs as diagnostic and therapeutic tools. The reduction of a 
protein to its short bioactive peptide motif is furthermore the underlying rational of many 
peptide therapeutics that are chemically complex but still synthetic well reachable active 
compounds.4,5  
The chemical complexity of peptide therapeutics has the advantage of preserving the 
specific recognition and its synthesis works via well-established protocols.6 Further 
modification though comes with challenges. To label or modulate proteins and bioactive 
peptides in order to use them as tools in research, diagnostic settings or therapies, one 
encounters challenging chemical endeavors that formed the field of chemical biology. Here, 
chemoselective reactions have been developed that are fast and can be carried out in 
presence of all other naturally occurring functionalities in an aqueous environment at 
ambient temperatures.7  
This thesis evolves around the development of a chemoselective reaction that allows the 
connection of a bioactive peptide to a protein as well as the modulation of a bioactive 
peptide structure derived from a proteins core binding motif. Further it is shown how the 
specificity of a bioactive peptide can be used for the inhibition of viral infections.  
Introduction 
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4.2 Bioactive peptides  
 
Cellular processes are orchestrated through a dense network of proteins. They interact with 
ligands or other proteins and thereby regulate cellular function. This molecular machinery is 
build upon the specific recognition of a protein by its binding partner and the ability of them 
to discriminate between those. Interactions can either be transient or stable, but are usually 
highly specific and noncovalent. These binding characteristics can be recreated in short 
synthetic peptides. Once exhibiting distinct functions in a biological setting, inspired from 
their protein lead structure they are termed “bioactive peptides”. 
 
4.2.1 Protein binding site mimicking peptides 
 
Peptides are a special class of bioactive molecules, because they are neither small 
molecules nor big proteins but combine many advantageous characteristics of these two 
groups. They offer a high selectivity and potency for their destined target, similar to 
proteins, but their synthesis is more feasible, controllable and can be scaled up. In contrast 
to small molecules they have a predictable and natural metabolism, which makes them 
mostly well-tolerated in vivo.4,5 The easy synthesis of peptides by solid phase supported 
standard protocols, allow introduction of unnatural amino acids, which can be used to 
incorporate a number of complex modifications by chemoselective reactions. Those 
reactions have been under intense investigation in recent years (see chapter 4.3).7 They 
make it easy to mimic a structural element found in nature8, modify the biomolecule of 
interest to the researchers need or apply it in a diagnostic or therapeutic set up in a variable 
manner. Still some drawbacks of bioactive peptides can be their rapid digestion by 
proteases and their fast elimination. Also the threat of an inherent immunogenicity is 
concerning when thinking of a therapeutic application. Still there are over 60 peptide drugs 
approved in the US and other major markets around the world with numerous being 
evaluated in clinical trials, because their advantages can often outweigh their drawbacks. 
Improvements on stability and half-life’s has been made over the years.9 Peptide drugs are 
targeting receptors, enzymes and are also used to disrupt Protein-Protein-Interactions. 
Currently some of the most relevant peptidic drugs are used for treatment of osteoporosis 
(Teriparatide)10, diabetes (Exenatide, Liraglutide)11, growth disorder (Lanreotide), HIV 
(Enfuvirtid) and pain (Ziconotide)12 with structures derived from native proteins.  
Recent developments in the peptide therapeutic field are results of improved ways of target 
identification. For one, structural biology methods have rapidly improved over the last years 
giving rise to more structural insides into binding events of proteins and hence allow better 
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rational lead development.13 Further improvement was also made in the library based 
screening technologies, allowing the systematic de novo target-directed lead creation.  
For the later especially the emergence and evolution of focused library screening 
approaches makes it easy nowadays to generate highly affine peptidic binders. The big 
advantage of library-based screening technologies is its big variance of binders tested. 
Essential for the process that usually consists of library construction, selection of this library 
for a specific target in several rounds and a final analysis step is the compartmentalization 
and/or covalent linkage between pheno- and genotype of the binder. Phage display is most 
commonly used to achieve this linkage.14 Here filamentous phages are expressing multiple 
copies of a peptide or protein on their coat protein, with the cDNA encoding these 
peptides/proteins compartmentalized inside the phage itself (Figure 1A).15 After phage 
expression and affinity panning the library of binders against an immobilized target, the 
unbound phages are washed off and another round of selection is started. After several 
rounds only highly affine binders are left and their amino acid sequence can be conveniently 
analyzed throughout their compartmentalized cDNA. This process is limited by the usage of 
in vivo and in vitro steps to a library size in the order of 109 consisting mainly of peptides 
composed of native amino acids. The phage display system gives the opportunity to 
incorporate a chemically or enzymatic post-translational modification step to the selection, 
which hence widens its structural variety to some extend.16,17 The Heinis group also reported 
on the post-translational intramolecular alkylation of cysteines in the peptide structure, to 
generate constraint bicyclic peptides for even higher affinity and selectivity.18–20  
To significantly maximizing the used focused libraries, new pure in vitro technologies have 
been developed recently and give access to rare sequences. Especially mRNA display 
techniques combined with next generation sequencing gave rise to a huge number of new 
peptidic binders.21–25 In mRNA-display the covalent linkage between the encoding mRNA 
and the to be screened peptide binder is enabled by puromycin (Figure 1B).26 Puromycin 
resembles the structure of a tyrosine covalently linked to the 3’carbon of an adenine 
nucleoside via an amide linkage. When puromycin modified mRNA-strands are translated, 
the translation is finished at the 3’ end with the transfer of the nascent peptide to the free 
amine of puromycin. This is only possible due to the inherent similarity of puromycine to 
tyrosine, which cannot be distinguished by the peptidyl transfer center of the ribosome, 
resulting in a covalent mRNA-peptide fusion library. After reverse transcription of the mRNA 
to a RNA/DNA hybrid, the peptidic library is screened for its affinity towards an immobilized 
target. The immobilization makes it easy to wash of all non-binding biomolecules. The 
RNA/DNA hybrid of the first round selection binders can then be amplified by PCR and 
conveniently analyzed by DNA sequencing. Binders of the first round can then again be 
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transcribed and affinity panned in another selection round. The realization of this process to 
be fully in vitro, also posed the opportunity to explore the usage of non-native amino acids. 
In an in vitro system one can simply add tRNAs loaded with unnatural amino acids by 
natural or modified aminoacyl tRNA synthetases (ARS) in the translation process.27 
 
Figure 1: Overview of library screening technologies A) Phage display and B) mRNA display. 
 
For this purpose the Suga lab developed promiscuous aminoacylating ribozymes, so called 
flexizymes, which can load a wide variety of unnatural amino acids onto tRNA and hence 
give rise to an extensive gene code reprogramming for the expression of complex non 
native peptides.28 The combination of the flexible in vitro translation (FIT) method with 
mRNA display, first demonstrated also by the Suga lab29, witnessed the breakthrough of 
library-based screening methods to the pharmaceutical industry. 
A less systematic approach towards finding highly specific peptidic binders is the 
inspiration from nature itself. With the emergence of improved and highly precise protein 
structure analysis methods, shown with the advances in electron microscopy lately, this 
rational approach might even gain more attention in the future. The idea of taking e.g. 
complementarity determining regions (CDR) of antibodies and use their structural 
information for the development of peptide binders was first reported on in the early 90s.30–32 
Either linear peptide sequences or important structural features, which were fused 
covalently into a peptidic structure were shown to create potent peptidic inhibitors.31,33–35 An 
example of simply using a linear peptidic sequence from a CDR domain for the creation of a 
peptidic hemagglutinin binding ligand, was reported by Memczak et al.. Here they reported 
the finding of a peptidic binder with micromolar affinity directly from the native CDR-
structure, which could even be improved by peptide microarray.33 Just recently a paper 
gained much attention in which the structural knowledge of the binding between 
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hemagglutinin (HA) and its complementary antibody was used to generate a peptidic 
infection inhibitor, that can bind HA with nanomolar affinity at the highly conserved stem 
region of the membrane protein and block the low pH conformational change that is 
associated with cellular membrane fusion.36 These examples are highlighting impressively 
the possibilities when combining structural information and peptide based inhibitor 
development.
 
4.2.2 Solid-Phase peptide synthesis 
 
The groundwork for the easy synthesis of bioactive peptides was laid in the 20th century. 
Emil Fischer could accomplish the first dipeptide synthesis over 100 years ago.37 Max 
Bergmann showed the effective amine protection of an amino acid with a carbobenzoxy 
group38 and finally Bruce Merrifield revolutionized the synthesis of peptides with inventing 
the solid-phase peptide synthesis (SPPS).39,40 Merrifield reported the synthesis of longer 
peptide fragments by attaching the amino acid’s C-terminus covalently to an insoluble resin. 
This approach gave the advantages of carrying out all reactions in one flask and without the 
purification of each coupling product, because one can easily filter off any excess reagent. 
From this report onwards researchers devoted a lot of time to developing better resins, 
linkers, protecting group strategies and monitoring of the individual steps.41,42 The general 
synthesis route is started by attaching the C-terminal residue to the solid support via its 
carboxyl group. In all resin bound synthesis steps the amino acids are protected with a 
temporary amine protecting group and a permanent side chain protecting group if needed. 
The key feature here is that the two different protecting groups have to be orthogonally 
cleavable. After immobilization of the first amino acid building block leftover reagents are 
washed off by simple filtration. After deprotection of the terminal amine the following 
activated fully protected amino acid can be coupled to the free amine. 
 
 
Figure 2: Principle of solid-phase peptide synthesis using the Fmoc-strategy.
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After another washing step the protected amine is deprotected and another amino acid can 
be added. This reaction scheme results in a C to N-term synthesis direction of the peptide. 
After the full stepwise addition of all amino acids, the protected peptide can be cleaved off 
from the resin with the same conditions the permanent side chain protecting groups are 
cleaved off to yield the unprotected peptide in solution (Figure 2). Nowadays, the most 
commonly used protecting group strategy is Fmoc-chemistry. Here the permanent side 
chain protecting groups are acid labile and the N-terminal temporary protecting group 
(Fmoc) is cleaved under basic conditions. For this strategy all natural amino acids are 
commercially available with appropriate protection. Furthermore there are many unnatural 
amino acids or ones that bear a post translational modification as well as non-peptidic 
building blocks available for the generation of a wide variety of peptides and 
peptidomimetics, which makes peptides very attractive from a pharmaceutical and an 
academic point of view.  
 
4.2.3 Stabilizing peptides in structure and function 
 
Because protein-protein interactions (PPI)s are regulating the vast majority of cellular 
processes their inhibition represents a major therapeutic goal. However, as PPIs have planar 
and large surface areas this goal is difficult to span with small molecule inhibitors. In 
addition does the development of small molecule inhibitors lack a rational starting point due 
to the absence of ligands in PPIs. Mostly one can only lean on the identification of “hot 
spots” involved in the interaction for the rational design of an inhibitor. These are amino 
acids that are contributing most to the interaction and are found in the structurally 
conserved region of the protein-protein interface.  
In the last years the possibility of using protein inspired inhibitors became more popular.43 
Here one of the interacting proteins is reduced to the size of its binding epitope, which is the 
starting point for the design of the inhibitor. It must be noted that the structural integrity of 
the binding epitopes is highly connected to the surrounding protein structure and most 
short peptidic sequences loose this structure when excised from the full-length protein. In 
addition to that, they also become more prone to degradation by proteases. Therefore, the 
demand for tools to mimic or stabilize these secondary structures, which not only provide 
the function embedded into the proteins structures, but also shield the peptide to a certain 
extend towards proteases is high. As α-helices are found to be contributing to 62% of all 
PPI interfaces44 and make up 40% of secondary structural motifs in proteins, it is of special 
interest to stabilize or induce this specific structural motif.  
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An α-helix is characterized by intramolecular hydrogen bonds between the amide proton of 
an amino acid with the carbonyl group of the amino acid four residues earlier (i, i + 4) (see 
Figure 3A). Salt bridges between side chain residues can achieve further stabilization. Since 
the 1980s researchers tried to stabilize or induce α-helicity by organic synthesis tools. The 
method of choice was to covalently link amino acid side chains in specific positions in the 
peptide structure. If length and position of this macrocyclization linkage was positioned 
right, helicity could be restored or induced, often rendering the peptide more stable towards 
proteases and in some cases also improving cell penetration properties.45 
One of the first side chain macrocyclization techniques was the covalent formation of a 
lactam between lysine and glutamic/aspartic acid residues (Figure 4a) and revealed 
preservation of helicity and activity of a cyclized growth hormone.46 From there onwards 
different length of side chains and position were investigated for the helical stabilization with 
lactam linkages and were successfully applied in stabilizing peptidic hormones, viral fusion 
inhibitors47,48, anti bacterials49, receptor agonists and antagonist50 and many more.51–57 Also 
early on, thiol-based cross-linking strategies have been employed for inducing helicity. 
Disulfide formation between a 2-amino-6-mercaptohexanoic acid and D-Cys at i, i+7 
position (Figure 3C and Figure 4b) yielded one of the first artificially constrained helical 
peptides.58 
 
Figure 3: Schematic structure of a α-helix A) hydrogen bonding in an α-helix B) stabilization of one turn by i, i+3 
or i, i+4 side chain linkage C) stabilization of two turns by i, i+7 side chain linkage. 
 
There were further reports on crosslinking L- and D-cysteine in i,i+3 position (Figure 3B and 
4c) and also on varying the linker length by employment of homocysteine.55,59 In order to 
gain more durable cross-linkers that withstands reductive conditions, thioether bonds were 
introduced for crosslinking (Figure 4d) and even developed for macrocyclization on protein 
level via genetic encoding.60,61 The lactamisation and the disulfide side chain linkage 
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strategies were so vastly used because the linkage could consists of proteogenic amino 
acids, which are cheap and easy to incorporate. Nevertheless one of the major drawbacks 
is an additional orthogonal protecting group strategy that is needed during the solid phase 
peptide synthesis and the inherent lability towards proteases or reductive conditions. A 
huge impact on the helical peptide cyclization field had the development of the 
“hydrocarbon peptide stapling technique” in 2000 by the Verdine lab.62 They published a 
linker in which olefinic α,α,-di-substituted amino acids were cross linked by ring closing 
metathesis. Here they combined methylation of the α-carbon of the amino acid, which is 
known to increase the helical predisposition and the covalent cross link of two unnatural 
olefinic amino acids by ring closing metathesis. The metathesis between two olefinic amino 
acids in a peptide was published before by Blackwell and Grubbs, for the crosslinking of 
adjacent O-allyl serine residues (Figure 4e).63  
 
 
Figure 4: Overview of different macrocyclization techniques for one component staples. 
 
The olefinic α,α,-di-substituted amino acids were incorporated at i, i + 3; i, i + 4 and i, i + 7 
positions in a peptide (Figure 3 and 5). For each position the stereochemistry on the α,α,-
disubstituted olefinic amino acids needed to be adjusted to generate the desired staple of 
one turn for the incorporation in i,i+3 and i,i+4 (Figure 4f)  position and for two turns when 
the covalent linker was formed in i,i+7 position (Figure 4g and 5). 62,64,65 An even further 
enhancement of helicity and notably also cell permeability, was gained by combining two or 
more separate staples in one peptide45 or even using an amino acid, which enables a dual 
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hydrocarbon staple for the creation of a double staple, which was termed “stitched 
peptide”.66 The all-hydrocarbon staple has since been used in addressing many different 
targets, one of the most recognized study showed the activation of apoptosis in vivo by an 
all-hydrocarbon stapled BH3 peptide.67 Just recently, chemically orthogonal ring-closing 
reactions have been reported, which allow formation of a defined double stapling of 
peptides. It was shown that ring closing olefin (RCM) and alkyne metathesis (RCAM) can be 
carried out consecutively on peptide resin to yield a bicyclic peptide.68 
The big advantage of covalently linking two functional groups that are not found in natural 
amino acids in a chemoselective fashion, is that one does not need to strategize about 
orthogonal protecting groups throughout SPPS. Hence more chemoselective reactions were 
explored for the intramolecular macrocyclization of peptides (see also Chapter 4.3). It was 
shown that copper catalyzed alkyne azide cycloaddition (CuAAC) (Figure 4h) and also oxime 
formation (Figure 4i) could achieve the same structure stabilizing effect as the lactam or 
hydrogencarbon linker could.69–71  
 
 
Figure 5: The α,α,-disubstituted olefinic amino acids used for creation of staples. 
 
While more chemical reactions were being used for the intramolecular staple, also more 
complex staple strategies with even further functionalization opportunities were introduced 
in form of two component staples (Figure 6).  
A two component staple, is a linker formed between two amino acids, which are bridged by 
a bifunctional linker, that is not part of the peptide itself.72 Its major advantage lays in the 
fact, that there can be complex moieties introduced into the peptide without the need of 
lengthy non-native amino acid synthesis. One of the first two-component staples was a 
photo switchable linker based on azobenzene (Figure 6a).73,74 By using a photoisomerizable 
crosslinker the α-helical structure was inducible upon irradiation. Furthermore the group of 
David Spring used e.g. a clickable linker that can be first functionalized with any tag of 
interest and then conjugated to a synthetic peptide (Figure 6b). In their study they report on 
the improved cellular uptake and hence improved activity by incorporating solubilizing poly-
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Arginine tags into the linker or using this technique for functionalization of a peptide 
generated from the p53 protein with TAMRA.75 To understand the linker’s influence on a 
broader spectrum the easy handling and incorporation of two-component linkers was used 
for different screens. The Inouye lab wanted to find the optimal length and rigidity for 
maximal helicity and therefore screened disuccinimidyl-linkers with alkylamine side chains 
(Figure 6c).76 The Greenbaum lab did a similar study with bis-electrophilic systems, which 
they reacted with cysteines (Figure 6d;e)77. Bis-arylation of two cysteines was also probed in 
i,i+4 position with hexafluorobenzene (Figure 6f) and could stabilize the helical character of 
a HIV-1 capsid binder.78 
 
Figure 6: Overview of different macrocyclization techniques for two component staples. 
 
Throughout those studies it was shown that helicity could be stabilized and induced by a 
wide variety of linkers. Furthermore, upon covalent macrocyclization the binding affinity 
towards the target was improved, which is correlating to the secondary peptide structure 
stabilization. But when some of the peptidic binders were tested in vitro it could be 
observed that the inhibitory efficiency was highly context dependent and an overall 
underlying rule for the potency of a peptidic inhibitor could not be deduced. A reason for 
this is that helicity seems to not be the most important factor in the success of a peptidic 
inhibitor. In order to be able to interfere with the PPI one critical characteristic is also the cell 
penetrating properties of the helical peptides when working in vivo. In the beginning of 
peptide stapling it was believed that cellular uptake is solely facilitated by a perfect helix, 
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which is supposed to enhance uptake by burying the hydrophilic amide backbone inside the 
peptide conformation and therefore masks the hydrophilicity of the peptide and enhance the 
interaction with the hydrophobic interior of cellular membrane. But because the cellular 
uptake mechanism was not well understood and most studies relied on a trial and error 
basis, more systematic studies were just undertaken recently to determine what makes a 
stapled peptide cell permeable and what hinders it cellular entry. 
For all-hydrocarbon stapled peptides the Verdine lab did a broad screen of about 200 
peptides, which proofed that helicity is not the only important characteristic for cellular 
uptake. Another essential factor is the formal charge of the peptide. They found the best 
cellular uptake for peptides with a formal charge of +3 to +5 and also very good uptake for 
+1 to +3 and +5 to +7 charged peptides.79 Further studies on the criteria for cell penetration 
manifested the interplay between positive charge and hydrophobicity. The Walensky lab 
looked into the importance of staple position, pI of the peptide and hydrophobicity.80 They 
could show similarly, that the hydrophobicity plays a huge role in cellular uptake, and that if 
the staple is positioned at the hydrophobic-hydrophilic boundary in the peptide and thereby 
is extending the hydrophobic space, the penetration properties are improved. They also 
found that a helicity between 60 – 89% is most optimal for cellular uptake. Contrary to what 
is often reported they could show that a hydrophobic peptide with lower pI values (8.8 – 
9.34) gave as good cell penetration as peptides with higher pIs. Moreover, they found that 
hydrophobic peptides with higher pI (9.76 – 10.3) were more likely to enhance cell lysis, 
which renders them inappropriate for cellular assays.81,82 Recently, also a systematical 
cellular uptake study for a variety of different staple linkers concluded that cell permeability 
could be greatly correlated to the relative hydrophobicity of a macrocyclized peptide which 
is also determined by the nature of its linker.83  
These complex studies show that not only affinity towards a target is important for creating 
a promising functional binder, but also its behavior in biological processes is crucial and 
needs to be understood on a broader level in order to be able to interfere or analyze the 
highly complex interplay of biological mechanisms. 
 
4.2.4 Cell Penetrating Peptides 
 
Cell penetrating peptides (CPP) have the ability to cross cell membranes effectively without 
the involvement of receptors. It was shown that the cell penetrating property of peptides 
can even be transferred to an attached cargo, which gets dragged into cells by the CPP. 
This fact makes them one of the most promising strategies for cellular delivery of 
therapeutic moieties like nucleic acids, drugs, imaging agents and biomolecules not only in 
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a pharmaceutical setting but also for basic academic research.84 There are different classes 
of cell penetrating peptides ranging from protein-derived to chimeric or synthetic short 
peptides sequences, with either amphipathic or cationic characteristics.  Two of the most 
intensively studied cationic CPPs are discussed here, the TAT-peptide, which is derived 
from the RNA-binding domain of the HIV-1 protein and Oligoarginine peptides, which are 
synthetic derivations of TAT.  
In 1988 two groups reported that, the HIV TAT transactivation factor protein can cross 
cellular membranes efficiently and localizes to the nucleus.85,86 From there on different 
studies showed that only a short fraction of the protein is responsible for this behavior. 
When reduced to this short peptidic fraction, it is able to facilitate cellular uptake of 
biomolecules upon covalent conjugation.87–89 Lebleu and co-workers showed that the basic 
sequence within this fragment is the actual driving force of cellular internalization, contrary 
to initial hypothesis that the helical structure of the TAT-protein is responsible. Hence they 
could show that using solely this basic 9-mer sequence was enough to facilitate cellular 
uptake of a cargo.90 Dowdy et al. even reported that the tat-peptide can deliver β-
galactosidase across the blood brain barrier.89 
 
 
Figure 7: Overview of different cellular uptake mechanisms. Figure adapted from Zhu et al.91. 
 
In an undertaking to elucidate the driving force of this uptake behavior the 9-mer TAT-
sequence (RKKRRQRRR) itself was under investigation.92–94 The TAT - RNA binding domain 
of HIV underwent an alanine scan, which sowed that any substitution of a basic amino acid 
resulted in reduced cellular uptake. Synthesis of an all D-amino acids peptide or replacing 
all non-arginines by arginines, resulted in cellular uptake. This proofed the peptide 
Introduction 
 21 
sequence to be non-specific for any sort of receptor. Also it was observed that an all-
arginine peptide exhibits an even superior uptake behavior than TAT itself.92–94 Because 
simple passive diffusion does not seem to be possible for the highly polar CPPs unraveling 
the cellular uptake mechanism was pressing, in order to be able to translate this remarkable 
behavior to improve cellular uptake of drugs, dyes, proteins and peptides. Early on it was 
reported that cellular uptake of CPPs is an energy independent pathway that is not sensitive 
towards endocytosis inhibitors and delivers the peptide directly into the cytosol.90,94 
However these findings were retracted and found to be mainly artifacts resulting from 
cellular fixation.95 In following studies the involvement of almost all endocytotic pathways in 
the cellular uptake, including macropinocytosis (Figure 7C)96, clathrin-mediated endocytosis 
(Figure 7D)97 and caveolae/lipid-raft-mediated endocytosis (Figure 7E)96,98,99 was 
implemented.  
But also in total contrast, there were still observations of direct translocation (Figure 7A) of 
labeled Tat-peptides in live cells, which could not emerge from fixation artifacts.100,101 It was 
shown that these contradictive findings are actually all valid next to each other, because the 
cellular uptake mechanism for CPP-Cargo-conjugates is highly dependent on transporter 
type, cargo type and size, cell type, concentration and also the method of uptake analysis. 
Especially big cargos, like proteins, are mainly taken up throughout endocytosis when linear 
arginine-rich peptides are conjugated.101,102 It was difficult to determine the exact 
classification of uptake mechanism, as it was observed that most of the times there is a co-
occurrence of competing uptake pathways and hence no universal uptake mechanism 
could be deduced.103–106 When using CPPs for the delivery of biomolecules into cells, the 
preferred uptake mechanism would be the direct penetration (Figure 7A) into cytosol. This 
would ensure that biomolecules would be able to reach their intracellular targets without the 
possibility to be rendered ineffective by being trapped in endosomes (Figure 7B-F). 
Therefore understanding the factors favoring direct membrane penetration is crucial.  
For a predominately direct penetration it is important to achieve a high cell surface 
adsorption. The Wender and Futaki labs demonstrated that the guanidinium head groups 
are highly important for cellular uptake, as they are forming bidentate hydrogen bonds with 
negatively charged cellular surface groups (phosphates, carboxylates, sulfates) and uptake 
was increased by a high number of guanidinium head groups (6-12 arginines) 
(Figure 8A).84,94,107 The high attraction of arginines toward negatively charged cellular 
surfaces is hence the underlying rational of all proposed mechanisms in a direct 
transduction into cells. A possible pore formation was evaluated in molecular dynamic 
simulations and electrophysiological experiments.108,109 They show that by increasing the 
peptide concentration on the cellular surface and subsequent interaction, the lipid 
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arrangement gets distorted and thinned out. Hence arginine side chains can interact with 
the distal bilayer, whereby the nucleation of a water pore is induced, resulting in the 
translocation of peptides through this pore (Figure 8B). Here pH was shown to have major 
influence on peptide binding to the lipids extracellularly and release from the lipid 
intracellularly, as the peptide binding to deprotonated lipids is observed in lower pH and its 
release at slightly higher pH.110 Another proposed mechanism for the transduction is the 
formation of a lipophilic ion pair, which is masking the polarity of the guanidinium group, 
making it possible to diffuse into the membrane. This concept was termed adaptive 
translocation (Figure 8C). Here the membrane potential is also important for the diffusion of 
peptides through the membrane, because highly charged peptides are driven to the inside 
of the cell by the intracellular lower voltage.107 It was shown that more curved membranes 
seem to be better penetrable, due to more intrinsic membrane defects, making it easier to 
interact with the lipid interior.104,111  
 
 
Figure 8: Proposed mechanisms for direct translocation of Arginine-rich cell penetrating peptides. Graphic 
adapted from Bechara et al.112 
 
Looking on improving the direct uptake into the cytosol, the facts known about the 
internalization were exploited. Building upon the theory of adaptive translocation and the 
observation that R8 could be extracted into the octanol phase in presence of sodium 
laurate, the Futaki and Matile labs showed that a direct translocation of smaller and bigger 
cargos with R8-peptides is possible in the presence of the hydrophobic counteranion 
pyrenebutyrate (PyB).113–115 Further a membrane curvature inducing peptide (EpN18) was 
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co-administered with the CPP-cargo and resulted in direct cell penetration.116 The Futaki lab 
could pinpoint the effect of the PyB and EpN18 towards a loosening of the lipid packing, 
which allowed for a better interaction of hydrophobic peptide backbone with the 
hydrophobic lipid core.117 A totally different approach toward the improvement of direct 
cellular penetration was achieved by the Cardoso Lab. They investigated the influence of 
backbone rigidity and static presentation of the guanidinium groups on cell penetration and 
found that by cyclizing the peptide backbone they could achieve higher cellular uptake 
mainly into the cytosol and nucleolus for TAT and R10 without the need of any additives.118 
The increased uptake was explained by the larger distance between guanidine head groups, 
which was already observed to positively influence the direct cell penetration in a linear 
model and was recently also proven for rigid oligoprolines bearing guanidinium groups.119,120 
The improved efficiency of cyclized TAT and R10 peptides could even achieve the cellular 
delivery of bigger cargos, like proteins and nanobodies, directly into the cytosol, which is 
referred to as transduction in the following chapters.121,122 
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4.3  Bioconjugation Reactions 
 
The selective modification of a biomolecule with any given other functional moiety, like 
drugs, fluorophores, peptidic tags, post translational modifications, PEG, biotin etc. is a 
crucial task of chemical biology.123 Stable and defined conjugates are ideal in the creation of 
therapeutics, like antibody – drug – conjugates and protein or nanoparticle based materials. 
The requirements for bioconjugation reactions are numerous and complex. First of all 
bioconjugation reactions should be carried out under physiological pH, at moderate 
temperatures (20 – 37°C) and in aqueous buffered environment, in order to preserve 
structural and functional integrity of the conjugate. Furthermore, one seeks for site-specific 
reactions to be able to create a homogenous and structurally defined product. Hence 
chemoselective reactions are employed on native amino acid residues or even 
bioorthogonal reactions on non-native amino acids introduced into the biomolecule for the 
covalent functionalization.124,125	Throughout the combination of purely biochemical methods 
with organic chemistry new strategic approaches are created for studying and therefore 
understanding protein functions. 
 
4.3.1 Bioconjugation on native amino acids 
 
Nature provides us with a big variety of functional groups in protein structures, which are 
posing the opportunity of being used in diverse bioconjugation reactions. Solvent exposed 
amino acids have been used conveniently for the modification of proteins for decades, in 
numerous types of reactions. But as the big number of different reactive groups in the 
protein structure can be seen as an advantage, it can also be a major drawback.  
 
 
Figure 9: General principle of labeling natural amino acids for the incorporation of chemical tags. 
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Often the precise and selective labeling is not possible when using native side chain 
functionalities due to their multiple occurrences in the protein structure. To ensure 
selectivity, the protein structure and amino acid composition as such, have to be evaluated 
for each given experiment. Furthermore, also the desired reaction has to be validated for its 
purpose. However, if one chooses a reaction wisely and knows about their advantages and 
drawbacks, chemoselective reactions on natural residues are powerful tools for the 
modification of biomolecules without the need of lengthy biochemical protein modifications 
(Figure 9). 
 
4.3.1.1 Reactions with native cysteines 
 
Cysteine modifying reactions are widely favored over other native functionalities, because of 
the inherent high nucleophilicity of the sulfhydryl side chain, which is much more reactive 
than other nucleophiles found in the protein structure, rendering most reactions with 
cysteines chemoselective when done under appropriate conditions (Figure 10).126,127 
Moreover cysteines are of low abundance or found masked in disulfide bridges in 
proteins.128 Hence one can either introduce addressable cysteines by standard biochemical 
point mutations, leading to defined positions of the to be functionalized handle. Or one can 
reduce disulfide bridges and use the generated cysteines for conjugations, also at mostly 
defined position.129 One of the oldest methods for the modification of cysteines is the use of 
α-halocarbonyls, which are known for their fast and clean reaction with sulfhydryls since 
1935.130 Iodoacetyl-functionalized crosslinkers, biotinylation reagents, mass spectrometry 
tags etc. are commercially available and are used in many biological studies because of the 
ease and speed of this reaction. A major advantage is the stable and compact linkage that 
is formed. But it is also known, that the iodoacetylgroup is reacting in a low occurrence with 
other side chain functionalities, like amines from lysine or thiothers in methionines, when no 
cysteine is present or at a high excess of the reagent. One can circumvent these side 
reactions by using equimolar amounts or just slight excess of the compound and 
performing the conjugation reaction at pH 8.3, at which the reaction is the most specific for 
sulfhydryl groups.  
Vinylsulfones have also been described for labeling of proteins, especially for PEGylation. 
They react in a Michael-type addition selectively with cysteines at pH 7-8. Going to higher 
pH the reaction rate is increased but cysteine selectivity is lost and lysine conjugation 
byproducts observed. Even though the conjugation products are highly stable in aqueous 
systems and in presence of other nucleophiles this reaction is not the most popular choice, 
due to its slow kinetics compared to e.g maleimides. 
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Figure 10: Overview of well-known bioconjugation reactions on cysteine. 
Next to michael-type reactions, sulfhydryl-groups are also known to react under radical 
conditions. This has been utilized for bioconjugation reactions with terminal alkenes or 
alkynes in thiol-ene (TEC) or thiol-yne couplings (TYC) (Figure 10). The TEC starts with the 
formation of a thiyl radical by light and/or an initiator induction. The addition to the alkene 
occurs in an anti-Markovnikov fashion and is quenched by the abstraction of hydrogen from 
another sulfhydryl. The reaction was first used for the glycosylation of a viral capsid by the 
Davis group at rather low pH (pH4-6).131 TYC is conducted in a similar free-radical fashion, 
in which two thiol containing fragments are added to the alkyne, with the first step being 
again an anti-Markovnikov addition of a thiyl radical to the triple bond generating a vinyl 
thioether, which can undergo then a subsequent TEC reaction with a second thiol 
functionalized fragment. The limitation of these reactions however is the formation of thiyl 
radical, which could damage the protein. 
Employing disulfide formation of cysteines with a thiol containing tag was developed as 
another bioconjugation reaction. For this purpose it is essential to work with an activated 
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thiol otherwise the thermodynamic preference to undergo a thiol exchange is not given. An 
activated thiol is a disulfide-masked thiol with a good leaving group, which results in an 
unreactive thiol after the reaction. Commonly known activating groups are pyridyl disulfides, 
thiosulphonates, thiosulphates or 5-thio-2-nitrobenzoic acid (TNB)-like disulfides. Tags like 
fluorophores, biotinylation or PEGylation reagents are commercially available functionalized 
with those activating groups. Disulfide forming reactions have also been used for the 
generation of antibody – drug – conjugates (ADCs)132 and nanobody-CPP conjugates122 
exhibiting the advantage that the functional moiety is cleaved from its cargo inside cells due 
to the reductive conditions found there. But this feasible intracellular liberation strategy can 
also be the source of major inherent lability making it crucial to assess the compatibility of 
assay and conjugation technique. 
The most prominently used method for cysteine labeling to date is the coupling of a 
maleimide-containing molecule to cysteines. This reaction exhibits particularly fast kinetics 
and high selectivity under near neutral conditions (pH 6.4 – 7.4) (Scheme 1A).133 Maleimide 
chemistry is one of the main choices for the generation of ADCs and used in both ADCs on 
the market. Further it is part of 24 out of 34 ADCs in clinical trials and standardly used for 
protein labeling with affinity tags, fluorophores and conjugations to nanoparticles, which is 
highlighting its comfortable application.   
However, one major limitation of this chemistry has been addressed lately, i.e. the inherent 
lability of the formed thiosuccinimidyl adduct. Highly solvent-accessible conjugation sites 
were shown to undergo rapid thiol exchange with other reactive thiols in biologic 
environments, lowering the actual concentration of the effector molecule at the target site 
(Scheme 1A).134 To circumvent this loss of effector molecule, an exocyclic olefinic maleimide 
has been described recently, that allows the stable thiol addition to the maleimide 
(Scheme 1B).135 Thiol exchange reactions can also be prevented when the maleimide 
undergoes hydrolysis to thiomaleamic acid, which is rather slow process that only goes to 
completion after one month at 37°C. Hence efforts have been made to increase the velocity 
of this hydrolysis step (Scheme 1C). Researchers could achieve the complete hydrolysis 
after one hour incubation on ice.136,137 Still the hydrolysis is giving heterogeneous products 
and also the possibility of starting material undergoing hydrolysis, is reason enough to 
further engineer new reactions with the hope of finding new fast, selective and yet stable 
alternatives.  
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Scheme 1: Maleimide chemistry as bioconjugation method A) conventional maleimide labeling B) exocyclic 
olefinic maleimides135 give stable product resistant to thiol exchange C) strategies for fast maleimide 
hydrolysis136,137. 
 
In some cases, structure-stabilizing disulfides are being reduced and used in the 
conjugation with cysteine reactive labels, as seen prominently in ADCs. Hereby, the integrity 
of the protein can be at risk. To circumvent this, methods have been developed in which the 
disulfide is rebridged by the labeling technique itself. This methodology was reported for 
dibromomaleimides (Figure 11A)138, dithiophenolmaleimide (Figure 11A)139, bis-sulfone 
reagents (Figure 11B)140 or dibromopyridazinediones (Figure 11C)141. For a more stable 
conjugate a rapid maleimide hydrolysis was also developed for the dibromomaleimides 
recently.142 Dibromopyridazones were created as handle that can not only react with two 
cysteines, but are further bearing an alkyne and a strained alkyne handle, which can 
undergo bioorthogonal reactions with azides and were used to prepare antibodies 
conjugated with drugs, fluorophores and/or PEG modularly to the assays need (Figure 11C).  
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Figure 11: Disulfide rebridging approach with A) dibromo-or dithiophenolmaleimide B) bis-sulfone reagents and 
C) dibromopyridazones. 
 
Another cysteine employing reaction, which is not using the nucleophilicity of the sulfhydryl 
group, is the generation of an electrophilic center in form of a dehydroalanine, throughout a 
β-elimination of thiolate from the cysteine moiety. The dehydroalanine can then further be 
used for the addition of a wide variety of tags (Scheme 2A). There are different ways 
described in literature to achieve the β-elimination of thiolate ranging from oxidative- and 
reduction-elimination to base mediated eliminations to bis-alkylation-eliminations 
(Scheme 2B). Base mediated elimination of disulfides can be used on peptide level in 
organic solvents by strong bases but could not achieve dehydroalanine formation on protein 
level. Also reduction-elimination is used successfully on peptide level in organic solvents 
with strong bases, but could only be transfer to a protein substrate to some extend if this is 
stable to high pH. For proteins the most feasible procedures are oxidative-elimination or 
bis-alkylation-elimination.143 Recent studies showed that the oxidative elimination of 
cysteines to dehydroalanine could be achieved under relatively mild conditions, which are 
compatible with protein substrates. Here o-mesitylenesulfonylhydroxylamine (MSH, 
Scheme 2C) was used to selectively amidate cysteine followed by a fast elimination to 
dehydroalanine.144  
 
Scheme 2: A) Cysteine labeling via dehydroalanine generation B) Different β-elimination strategies C) Reagents 
used in oxidative-elimination and bis-alkylation-elimination. 
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In addition to this, the Davis group reported in a comprehensive study of dehydroalanine 
formation via different pathways, that the use of MSH on a more complex protein substrate 
resulted in non-selective amination. In contrast bis-alkylation-elimination could be evolved 
to work under mild conditions.143 Here, the Davis group reported that the water soluble α,α’-
dibromoadipic-bis-amide 1 (Scheme 2C) can yield the dehydroalanine after one hour at 
37°C at pH 7 - 8 for different protein substrates. After creation of dehydroalanine, the 
electrophilic center can be used for nucleophilic thiol addition reactions with labels or 
posttranslational modification analogues and could be shown on a number of model 
peptides and proteins. 140,143,145–147 However, the drawback of this method is the generation 
of a racemic mixture upon addition to the dehydroalanine. 
Despite the high number of cysteine modifiying methods still new reactions for thiol 
functionalization are developed, due to the undeniable power of the sulfhydryl moiety. A 
very impressive approach towards thiol functionalization was reported first in 2015 by the 
Buchwald and Pentelute labs. They used organometallic palladium reagents to arylate 
cysteine moieties in peptides and proteins.148 Via the aryl moiety they could introduce 
affinity tags, fluorophores, bioconjugation handles and even drugs, chemoselectively into 
proteins (Scheme 3A).  
 
Scheme 3: Organometallic reagents for cysteine bioconjugation. A) Palladium mediated arylation of cysteine.   
B) Cross-linking of cysteine and lysine carrying proteins. 
 
They also showed the crosslinking capability in peptides containing two cysteines of the 
palladium oxidative addition. In 2018 thy furthermore showed the usage of their palladium 
complex in a crosslinking approach between cysteines and lysine side chains.149 by 
introducing an electrophilic group into the palladium complex they created a bifunctional 
reagent, which is able to first undergo palladium mediated cysteine arylation followed by 
reaction with a neighboring nucleophile at the aryl moiety (Scheme 3B). Throughout this 
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bifunctional reagent they achieved peptide as well as protein crosslinking in an intra- or 
intermolecular fashion.  
 
4.3.1.2 Reactions on aspartic and glutamic acids  
 
Carboxylic acid side chains from aspartic and glutamic acids are not often targeted for 
bioconjugation, due to the carboxylates low reactivity in water, which demands activation in 
order to be used as good electrophile. When activating carboxylates with e.g. 
carbodiimides, the resulting activated acylisoureas is prone to hydrolyze with solvent water 
or react with different nucleophiles found in the protein structure itself, rendering them not 
chemoselective.150,151 Lately the Raines lab made use of carboxylates for bioconjugation by 
O-alkylating them with diazo compounds, which is yielding covalent ester bonds. These 
esters can be cleaved by naturally occurring esterases, making this conjugation especially 
interesting for a pro-drug inspired approach to bioconjugation.152  
The groundwork for their studies was laid in the 1960s. Back then stabilizing α-diazo amides 
was found to be limiting their promiscuity to a certain extend, showing that they are mainly 
reacting with carboxylic acids in aqueous environment. However, this reaction was also not 
fully chemoselective because S-alkylation, N-alkylation and phenol alkylation was found to a 
certain extend.153 With this observation even more stabilized diazo-compounds were 
explored and used in protein-based studies, especially for the mapping of reactive 
carboxylic acids in a protein structure. Nonetheless, a chemoselective and hydrolysis stable 
compound could never be generated and made the use of the O-alkylation by diazo-
compounds rather unpopular.154 Inspired by the overall versatility of diazo-compounds (also 
see chapter 4.3.2.2.) the Raines Lab set out to accomplish the task of tuning a diazo-
compound towards selectivity and stability. They achieved this throughout the basicity of 
either 9-diazofluorene or α-diazo (p-methylphenyl) glycin derivatives, which enable an 
efficient esterification of carboxylates in water that can further be cleaved by esterases 
(Scheme 4).155,156 Even though the diazo-compound is still prone to hydrolysis this side 
reaction was tuned to be a slow process, by balancing the basicity of the diazo compound, 
between being too low to not react and too high to lead to hydrolysis. 
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Scheme 4: Bioreversible esterification of carboxylic acids on proteins using diazo-compounds. Presumptive 
mechanism according to Roberts et al..157 
 
4.3.2 Bioconjugation reactions on unnatural amino acids  
 
When carrying out bioconjugations in a more complex environment, for example in a cell, in 
a complex protein mixture or on a multifunctional peptide, one can still aim for a truly site 
specific and defined labeling. For this purpose it is inevitable to employ bioorthogonal 
reactions. These are reactions, which can only occur between two unnatural moieties that 
are not found in a native protein or cellular environment.125  
 
Figure 12: Bioorthogonal chemical reporter strategy A) Chemical reporter usage for protein functionalization B) 
Chemical reporter usage in cellular glycan structures. 
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Glycans with a functional handle can for example be metabolically incorporated into the 
glycocalyx of the cell (Figure 12B). Alternatively non-native amino acids with bioorthogonal 
functional groups can be incorporated into proteins of interest by genetic code expansion 
(Figure 12A). These so-called chemical reporters can then be functionalized site specifically 
with a bioorthogonal tag (Figure 12).158 For the incorporation of bioorthogonal handles into 
proteins major advances have been made in the area of genetic code expansion 
techniques, throughout which unnatural amino acids can be incorporated into proteins 
genetically.159,160 Functional groups that can be introduced into peptides and proteins and 
further reacted in a bioorthogonal way comprise azides, alkynes, strained alkynes, ketones, 
alkenes, strained alkenes, tetrazoles, anilines, 1,2-amino thiols, aryl halides and boronic 
acids.161 One of the most versatile and popular functional group is the azide, because it can 
undergo numerous bioorthogonal reactions, is inert in aqueous environment and one of the 
smallest modifications possible.  
 
4.3.2.1 Alkyne azide cycloadditions 
 
The preparation of triazoles from azides and alkynes by a 1,3-dipolar cycloaddition is known 
since the 19th century162 but was famously driven forward by Rolf Huisgen between the 
1950s – 1970s using organic reactions at high temperatures163. The starting point of the 
immense attention this cycloaddition has gained in the last 15 years in life science 
applications, are two reports from 2002 from the Sharpless and Meldal labs.164,165  
Here, it was shown that the cycloaddition reaction between azides and alkynes can be 
catalyzed by a copper (I) catalyst, which promotes the cycloaddition regiospecifically to the 
1,4-disubstituted 1,2,3-triazole, at room temperatures in aqueous environment with 
increased reaction rates, compared to the thermal process used by Huisgen (Scheme 5A).166 
These properties are exactly what is needed for a truly bioorthogonal reaction and the 
reaction was therefore used in numerous applications in the life science field. To enhance 
the efficiency of the reaction, copper (I) stabilizing ligands were developed and advanced 
over the years. Mostly polytriazoles like TBTA167, THPTA168 or BTTAA169 are being used as 
simple additives (Scheme 5B). Not only do these ligands stabilize the copper (I) by 
complexation, but also reduce its cytotoxic effect by coordinating to copper. Recently the in 
cellulo use of copper catalyzed alkyne azide cycloaddition (CuAAC) using the BTTAA ligand 
conjugated to a CPP has been reported.170 But as copper is still avoided in vivo due to its 
cytotoxicity171 new ligands are being developed in order to increase the copper activity and 
to be able to lower the copper content in the reaction. Betaine (2) is one ligand that can be 
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used with copper contents as low as 2.5 ppm, making it rather safe to use it also in in vivo 
settings.172 
 
 
Scheme 5: A) Mechanism of the CuAAC like proposed by Worreell et al.173 B) Ligands for the stabilization of 
copper(I) in the CuAAC. 
 
Parallel to the advances of improving copper ligands, researchers still aimed to use no 
metal at all for bioconjugations. Affords were made to establish other means of activation to 
facilitate the cycloaddition and were found by the Bertozzi lab in old reports, which showed 
that highly strained cyclic alkynes undergo fast reactions with organic azides.174 Inspired by 
these studies they synthesized a simple cyclooctyne (OCT, Figure 13), conjugated it to a 
biotin and could show rapid cycloaddition to an azide-bearing carbohydrate, which was 
metabolically incorporated into live cells without any catalyst needed.175 It was simply 
enough to use the enthalpically favored release of ring-strain as catalytic driving force and 
therefore they termed this reaction strain promoted alkyne azide cycloaddition (SPAAC). 
Due to low water solubility and slower reaction kinetics compared to CuAAC, the first 
cyclooctynes were synthetically improved to exhibit faster kinetics and lower lipophilicity 
over the last years. Higher reaction rates were achieved by electronic activation of the triple 
bond through electron withdrawing fluorine adjacent to the alkyne (DIFO) (Figure 13).176 
Overall ring strain on the other hand was improved by fusing rigid aromatic rings to the core 
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octyne (DIBO or the more hydrophilic DIBAC) (Figure 13).177,178 Due to the demanding 
synthesis of these improved cyclooctyne derivatives, a more feasible synthesis was also 
probed by fusing cyclopropane to the cyclooctyne (BCN), which also increased ring strain 
(Figure 13).179 The downside of increasing the reactivity of the alkyne however is the loss of 
specificity towards azides and the increase of thiol-yne side reaction to a certain degree.180  
 
Figure 13: Different strained alkynes used for SPAAC. 
 
4.3.2.2 Other cycloaddition reaction 
 
In the search for more reactions that are compatible in a bioorthogonal chemical reporter 
strategy, strained alkynes were also reacted in a 1,3-dipolar cycloaddition with nitrones to 
yield N-alkylated isoxazolines (Scheme 6A).181,182 This so called strain promoted alkyne-
nitrone cycloaddition (SPANC) was significantly faster than the cycloaddition with azides. 
The reaction was used in the bioorthogonal labeling of proteins181,183,184 and cellular 
surfaces185. Even though the reaction exhibits fast kinetics comparable to CuAAC, the 
incorporation of the nitrone reporter is not trivial. Nitrones are prone to hydrolysis and are in 
many cases incorporated by an N-terminal serine, which upon oxidation to an aldehyde can 
be converted to the nitrone. This oxidation step on protein level can be harmful to the 
protein structure and is furthermore limiting the conjugation to the N-terminal site.  
Another 1,3-dipolar addition known is the reaction of diazo compounds with alkynes and 
alkenes (Scheme 6B).163,186 The reaction was tuned and could give higher reaction rates 
compared to azides.187,188 Because diazo compounds are more electron rich than azides, 
they also exhibit reactivity towards unstrained terminal alkenes and alkynes.189–192 Stabilized 
diazo groups were further shown to be metabolically incorporated into mammalian cells.193 
One downside to the reaction is however the diazo group’s tendency to undergo hydrolysis. 
 
 
Scheme 6: Strain promoted labeling using A) nitrones (SPANC) B) diazo compounds. 
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Next to the 1,3-dipolar cycloadditions, Diels-Alder-Reactions achieved a lot of attention in 
the field of bioorthogonal reactions. It was observed that tetrazines react in an extremely 
fast fashion with strained alkenes and alkynes like transcyclooctene, norbonene or BCN in 
an inverse-electron demand Diels-Alder reaction (IEDDA) (Scheme 7A).194,195 Its reaction rate 
is outcompeting all known bioorthogonal reactions with nitrogen gas as only byproduct.124 
The reaction kinetics for this bioorthogonal reaction were further fine-tuned by changing the 
electron deficiency of the substituents on the 1,2,4,5-tetrazine core motif or by modulating 
the ring strain and electronic effects of the dienophile (Scheme 7B/C).196  
 
 
Scheme 7: A) Reaction mechanism of the IEDDA reaction Overview of B) dienophiles and C) dienes used in 
bioconjugations.  
 
In early reports, the rather bulky functional chemical reporters were incorporated into 
proteins by other protein conjugation strategies, which resulted in a two step 
functionalization approach.194,195 Due to its remarkable reaction kinetics many groups were 
interested in genetically encoding possibilities for strained alkenes and alkynes as well as 
tetrazines, which would elevate the reactions applicability immensely. Only four years after 
the first description of the IDDEA reaction in a bioorthogonal context, the genetic encoding 
of norbonenes197,198, transcyclooctenes197,198, cyclooctynes198, bicyclononynes197 and 
tetrazines199 was accomplished, allowing convenient cell surface and intracellular labeling of 
proteins (Scheme 7B/C). Due to the fast kinetics and the high fluorogenicity of tetrazines 
IEDDA was also exploited for fluorogenic applications and is the go to reaction for 
bioorthogonal labeling in vivo nowadays.200–203  
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4.3.2.3 Staudinger type reactions 
 
Another reaction in which azides are participating are Staudinger type reactions. In the 
classical Staudinger reaction reported by Hermann Staudinger in 1919 an azide is reacting 
with a phosphine to an iminophosphorane, which hydrolyses to phosphine oxide and amine 
in water (Scheme 8A).204 In 2000 the Bertozzi lab discovered the utility of the Staudinger 
reaction for biomodification means, which they called Staudinger ligation (Scheme 8B).205 
They reported that one could label metabolically incorporated azido carbohydrates with a 
biotin-phosphine on cellular surfaces by using a version of the Staudinger reaction in which 
the phosphine and an electronic trap are tethered to the same phenyl group. The aza-ylide 
formed when azide and phosphine react can attack the internal electrophile and create an 
amide that is ensuring the covalent bond between carbohydrate and functional moiety. In 
mechanistic studies they could show that the rate-limiting step is the formation of the 
phospazide throughout the nucleophilic attack of phosphine on the azide. Hence electron 
donating groups on a phenylgroup that is directly attached to the phosphorous atom were 
shown to accelerate the rate of reaction.206 
 
 
Scheme 8: A) Mechanism of the Staudinger Reduction. B) Mechanism of the Staudinger Ligation. C) Mechanism 
of the traceless Staudinger Ligation. 
 
Also in 2000 the Bertozzi and the Raines lab further expanded this reaction to a traceless 
version. In this variant the phosphine oxide can be cleaved throughout the hydrolysis step, 
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which is generating a native amide bond (Scheme 8C).207,208 The reaction was shown to be 
chemoselective and could be used on peptide level retaining stereoselectivity of the linked 
amino acids.209–212 From here on many aspects of the Staudinger ligation were studied in 
detail. The electron density on the phosphorous atom was shown to play an important role 
in the reaction rate. It was demonstrated that an electron-donating group on the 
phospinothiol is accelerating the intermolecular reaction between azides and phosphines as 
observed for the non-traceless Staudinger ligation. The more electron-donating the 
substituent on phosphorous the more protonation of the nitrogen atom in the 
iminophosphorane stage and hence formation of amine byproduct is observed as well as 
unwanted oxidation of phosphorous (Scheme 8C). Here, they also stressed the high 
influence of the solvent on the electron density on phosphorous.212,213 The Raines Lab also 
achieved the synthesis of a water soluble phosphine, that can undergo Staudinger ligation 
in an aqueous environment.214,215 Furthermore the Hackenberger lab demonstrated the 
feasible use of borane protection of phosphines against oxidation and showed the 
deprotection mediated cyclization of peptides using the Staudinger Ligation under acidic 
conditions.216,217 The Bertozzi lab could further generate fluorogenic phosphines, which are 
turned on upon reaction with an azide.218,219 As described the traceless Staudinger Ligation 
has been used as bioorthogonal reaction but often the sensitivity of phosphorous towards 
oxidation and the iminophosphorane’s tendency to hydrolyze to its amine, limits this 
reaction’s use and scope. 
A further development in Staudinger type reactions was reported in 2009 by the 
Hackenberger lab. They chemoselectively reacted an azido-functionalized biomolecule with 
phosphites yielding phosphoramidates (Scheme 9A).220 The oxygen substituent on 
phosphorous in phosphites has a strong negative inductive effect that is making the 
phosphorous atom somewhat more resistant to oxidation. Furthermore changing the 
substituents on phosphorous is rather easy in phosphites and makes this reaction 
interesting for the synthesis of functional tags. Due to its versatility, this reaction could be 
used for the site-specific incorporation of phosphorylated amino acids,220,221 
PEGylations222,223, lipidations224, biotin tags225 or glycans226,227. The ability of using this 
reaction to introduce site specifically photo-caged phospholysines and phosphocysteines 
into peptides and proteins is especially interesting, because this could not be done in such 
an elegant fashion before. Most notably is that the photo-caging group is protecting the 
highly instable post translational modification (PTM) from hydrolysis during the synthesis 
and storage and is hence opening a new way of generating and validating analytical 
methods for e.g. proteomics.  
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Scheme 9: A) Mechanism of the Staudinger Phosphite reaction. B) The unsymmetrical Staudinger Phosphite 
Reaction . C) Two different hydrolysis mechanisms. 
 
A characteristic of the trifunctional phosphorous building block is the introduction of two 
equivalents of functional substituents into the biomolecule, which can be a big advantage 
e.g. for the PEGylation of a protein. If one only wants to incorporate one tag the 
Hackenberger Lab also showed the versatile usage of unsymmetrical phosphites 
(Scheme 9B).224,225 Here they showed that by using good leaving groups like benzyl- and 
pyridyl-substituents they can control the hydrolysis in the final step, generating the wanted 
tagged biomolecule in high yields. The hydrolysis could occur here via two different 
pathways, either by an Arbuzov-Type rearrangement or via a nucleophilic attack by water at 
the phosphonimidate stage.228,229 Another way of ensuring control over which of the three 
substituents on phosphorous is being kept in the molecule of interest throughout the 
hydrolysis step, was the development of the flexible Staudinger-phosphonite reaction. 
Phosphonites consist of one stable phosphorous – carbon bond, that can not be cleaved 
upon hydrolysis (Scheme 10A) and were first used on a protein for PEGylation purposes.230 
 
 
 
Scheme 10: A) Mechanism of the Staudinger Phosphonite reaction. B) Formal azide-azide conjugation using 
CuAAC in combination with the Staudinger Phosphonite Reaction. 
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This reaction was further developed into a formal azide-azide conjugation reaction. Here it 
was shown that it is possible to introduce an alkyne into the phosphonite, which can be 
utilized as bioorthogonal handle for the introduction of functional moieties by CuAAC 
(Scheme 10B).231–233 The azido-group is undergoing CuAAC as well as Staudinger reactions, 
which seems to render this combination of reactions not chemoselective to each other, but 
the Hackenberger lab could show, that by protecting the phosphorous using borane they 
can totally prohibit the occurrence of the Staudinger phosphonite reaction pathway and only 
generate the product formed via CuAAC (Scheme 10B). Upon borane deprotection they 
could then achieve the selective reaction with a second azido-functionalized moiety in a 
Staudinger Phosphonite reaction to yield a phosphonamidate, which formally connects two 
azido building blocks. 
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5 Objectives 
 
Peptides form a special class of molecules because they are highly complex in structure 
and chemical composition, yet easily synthetically accessible. Some functions of full-length 
proteins were shown to be reducible to an active structural motif. When reduced to this 
peptidic motif a biological active peptide can be gained. Those small peptidic protein 
mimics are of great potential when thinking of protein – protein inhibitors, protein – ligand 
inhibitors or even when using peptides as functional tags, as known for cell penetrating 
peptides. Hence peptides are getting a lot of attention in the field of peptide therapeutics. 
When working with biological active peptides in therapeutic or methodological applications 
one needs to plan strategically due to their complex chemical composition. Here 
conjugation, as well as modification approaches need to be addressed by chemoselective 
chemistry. 
The aim of this work evolved around those two major topics. For once different biological 
active peptides were explored as part of an inhibitor, as inhibitor by itself or as functional 
tag for the cellular delivery of proteins. Furthermore novel chemoselective bioconjugation 
techniques were explored for the conjugation of biological active peptides to protein or 
polymer cargos. One bioconjugation technique was further developed for an intramolecular 
macrocyclization modulation of biological active peptides to stabilize and elevate their 
function. In detail the four different goals evolving around biological active peptides were: 
 
1. Generation of a multivalent protein – ligand inhibitor for the influenza virus, 
comprised of a peptidic ligand multivalently displayed on a polymeric scaffold, to 
block the protein – ligand interaction.  
 
2. Development of a bioconjugation method, designed to react a phosphonite linker 
chemoselectively with a peptidic tag, upon which a cysteine reactive center is 
formed that can be reliably conjugated to proteins to yield stable peptide – 
polymer conjugates. 
 
3. The installation of a structure stabilizing linker into two different peptide motifs, 
by which these peptides gain a specific biologic function.  
 
4. Conjugation of functional peptide tags to proteins via a chemoselective and 
bioreversible conjugation technique.  
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Project 1 – Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus Inhibition 
Many cellular recognition processes are of multivalent nature. Underlying monovalent 
protein – ligand interactions are often weak and only a high number of ligands binding to the 
target are giving a precise and tight recognition. This also holds true for the first binding 
step in an influenza virus infection. Here, the influenza virus membrane protein 
Hemagglutinin (HA) is binding to sialic acids on the cellular surface.  
Inspired by nature’s example we envisioned the generation of an affine multivalent binder 
that is build of a peptidic ligand to HA and a polymeric nanoparticle. The HA binding peptide 
was derived from the CDR domain of a HA binding antibody and was supposed to be 
chemoselectively conjugated to the nanoparticle in a multivalent fashion. This functional 
nanoparticle is thought to block HA on the virus surface and hence make an effective 
binding to the cellular surface impossible. Differently sized nanoparticles decorated with this 
peptide were supposed to be screened in vitro as well as in vivo. 
 
Project 2 – Staudinger Induced Thiol Addition as cysteine reactive conjugation 
Popular bioconjugation reactions employ cysteine reactive probes, because the high 
nucleophilicity of cysteines makes chemoselective reactions possible. Furthermore, the low 
abundance of cysteines and their tendency to be masked in disulfides makes their usage 
attractive for controlled site-specific modifications. The most popular cysteine reactive 
conjugation for biological purposes to date is the maleimide reaction, which suffers from 
instabilities and especially thiol exchange reactions when circulating in vivo.  
Here we wanted to apply the novel Staudinger induced thiol addition, developed in our lab, 
as new bioconjugation reaction for labeling proteins throughout a thiol addition of the 
protein to a modified peptidic tag. The linker molecule was envisioned to be an electron rich 
alkyne phosphonite that can undergo chemoselective Staudinger phosphonite reaction with 
an azide incorporated into the peptidic tag. Upon formation of the phosphonamidate the 
alkyne becomes electron poor, making it susceptible for a thiol addition by a protein. The 
stability of phosphonamidate as well as the thiol addition product was envisioned to be 
tested in detail and the applicability should be evaluated in vitro.  
 
Project 3 – Intramolecular Staudinger Induced Thiol Addition as new peptide 
cyclization method 
One of the major concern when dealing with biological active peptides that are derived from 
a certain part of a protein is loss of structural integrity, stability and hence loss of intended 
function. As already summed up in the introduction, there are numerous ways of installing a 
covalent linker inside the peptide structure, which is stabilizing its structural characteristic 
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found in the native protein. Especially for α-helical motifs, the so called “stapling” gained a 
lot of attention. Furthermore, macrocyclization techniques are more generally used to either 
render peptides more stable in vivo or in special cases to enhance function like shown 
previously for cCPPs.  
In this project we wanted to introduce a novel highly flexible chemoselective 
macrocyclization method, which can be used for side chain stapling, as well as for 
macrocyclization reactions. This reaction was intended to be an intramolecular variant of the 
Staudinger induced thiol addition that has been used in project 2. The first application for 
this intramolecular reaction was the α-helical stabilization of a peptide sequence, which was 
derived from the protein structure of a protein involved in a PPI and should pose as inhibitor 
of exactly this interaction. Another application was thought to be the macrocyclization of a 
cell penetrating peptide. Upon macrocyclization the cell penetrating peptides ability to 
transduce a protein cargo into cells was tested. 
 
Project 4 – Diazo-functionalized CPPs for bioreversible esterification of proteins  
It has been reported that highly positively charged cell penetrating peptides derived from 
the RNA binding protein TAT exhibit a high affinity towards the RNA containing nucleolus 
inside the cell. Because this inherent attraction could pose disadvantages for some cargos 
that are supposed to be delivered into the cytosol, a bioreversible but covalent 
bioconjugation method should be explored in this project.  
Here an esterification of a protein’s carboxyl groups via a diazo building block in an O-
alkylation was aimed at. The ester linkage was then thought to be cleavable by endogenous 
esterases inside the cell, to deliver native protein into the cytosol followed by the traceless 
removal of the peptidic tag. The functionalization was envisioned to be tested by two 
different routes with either directly functionalizing the peptide with a diazo group at the N-
terminus or by esterifying the protein with a chemical reporter that could subsequently be 
functionalized with a peptide. Finally the tagged protein should be evaluated in vitro, with 
high emphasis on the ester cleavage properties.  
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6 Results and Discussion  
6.1  Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus 
Inhibition 
6.1.1 Introduction to multivalent entry blockers for Influenza virus 
 
The first step of infection with the influenza A Virus (IAV) is its binding to the host cell. The 
IAV binds to the cell surface via its trimeric spike protein hemagglutinin (HA), which 
recognizes sialic acids (SA) on the glycocalyx of cellular membranes.234,235 Because the 
binding affinity of a single HA receptor binding site to a single SA is rather weak (~2 mM), a 
tight binding can only be achieved throughout multiple ligand-receptor binding events 
between virus (0.02-0.04 HA/nm) and the SA glycoconjugates on the glycocalyx (0.5-2 
SA/nm).236,237 
Because Multivalency is such a prominent work-principle, the idea of using this 
phenomenon to build synthetic entry blockers for the influenza virus became popular in the 
1990s and was pioneered by Whitesides and coworkers.236,238–240 The underlying idea was to 
create an entry blocker that consists of a large number of low affinity SA derived ligands 
tethered together on a large scaffold, which was envisioned to result in an high HA avidity. 
The scaffolds used to achieve this were ranging from polymers,239,241,242 dendrimers,243–246 
liposomes,238,247 proteins248 to even gold nanoparticles249.  
Here, polyacrylamide-based inhibitors were one of the most successful scaffolds, giving the 
most affine binder when large numbers of SA were presented.239 However those scaffolds 
had also a major disadvantage, which was their degradation products cytotoxicity.239,250–253 
Hence, using biocompatible polymers for example polyglycerol became desirable and was 
shown successfully by the Haag lab.241  
Not only the scaffold was improved from the first reports but also the HA binding ligands. 
Here alternatives like peptides targeting HA were taken into account, due to their presumed 
higher affinity and selectivity.35,254,255 Also peptides can be produced easily and changes to 
their structure and hence affinity towards a target can be optimized and screened more 
effectively compared to small molecules (see Chapter 4.2.2.). 
In 2006 a peptide derived from the signal sequence of fibroblast growth factor 4 has been 
shown to inhibit infection by influenza virus.255 Thereafter, a peptide was optimized for HA 
binding by selection from a phage-displayed random peptide library.254 This work also 
showed a multivalent improvement of its binding properties by conjugation to either an 
amphiphilic N-stearoyl derivative, which formed self-assembled multivalent structures with 
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enhanced binding capabilities or by presenting up to six peptide copies on a carbosilane 
dendrimer.254,256,257 
Memczak et al. recently reported peptide sequences directly obtained from an HA binding 
antibody. They could reduce the CDR binding part of the antibody to a 15 amino acid long 
wild type peptide sequence (PeB). This sequence they took as starting point for MD 
simulations and further microarray screens, in which they determined an even more affine 
double mutant peptide sequence (PeBGF), which binds to HA monovalently in the 
micromolar range.33  
 
6.1.2 Outline of the project 
 
In this project, the aim was the design of a multivalent entry blocker for the influenza A virus 
(IAV), based on a biocompatible hyperbranched polyglycerol scaffold conjugated to multiple 
HA binding peptides. Both peptides PeB and PeBGF reported previously by Memczal et al. 
were planned to be conjugated onto polyglycerol and should be compared to each other. 
Due to their monovalent more affine binding to HA than the natural ligand SA, we envisioned 
these ligands to have the potential to yield highly affine virus entry blocker, when multiply 
displayed as IAV binding nanoparticle. Here, also the multivalent difference between the 
monovalently weaker binding wild type sequence (PeB) and its improved sequence (PeBGF) 
were of interest.  
The conjugation of peptide to the polymer was planned via the chemoselective CuAAC, 
therefor the polymer was functionalized with multiple azido groups and the peptide with a 
single alkyne (Figure 14). Here, peptide – polymer conjugates with varying scaffold sizes and 
peptide ligand densities on the polymer were to be synthesized, characterized and the 
effect of size and ligand density was supposed to be analyzed in in vitro assays. Finally the 
best binders were planned to be tested in an in vivo setting.  
 
 
Figure 14: Schematic presentation of the peptide – polymer conjugate synthesis. 
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6.1.3 Responsibility assignment 
 
Christian P. R. Hackenberger and Andreas Herrmann conceptualized the project. Daniel 
Lauster conducted all in vitro assays, namely the hemagglutination inhibiton assay, infection 
inhibition assay, and cellular fluorescence assay. He also conducted some of the in vivo 
experiments. The author synthesized the peptides, optimized their purification and 
conducted the conjugation reaction with the polymers, including purification and 
characterization by NMR and DLS. Markus Bardua and Ute Hoffmann conducted the in vivo 
experiments. Kai Ludwig analyzed the nanoparticle binding to virus by cryo-EM. Markus 
Hellmund synthesized the polymers for the conjugation reactions. Ute Hoffmann and Alf 
Hamann were responsible for the design of the in vivo study. Christoph Böttcher designed 
the cryo-EM experiments. Rainer Haag conceptualized the polymer synthesis. 
This chapter was published under the title “Multivalent Peptide-Nanoparticle Conjugates for 
Influenza-Virus Inhibition” in Angew. Chem. Int. Ed. 2017, 56, 5931–5936.258 The author, 
Daniel Lauster, Christian P.R. Hackenberger and Andreas Herrmann wrote the manuscript. 
Markus Bardua, Kai Ludwig, Markus Hellmund, Ute Hoffman, Alf Hamann, Christoph 
Böttcher and Rainer Haag proofread the manuscript. 
 
6.1.4 Synthesis of peptide-polymer conjugates 
 
We started our investigations into multivalent peptide – polymer conjugates by first 
synthesizing the peptidic ligands. The hydrophilic and biocompatible polyglycerol scaffolds 
functionalized with azido groups (Figure 15A) were obtained from the lab of Prof. Dr. Rainer 
Haag. In order to be able to conjugate the peptides to the azido-polymer via CuAAC, the HA 
binding peptides PeB and PeBGF were synthesized with an alkyne handle N-terminally. The 
15 amino acid long peptide sequences PeB (wild type) and PeBGF (mutant) only differed by 
two site mutations (Figure 15B). It has been reported that these two mutations in PeBGF 
increase the affinity of the wild type PeB towards HA.33 However, these mutations also 
render PeBGF more hydrophobic compared to PeB, which could be of relevance in in vitro 
and in vivo studies.  
PeB and PeBGF were synthesized via solid phase peptide synthesis and both were N-
terminally caped with 4-pentynoic acid. After acidic cleavage of the peptide from rink-amide 
resin using a TFA/TIS/water mixture the crude peptides were purified by preparative HPLC 
and gained in moderate yields of 14%. It was observed that both peptides are badly soluble 
in acidic aqueous media, in which they behave gel-like. Therefore, purification of the 
Results and Discussion 
 47 
concentrated crude peptide had to be carried out under basic conditions (pH 9.0) in which 
both peptides were well soluble.  
With both alkyne-functionalized peptides in hand the screening of the optimal polymeric 
scaffold was started. Here, we chose to investigate the antiviral potential of four different 
polymers with molecular weights ranging from 7.7 kDa to 340 kDa 3a – 6a. Furthermore the 
ligand density on higher molecular weight compounds was analyzed, because it was 
emphasized previously in a study based on PAMAM as polymeric scaffold, that low ligand 
density and larger particle sizes can positively influence the inhibitory potential.259 For the 
synthesis of peptide – polymer conjugates with lower ligand densities polymeric starting 
material with an azide degree of functionalization of 10% was chosen (5a10%/ 6a10%) and for 
peptide – polymer conjugates with higher ligand densities a polymer with an azide degree of 
functionalization of 30% was chosen (5a30%/ 6a30%). Meaning that either 10% or 30% of all 
polymeric alcohol end groups were transferred into an azide. 
 
 
Figure 15: A) Representative structure of hyperbranched polyglycerol. B) Peptide sequence of the to be 
conjugated peptides PeB and PeBGF. C). CuAAC conjugation between peptide and polymer (for polymer sizes 
see table 1). D) DLS data for screening of different molecular-weight dendritic PGs conjugated to PeB peptides. 
 
The CuAAC between peptide and polymer was carried out in basic ammonium bicarbonate 
buffer (pH 9.0) at room temperature overnight (Figure 15C). Here, the basic medium was 
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again chosen to facilitate good solubility of the peptides. The reaction mixture was pre-
purified by dialysis over several days against a mixture of 10 mM ammonium bicarbonate 
buffer (pH 9.0) with 10% acetonitrile, followed by size exclusion chromatography. Finally, 
the conjugation products were analyzed by NMR spectroscopy (see Chapter 8.2.3 Figure 
8.3 and Chapter 10 Figure 10.1. to 10.11) and DLS (Figure 15D and Figure 8.4.) to obtain the 
degree of functionalization, number of ligands and the diameter of each conjugate (Table 1). 
Individual ligand densities for each compound could be determined from these parameters. 
One has to note that the ligand number for all nanoparticles is only an average number, 
which is based on the polymeric molecular weight distribution of the polyglycerol itself (see 
Chapter 8.2.2. Table 8.1). 
 
Table 1: Overview over Polyglycerol – Peptide conjugates.  
No. Compound 
Mp core 
[kDa]a 
DFb  
[%] 
Lig.c 
Diameterd 
[nm] 
Densitye 
[Lig./nm2] 
3a dPG8 7.7 0 0 2.4 ± 0.1 0.0 
3b dPG8PeB26 7.7 26 24 6.4 ± 0.7  1.3 
3c dPG8PeBGF30 7.7 30 31 10.3 ± 0.6 1.7 
4a dPG14 14.4 0 0 5.1 ± 0.5 0.0 
4b dPG14PeB19 14.4 19 37 11.3 ± 3.1 0.5 
4c dPG14PeBGF19 14.4 19 36 11.3 ± 1.4 0.5 
5a dPG100 100 0 0 8.0 ± 0.4 0.0 
5b dPG100PeB8 100 8 108 16.5 ± 2.7 0.5 
5c dPG100PeB21 100 21 284 20.2 ± 2.2 1.4 
5d dPG100PeBGF10 100 10 135 22.4 ± 2.8 0.7 
5e dPG100PeBGF29 100 29 392 15.1 ± 0.7 2.0 
6a dPG340 340 0 0 11.7 ± 0.4 0.0 
6b dPG340PeB9 340 9 414 17.9 ± 0.9 1.0 
6c dPG340PeB15 340 15 690 24.8 ± 4.3 1.7 
6d dPG340PeBGF10 340 10 460 27.6 ± 5.9 1.1 
6e dPG340PeBGF16 340 16 736 29.8 ± 1.4 1.8 
a) Molar mass at peak maximum (Mp) of polyglycerol. b) Degree of functionalization of all end groups determined 
by 1H-NMR c) Average number of all ligands (Lig.) calculated from DF. d) Diameter determined from DLS 
measurements in 10 mM ammonium bicarbonate buffer (Values represent the means with the standard error of 
the mean (s.e.m.) of at least three measurements). e) Ligand density based on mean diameter of a sphere 
divided by the amount of ligands. 
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After characterization, all compounds were subjected to a hemagglutination inhibition assay 
(HAI) to assess their inhibitory potential. Therefore, the IAV Aichi H3N2 (X31) was pretreated 
with different concentrations of a peptide – polymer conjugate, followed by the incubation 
with a suspension of human erythrocytes. Influenza virus binding toward red blood cells 
could be observed by formation of a gel like clot, so called agglutination. Therefor, the 
lowest concentration of peptide – polymer nanoparticle, which was able to inhibit this visible 
agglutination, was defined as inhibition constant (KiHAI) and was determined in at least three 
replicates (Table 2) by Daniel Lauster in the Herrmann Lab. 
 
Table 2: Results of HAI assay with human erythrocytes and infection inhibition assay of MDCK II cells. n.d. = not 
determined; - = no inhibition or binding.  
No. KiHAILig [µm]a KiHAINP [nm]b IC50 Lig [µm]c IC50 NP [nm]d 
3a - - - - 
3b 54 ± 15 2250 ± 629 - - 
3c 69 ± 9 2218 ± 295 - - 
4a - - - - 
4b 2 ± 1 62 ± 14 - - 
4c 4 ± 1 99 ± 32 34.6 ± 0.1 960.6 ± 2.7 
5a n.d. n.d. - - 
5b 31 ± 0 289 ± 0 0.8 ± 0.1 7.5 ± 1.0 
5c 75 ± 29 264 ± 102 4.4 ± 0.6 15.4 ± 0.6 
5d 33 ± 8 247 ± 62 2.5 ± 0.1 18.5 ± 0.5 
5e 42 ± 8 106 ± 21 17.3 ± 0.1 44.2 ± 0.2 
6a - - - - 
6b 4 ± 1 9 ± 2 0.3 ± 0.1 0.6 ± 0.3  
6c 163 ± 22 236 ± 31 69.5 ± 0.0 100.7 ± 0.1 
6d 12 ± 3 25 ± 6  0.2 ± 0.0 0.4 ± 0.1 
6e 15 ± 6 20 ± 7 0.9 ± 0.0 1.2 ± 0.1 
a) Value for HAI assay for ligand concentration with the s.e.m. (n ≥ 3). b) Value for HAI assay for nanoparticle 
concentration with the s.e.m. (n ≥ 3). c) IC50 values derived from a four parametric logistic fit shown with an 
asymmetric standard error (SE) of the logIC50. 
 
This assay showed, that increasing the molecular weight of the polymer backbone results in 
a drop of the KiHAI to low nanomolar values (Table 2, 6b, 6d, 6e). Furthermore, it was 
observed that a higher degree of ligand functionalization was indeed not substantially 
increasing the inhibitory potential of the conjugate. The same trend was observed in 
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infection inhibition experiments, where cell viability of MDCK II cells was measured after 
incubation with a virus – inhibitor mixture. In this assay IC50 values in the sub nanomolar 
range were observed for the largest nanoparticles with low peptide densities (Table 2, 6b, 
6d). From those values a multivalent enhancement factor of 129 for PeB and 136 for PeBGF 
could be deduced (for calculation see Chapter 8.2.3). We appointed the drastic increase in 
effectiveness for larger constructs to the steric shielding character of the multivalent 
scaffolds, which can contribute additionally to the affinity of the peptidic ligand.260 
In the HAI as well as the infection inhibition assay it was observed, that the difference in 
binding affinity between the monovalent mutant peptide PeBGF and the wild type peptide 
PeB did not transfer toward the multivalent scenario. To investigate this further, a 
microscale thermophoresis (MST) experiment was set up to measure directly the binding of 
the best binders (6b and 6d) toward fluorescently labeled X31 virus. Here, it was observed 
for the nanoparticles with a 340 kDa scaffold and a low ligand valency, that the mutant 
peptide nanoparticle dPG340PeBGF10 6d is indeed binding IAV with 10 times higher affinity 
(KDapp of 3.1 µM peptide or 6.8 ± 1.1 nM multivalent nanoparticles) compared to the wild 
type peptide nanoparticle dPG340PeB9 6b (KDapp of 36.6 µM or 88.3 ± 13.6 nM of the 
multivalent nanoparticles) (Figure 16A). Therefore, we suspect that in the in vitro 
experiments pure affinity is not the sole factor in a successful inhibition. 
 
 
Figure 16: A) MST measurements with 340 kDa PGs against fluorescently labeled X31 virus. Error bars indicate 
the s.e.m. (n ≥ 3). B) In vitro infection test in BALB/c mice treated with pre-incubated X31 at indicated inhibitor 
amounts by an single intranasal dose. Inhibitor concentrations are referring to the nanoparticle concentration. 
 
To further look into the binding between peptide – polymer conjugates and virus, cryo-EM 
microscopy was conducted by Dr. Kai Ludwig in the lab of Prof. Dr. Böttcher. It was 
observed that nanoparticles without any peptide attached did not interact with the virus. In 
contrast, incubating virus with 6d clearly showed the virus surface being covered with 
nanoparticle (Figure 17). 
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Figure 17: A) Cryo-EM image of 6d incubated with Inluenza Virus X31. B) Detailed view of black frame in A. 
Bound nanoparticles 6d are outlined in yellow, virons in blue and corona formed by HA in red. C) Incubation of 
X31 with negative control 6a. All scale bars corresponds to 100 nm. 
 
After these promising in vitro results, we aimed to test the peptide – polymer nanoparticles 
6b and 6d in in vivo experiments. Here, sedated 8-weeks old BALB/c mice (body weight 
~20 g) were infected upon intranasal administration with an inhibitor-virus mix and were 
monitored daily for 10 days on their body weight. The infection is manifested in the mouse 
model by a gradual loss of weight until day four and a slow recovery of weight until day 10 
(Figure 16B; see positive control (Infected, PBS treated)). 
While the control construct dPG340 6a did not protect from infection, mice treated with a 
single dose dPG340PeB9 6b (11.5 nmol/kg) maintained their body weight until day 4 
(Figure 16B) but then started to loose weight on day 5. This could pinpoint toward peptide 
degradation and hence a second inhibitor dosing on day 4 would be necessary to continue 
protection from infection. However, such a procedure was not applicable in the give in vivo 
experiment.  
A similar dosage with the dPG340PeBGF10 6d was not feasible as we were facing solubility 
problems at higher concentrations. Lower inhibitor dosages with both inhibitors at 
~2 nmol/kg concentrations did not significantly protect from infection. Nevertheless, mice 
treated with dPG340PeB9 6b protected the mice to a substantial higher extent as 
dPG340PeBGF10 6d at similar inhibitor dosage. Because we observed lower solubility for 
PeBGF  , we cannot exclude unspecific binding of the coated nanoparticles to respiratory 
structures, interfering with virus inhibition. Already during handling of conjugates carrying 
PeBGF and handling of the peptide alone, it was appreciable that for PeBGF already slight 
changes to the pH resulted in some aggregation. 
All in all, comparing dPG340PeB9 6b with multivalent siallyllactose (SL) presenting PAMAM 
dendrimes (50 µmol SL/kg)259, 6b was about ten times more efficient in protecting infection 
of mice (4.8 µmol PeB ligands/kg), revealing an advantage of more affine peptidic ligands 
over SA. 
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6.1.5 Conclusion and Outlook 
 
In conclusion we could show the synthesis and application of a non-toxic influenza virus 
inhibitors based on a multivalent covalent peptide display on dendritic polymers. The highly 
potent influenza virus inhibitors effectiveness can be explained by the multivalent effect of 
numerous peptidic ligands binding towards the virus in co-occurrence with a steric shielding 
by the polymeric backbone. Although biocompatible dPGs decorated with PeBGF showed 
higher affinity compared to those conjugated to PeB in MST experiments, we concluded 
that affinity is not the only factor determining effectiveness. Because we observed that the 
presumed lower affine dPG-PeB conjugates are superior to dPG-PeBGF in some HAI assays, 
infection inhibition assays and in vivo experiments. We presume that the underlying rational 
behind this behavior is indeed the higher hydrophobicity and hence lower solubility of dPG-
PeBGF.  
In this project we could show the feasibility of peptide ligands, which can be evolved and 
further modified to bind to different receptors, which in combination with nanoparticle 
engineering, opens further avenues to target other disease-relevant multivalent receptors 
than the one studied. Therefore, as an outlook this concept could be transferred to many 
different targets. Also one could think of using more defined scaffolds that can already 
guide the binding by structurally predefining the ligands.  
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6.2 Staudinger-induced thiol addition as cysteine reactive conjugation 
6.2.1 Outline of the Project 
 
In this project we aim to apply a novel chemoselective reaction toward the conjugation of 
biological active peptides to functional proteins. The focus was on the Staudinger-induced 
thiol addition, which was recently developed in our lab. The reaction is derived from the 
Staudinger-phosphonite reaction and its use in a formal azide – azide conjugation (see 
chapter 4.3.2.3.), in which an alkyne phosphonite 7 was employed in a CuAAC.231 Now in 
the Staudinger-induced thiol addition however, this electron rich alkyne phosphonite 7 is 
first reacted chemoselectively with an azide in a Staudinger-phosphonite reaction, resulting 
in the formation of an electron poor alkyne phosphonamidate 8, which is susceptible to the 
addition of a thiol-containing molecule to yield the addition product 9 in a second 
chemoselective reaction. This reaction cascade was first investigated on small molecule 
level in our lab and is used in this project to bioconjugate unprotected peptides to proteins.  
More specifically, we aimed to use the Staudinger-phosphonite reaction for the modification 
of proteins with cyclic peptides ranging from the small model peptides like the integrin 
binder c(RGDfK)261 to cyclic cell penetrating peptides (Figure 18). The chemoselective 
Staudinger-phosphonite reaction allows for the site-specific functionalization of an 
unprotected peptide via an azido moiety, which can be easily incorporated during SPPS. 
The consecutive thiol addition was planned for a model protein exhibiting only one 
addressable cysteine and equipped with an inherent function that can be used in in vitro 
assays. As model system we chose the eGFP mutant C70M S147C developed in our lab.262  
 
Figure 18: Concept of the Staudinger induced thiol addition for bioconjugation of peptides to proteins. 
 
Here the inherent fluorescence of GFP could be used to further assess the biological 
behavior of the peptide – protein conjugates and to compare these to similar conjugates 
generated by different bioconjugation techniques. Furthermore, the stability of the activated 
electron-poor alkyne 8 as well as the thiol addition product 9 should be evaluated.  
Results and Discussion 
 54 
6.2.2 Responsibility Assignment 
 
Christian P. R. Hackenberger conceptualized and designed the project. Tom Sauer 
developed the initial Staudinger phosphonite reaction and following thiol addition on small 
molecules. The author synthesized all peptides and conducted Staudinger phosphonite 
reactions on these peptides as well as thiol additions to glutathione and GFP. The author 
furthermore characterized of all compounds, measured their stability and used the 
conjugates in FACS experiments. In parallel to this work, the Staudinger induced thiol 
addition was studied in further detail by Marc-Andre Kasper on small molecule level and in 
the generation of ADCs, which provided mechanistic insights and further details concerning 
the stability and scope of this reaction. The author conducted the mutagenesis, expression 
and purification of hsGFP S3C. Kristin Kemnitz-Hassanin expressed and purified eGFP 
C70M S147C according to the protocol of Dominik Schumacher, developed in his PhD 
thesis.262 Initial cellular uptake studies were carried out by Henry D. Herce in the group of 
Prof. Dr. Christina Cardoso and were then transferred to the author, who conducted all 
quantified assays shown in this thesis. 
 
6.2.3 Establishment of Staudinger induced thiol addition with unprotected peptides and 
stability measurements in a model system  
 
The Staudinger induced thiol addition for the conjugation of unprotected bioactive peptides 
to proteins was first established on the model peptide c(RGDfK). The peptide was 
synthesized on solid support according to a published protocol263, differing only in the 
protecting group used on lysine. The Dde protected lysine residue was deprotected 
selectively after head-to-tail macrocyclization and the free ε-amine was reacted with 4-
azidobenzoic acid to give the azido-c(RGDfK) 11 after cleavage from trityl resin. With this 
peptide in hand, we started our investigations into the Staudinger-phosphonite reaction on 
unprotected peptides. The reaction of phosphonite 7 with 11 showed clean conversion to 
the alkyne-c(RGDfK) 12 when carried out in dry DMSO under exclusion of air (Figure 19A). 
Product 12 could be isolated after preparative HPLC in good yields of 54%. The feasibility 
of the thiol addition to the electron-poor alkyne 12 was first tested with glutathione 13. 
When reacting 12 and 13 in equimolar ratio in a mildly basic buffer, the thiol addition 
proceeded quantitatively in less than ten minutes according to LC-UV/MS (Figure 19B).  
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Figure 19: A) Peptide synthesis, Staudinger phosphonite reaction and thiol addition for a modelsystem. B) LC-
UV spectra for the thiol addition of 13 to 12. 
 
The stability of the alkyne 12 as well as the thiol addition product 14 was investigated over a 
broad pH spectrum. The compounds were incubated in buffers ranging from pH 1 to pH 12 
and peptide integrity was assessed via LC-UV/MS read out in presence of an internal 
standard. Here it could be shown that the electron poor alkyne 12 was completely stable at 
neutral pH and only about 10% of hydrolysis could be detected after 24 hours incubation at 
slightly basic and acid pH. High levels of hydrolysis were observed for pH 1.0 and pH 12.0 
after 24 hours incubation. Interestingly, the thiol addition to the alkyne augmented the 
stability of 14 in comparison to 12. 14 showed almost no decay over two days at pH 2.3 to 
pH 9.0. Furthermore, hydrolysis at pH 1.0 and pH 12.0 was slowed down significantly in 
comparison to 12 (Figure 20). Next, we tested if 14 was prone to thiol exchange in the 
presence of high amounts of external thiols, because thiol exchange reactions are the major 
drawback of the ubiquitously used maleimide reaction (see Chapter 4.3.1.1). 
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Figure 20: Stability studies of compounds A) 12 and B) 14 at different pH with read out by LC-UV. 
 
Upon incubation with 100 eq. of MesNa at neutral pH 14 was completely stable over several 
days (Figure 21). When incubating with DTT at pH 7.4, a small additional peak was observed 
in the LC-UV after more than a day, which was correlated by LC-MS measurements to an 
addition of DTT to the alkene in compound 14 (Figure 21B). Here, it is important to note that 
this addition to the alkene did not result in elimination of the covalently attached glutathione, 
which was verified by MS. The same thiol addition to the alkene was observed to a higher 
extend when incubating with 100 eq. of MesNa or DTT at pH 9.0, but no glutathione 
elimination could be detected despite the use of slightly elevated pH values either (Figure 
21B). The observed thiol addition to 14 is a result of the still imminent electrophilicity of the 
alkene in the product. In conclusion it could be shown that treatment of 14 with high 
amounts of external thiols at physiological and slightly basic pH does not lead to the 
elimination of the conjugated cargo (Figure 21B). Furthermore, the alkyne starting material 
12, as well as the thiol addition product 14 were stable towards hydrolysis under 
physiological conditions. Compared to maleimides, which have been shown to undergo 
thiol exchange, these characteristics could be of great importance in the field of cysteine 
bioconjugation, especially when thinking about in vivo pharmaceutical applications. 
However, to verify the phosphonamidat stability in vivo, more stability studies have to be 
conducted e.g. in serum.  
 
Figure 21: A) Product integrity upon incubation with high amounts of external thiols measured by LC-UV/MS 
over time.  B) Overview over stability of peptide 14 and its reaction with external thiols at different pH values.   
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6.2.4 Thiol addition on protein level and in vitro application.  
 
Encouraged by the feasible thiol addition reaction with glutathione and the stability of the 
conjugation product, we probed the thiol addition on protein level. Here, we chose a variant 
of eGFP (eGFP C70M S147C) as model protein with only one addressable cysteine that was 
previously developed in our group.262 To our satisfaction, 12 reacted readily with the protein 
at quantitative yields without any side reactions or multiple additions to the protein, even 
when running the reaction at neutral pH in PBS (Figure 22A/B). After simple spin filtration to 
remove the excess peptide 12, the pure cRGD-tagged eGFP 15 was isolated.  
 
 
Figure 22: A) Synthesis of cRGD-tagged eGFP 15. B) MALDI-TOF of thiol addition. C) Analysis of cellular 
labeling with 40µM protein in U87MG cells by FACS. Error bars correspond to the s.e.m. n=3. Data underwent 
statistical analysis using a one-way ANOVA followed by a Tukey’s multiple comparison to the PBS treated 
control. ***=p<0.001. 
 
To prove the in vitro applicability of the conjugate, a FACS assay with U87MG glioblastoma 
cells, which are known to overexpress integrins on their surface, was set up. Upon 
incubating cells with 40 µM of 15 for four hours, RGD-mediated binding could be analyzed 
by the inherent fluorescence of eGFP in flow cytometry measurements. Here, a significant 
increase of cellular fluorescence was observed upon incubating cells with 15 in comparison 
to a PBS control and a non-tagged eGFP (Figure 22C). Nevertheless, a large amount of 
fluorescence was observed when incubating the U87MG cells with non-tagged eGFP, 
suggesting a high unspecific binding of the protein to the cellular membrane, which could 
not be eliminated by thorough washing prior to the measurements. Furthermore, we 
observed cell detachment from the culture flask during treatment with 15, probably due to 
binding of 15 to integrin and hence hindering the integrin to interact with the extracellular 
matrix. Due to these drawbacks of the assay set up and the desire to test the 
bioconjugation reaction with a more complex biologically active peptide, we planned an 
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analogous synthesis route for tagging eGFP with the cyclic cell penetrating peptides c(Tat) 
and c(R10). 
 
6.2.5 Cell penetrating peptide – protein conjugates 
 
It has been shown previously that the conjugation of c(Tat) or c(R10) peptides to cargos can 
drastically enhance their cellular uptake, even if this cargo is large in size, e.g. a 
protein.121,122 Nischan et al. demonstrated the effective cytosolic uptake of GFP conjugated 
covalently to c(Tat) via CuAAC into HeLa cells. We wanted to follow up on this concept and 
use the novel Staudinger induced thiol addition as an alternative bioconjugation reaction to 
generate the c(Tat)-tagged GFP in a copper-free manner and without the need of 
introducing unnatural amino acids into the protein. Furthermore, it has been reported that 
the poly-arginine peptide c(R10) shows even higher transduction efficiency than c(Tat). This 
has been shown for nanobodies122, which are half the size of GFP and should now also be 
assessed with GFP as cargo.  
We synthesized the already published lactam cyclized CPPs with a PEG-linker and 
conjugated 4-benzoic acid to the N-terminus via SPPS on rink amide resin (Scheme 11A/B).  
 
Scheme 11: A) Structure of 16. B) Structure of 17. C) Conjugation of c(CPP) to eGFP via Staudinger induced 
Thiol addition D) Structure of positive control 22 used in cellular uptake. 
 
The azido-functionalized peptides 16/17 were gained after acidic cleavage and purification 
via preparative HPLC. The pure azido-peptides 16/17 underwent clean reaction with 
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phosphonite 7 in a Staudinger phosphonite reaction to 18/19. After HPLC purification, the 
thiol addition of eGFP C70M S147C to 18/19 was carried out in PBS at 37°C. For a 
quantitative conversion either lower equivalents (6 eq.) of peptide were reacted over night at 
37°C or slightly higher amounts of peptide (20 eq.) gave the product quantitatively after 
incubation for three hours at 37°C in PBS (Scheme 11C). The reaction conditions were 
varied depending on the availability of peptidic starting material. The purification from 
excess peptide could be easily achieved, either by spin filtration (mass weight cut-off 
membrane of 10 kDa) or by using desalting columns (mass weight cut off of 7 kDa). The 
quantitative conversion to the thiol addition product with even larger and more complex 
peptides shows the general utility of this bioconjugation reaction. 
In vitro applicability was verified with cellular uptake studies in HeLa cells, with an 
analogous experimental setup to already published studies.121,122 In short, HeLa cells were 
incubated with varying concentrations of 20, 21 or non-tagged eGFP in HEPES buffer for 
one hour at 37°C. After careful washing with DMEM medium including 10% FBS the cells 
were imaged using a confocal fluorescence microscope. For quantifying the cytosolic 
cellular uptake, the inherent attraction of c(Tat) and c(R10) to the negatively charged 
nucleolus was used. Every cell that exhibited nucleolar GFP fluorescence was counted as 
positive for c(CPP)-mediated cytosolic transduction. The uptake was compared to the 
incubation with non c(CPP) tagged eGFP, which showed no transduction into cells and no 
membrane localization (Figure 23A). As positive control, we incubated cells with TAMRA 
tagged c(R10) peptide 22, which is known to be able to transduce effectively into HeLa cells 
(Scheme 9D, Figure 23B).118 Upon covalent attachment of c(CPP)s to eGFP, protein 
transduction could be clearly observed at all tested concentrations. Using c(Tat)-conjugate 
20 the percentage of cellular uptake increased slightly from 20 µM to 50 µM, but not at a 
significant rate (Figure 23 C). Incubation with c(R10)-conjugate 21 also showed a slight 
increase going from 20 µM to 30 µM, followed by a slight decrease when going up to 50 µM 
(Figure 23C). This behavior can be attributed to 21’s tendency to aggregate. Aggregation 
was already observed after storing 21 for 48 hours at concentrations exceeding 50 µM at 
4°C. Even though c(R10) seems to be slightly more effective in transducing GFP into cells at 
lower concentrations, this difference is not significant (Figure 23C). In comparison, Herce et 
al. reported a three-fold increase in the number of cells that take up their nanobody-CPP-
conjugate for c(R10) compared to c(Tat).122 An explanation for this uptake difference could 
be the significantly lower molecular weight of nanobodies in comparison to eGFP, which 
would be in accordance to previous reports, that the transduction ability of CPP’s is highly 
dependent on the nature of the cargo.101  
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Figure 23: A) Confocal images of cellular uptake of c(CPP) tagged eGFP in HeLa cells at 30 µM. Scale bar = 
20 µm B) Cellular uptake with 5 µM of positive control 22 (TAMRA labeled c(R10)). Scale bar = 20 µm. 
C) Quantification of cellular uptake with eGFP of biological replicates with n≥3. 
 
In order to be able to directly compare the cellular uptake to the results of Nischan et al., 
who also reported cellular uptake with a GFP-c(Tat) conjugates. We set out to study the 
Staudinger-induced thiol addition on the same hsGFP-variant they used. This hsGFP differs 
from eGFP in its protein structure by several point mutations (see Figure 8.10 in Chapter 
8.2.3 for a detailed sequence comparison). Furthermore, Nischan et al. conjugated the c(Tat) 
peptide to the N-terminus throughout CuAAC. In our previous Staudinger-induced thiol 
additions with eGFP C70M S147C, the peptide was conjugated to C147 at the barrel in the 
middle of the protein structure. To find out if the differences in protein sequences and 
attachment point have an effect on cellular transduction, we mutated the hsGFP to contain 
a single addressable N-terminal cysteine for the conjugation with 18. C71 was mutated to 
methionine and the N-terminal S3 to cysteine. Expression of the mutated hsGFP S3C C71M 
was tested in the E. coli strains T7, BL21 and Rosetta (Figure 24A) and was finally 
expressed in bigger scale in BL21 cells at 18°C overnight. The protein was purified by Ni-
NTA column, followed by TEV cleavage and a second purification over a nickel column to 
remove the uncleaved protein and the His-tagged TEV protease. This resulted in the 
isolation of pure hsGFP S3C C71M, which was further verified by MALDI-TOF and SDS-
page (Figure 24B). The N-terminal cysteine was found to be prone to form homodimers and 
therefore had to be reduced with TCEP prior to thiol addition to 18. The addition reaction to 
form the c(Tat)-hsGFP 23 was again quantitative.  
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Figure 24: A) Testexpression of hsGFP S3C C71M in different cell strains. B) Purification of hsGFP S3C C71M 
after TEV cleavage. Pooled fractions are marked in red. C) Confocal images of cellular uptake of 22 in HeLa cells 
at 50 µM. Scale bar = 20 µm D) Quantification of cellular uptake with hsGFP for biological replicates with n≥3. 
 
Interestingly, cellular uptake with 23 at 50 µM protein concentration did not differ much from 
the eGFP mutant 20 and the uptake efficiency was similar to the report from Nischan et al. 
(Figure 24C/D). However, hsGFP 23 displayed a higher interaction with the cellular 
membrane as observed by confocal fluorescence microscopy (Figure 24C), than the eGFP 
construct 20 (Figure 23A). This could pin-point towards a more difficult membrane crossing 
of the hsGFP variant. Lowering the concentration to 30 µM, showed a drastic decrease in 
cellular uptake for the N-terminal tagged hsGFP 23 compared to eGFP 20 (Figure 24D), 
again with high fluorescence at the cellular membrane but lower cytosolic distribution. From 
these cellular images we concluded that the membrane crossing is hindered for the hsGFP 
variant at lower concentrations. Because low concentrations were previously not tested by 
Nischan et al. and the uptake at higher concentrations is comparable to the literature known 
CuAAC conjugated c(Tat)-GFP we conclude that the Staudinger-induced thiol addition is 
generally suitable for in vitro applications.  
To compare the reaction to other cysteine bioconjugation methods, we synthesized c(Tat) 
exhibiting a maleimide in 24 or iodoacetyl in 25 at the N-terminus. After purification, thiol 
addition to the eGFP C70M S147C was carried out with 6 eq. of 24 at 16°C for four hours 
and with 6 eq. 25 at room temperature for three hours (Scheme 12). Conversion to 26 and 
27 was rapid and no unreacted eGFP was observed after four or three hours of reaction 
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time. It should be noted that traces of a side product, corresponding to a double c(Tat) 
addition were observed in the MALDI-TOF spectra during the reaction to 26 (Figure 25A). 
 
Scheme 12: Covalent conjugation of c(Tat) and eGFP via N-terminal A) maleimide or B) iodoacetyl functionality. 
 
Upon cell treatment with the two c(Tat) tagged proteins 26 and 27, we again observed high 
GFP fluorescence in the nucleoli of the cells (Figure 25C). This distinct fluorescence was 
used for quantification (Figure 25B). Here, a significant difference was observed for the 
uptake of 26 compared to 20, with up to 20% more uptake at a concentration of 50 µM for 
26. A possible explanation could be the better cell penetrating properties of the partly 
double conjugated eGFP side product, which had formed during the reaction to 26. 27 
however, showed a slight, but not significant increase in cellular uptake compared to 20. As 
these differences were generated from only three biological replicates, an in depth analysis 
of the bioconjugation influence on the cellular uptake would have to be deducted with more 
replicates at diverse concentrations and on a more elaborated system.  
 
Figure 25: A) MALDI-TOF of bioconjugation to 26 and 27 B) Quantification of cellular uptake with eGFP. Error 
bars correspond to the s.e.m. n≥3. Data underwent statistical analysis using a one-way ANOVA followed by a 
Tukey’s multiple comparison to the PBS treated control. *= p<0.05. C) Confocal images of cellular uptake of 
c(CPP) tagged eGFP in HeLa cells at 30 µM. Scale bar = 20 µm. 
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Nonetheless, in principle this comparison shows that all three cysteine reactive conjugation 
techniques can be used for the covalent labeling of eGFP with c(Tat). Furthermore, all three 
strategies delivered cell permeable eGFP constructs, which could localize in the cytosol and 
the nucleoli inside HeLa cells.  
 
6.2.6 Conclusion and Outlook 
 
In summary, we developed a new cysteine reactive bioconjugation technique for the 
covalent conjugation of unprotected peptides to proteins. We showed that the 
chemoselective Staudinger-phosphonite reaction of alkyne phosphonite 7 with an aromatic 
azide, which was incorporated into the peptide by SPPS, readily delivers the reactive alkyne 
peptide 8 in good isolated yields. Furthermore, we showed that the alkyne peptide 8 is 
stable at neutral to slightly acid or basic conditions for days. Thiol addition to the alkyne 
proceeded fast and quantitative for small molecule thiols as well as for larger, thiol-
containing GFP constructs. Thiol addition product 14 was stable over days at pH between 
2.3 and 9.0 and resistant towards thiol exchange reaction with external thiols, even at high 
thiol concentrations and at basic pH. We further could verified that the conjugation products 
were applicable in in vitro applications by using the Staudinger-induced thiol addition to 
conjugate c(CPP)s to thiol-containing GFP proteins and using the resulting conjugates in 
cellular transduction assays.  
Currently, there are ongoing studies in the group to further explore the broad versatility of 
the Staudinger-induced thiol addition for bioconjugation purposes, especially for 
pharmaceutical applications.  
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6.3 Intramolecular Staudinger-induced thiol addition as a new peptide 
cyclization method 
6.3.1 Introduction of the BCL9 – β-Catenin interaction as therapeutic target  
 
The Wnt signaling cascade is a highly conserved signal transduction pathway that 
influences embryonic development and homeostasis, cell regeneration and renewal in adult 
organisms. During the development stages, the pathway is strictly regulated and any 
mutation or deregulation can trigger diseases. A deregulated Wnt signaling pathway is often 
reported for different cancer types.264–266 There are mainly two different types of Wnt 
signaling cascades: a canonical and noncanonical pathway. Here, we focus on the 
canonical pathway that can lead to gene transcription and is mostly influenced by the 
stability of the protein β-Catenin.  
β-Catenin exhibits two major functionalities. It can be involved in signaling and also in 
structural processes. Structurally, it consists of a central region that is build up from 12 rigid 
Armadillo repeats (R1-12) flanked by specific N- and C-terminal regions that are, in contrast, 
somewhat flexible. In the absence of Wnt ligands β-Catenin is found in the cytoplasm. Here, 
it gets regulated by recruitment into a destruction complex consisting of adenomatous 
polyposis coli (APC), axin and glycogen synthase kinase 3β (GSK3β), where it is 
phosphorylated and targeted for degradation. Low β-Catenin levels and repression of Wnt-
specific target genes characterize the non-activated state.  
If the Wnt signaling pathway gets activated by binding of Wnt proteins to the cell receptor 
frizzled and the Low-density lipoprotein receptors (LRP5/LRP6), the destruction complex 
that regulates β-Catenin is inhibited, leading to a high cytosolic β-Catenin concentration. 
Upon cytosolic enrichment, β-Catenin can translocate into the nucleus, where it forms a 
transcriptionally active complex with LEF, TCF and co-activators such as B-cell 
lymphoma 9 (BCL9) or Pygopus. Upon formation of this transcription complex cell 
proliferation, migration and survival genes are expressed, which drive oncogenesis.266,267 
Many different components in this pathway can act as oncogenes or tumor suppressors. 
One of the oncogenes was found to be the protein BCL9 that is involved in formation of the 
transcription complex.268 It was reported that BCL9 enhances β-Catenin-mediated 
transcriptional activity and BCL9 knockdown increases the survival rate of xenograft mouse 
models. Most significantly oncogenic Wnt target expression could be downregulated by 
shRNA.268 Further it was shown that the PPI between BCL9 and β-Catenin could be 
disrupted by a short peptide that is derived from the structure of BCL9 itself and is 
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stabilized in its α-helical structure by peptide stapling (see chapter 4.2.3). By disrupting the 
PPI with the stabilized peptide oncogenic Wnt transcription was selectively suppressed.269 
6.3.2 Outline of the Project 
 
In this project we aim to engineer an intramolecular variant of the Staudinger-induced thiol 
addition for the cyclization of peptides, in particular to stabilize peptidic structures by 
covalent linkage of two side chains (see chapter 4.2.3). We envisioned incorporating an 
azide and a thiol into a peptide sequence by SPPS, which can then be bridged with an 
unsaturated electron-rich phosphonite. We propose that the phosphonite first reacts 
chemoselectively with the azido moiety of the peptide, upon which an electron poor 
unsaturated phosphonamidate is formed, which is susceptible toward thiol addition as 
shown before (see chapter 6.2). Because the thiol moiety is present intramolecularly in the 
peptide, the addition to the unsaturated phosphonite yields a macrocyclized peptide. The 
order in which the reaction cascade is taking place is controlled, because the thiol reactivity 
is only induced upon Staudinger-phosphonite reaction and the thiol addition can only occur 
on the electron-poor unsaturated phosphonamidate. The interesting aspect in comparison 
to other macrocyclization strategies is that the Staudinger-induced thiol addition is a 
chemoselective way to introduce an electrophilic center into a peptide. Furthermore the 
third substituent on phosphorous that is not directly involved in the bridging of azide and 
cysteine can be further functionalized to fine-tune the peptide’s properties. 
 
 
Figure 26: Schematic project outline of intramolecular peptide stapling using the Staudinger-induced thiol 
addition. 
 
We envisioned the application of this macrocyclization reaction on two different peptide 
substrates. One is the BCL9 derived peptide, which has been previously shown to be 
structurally stabilized in its α-helix by stapling and can effectively inhibit the PPI between the 
BCL9-protein and β-Catenin when present in its cyclized form (Figure 26).269 The other 
peptide is the literature known cell-penetrating peptide cR10, which has been discussed in 
this thesis before (see chapter 6.2).118,122 The macrocyclization of the poly-arginine peptide 
enhances cellular uptake and provides cytosolic delivery of protein cargos.118,121,122 
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In addition to establishing a new synthetic route to macrocyclized peptides via the 
Staudinger-induced thiol addition, we aim for the validation of the intact biological activity 
after macrocyclization and seek to compare our technique with reported strategies. In case 
of the stapled BCL9 peptide, in vitro activity can be demonstrated by its disruption ability of 
the BCL9/β-Catenin complex. For the cell penetrating peptide (cR10), the cytosolic cellular 
delivery properties of the CPP-conjugated eGFP are compared to the lactam-cyclized cR10 
(see chapter 6.2). 
6.3.3 Responsibility Assignment 
 
Christian P. R. Hackenberger conceptualized and designed the project. The author 
synthesized all peptides, conducted the cyclization reactions, characterizations and cellular 
uptake studies. The cyclization reactions with alkene-phosphonites were based on previous 
experiments by Marc-Andre Kasper, who developed the Staudinger induced thiol addition 
with alkene phosphonites for intermolecular reaction with small molecules and ADCs in the 
Hackenberger lab. The homogenous time resolved fluorescence (HTRF) setup was 
discussed with Dr. Jens Peter von Kries and the assay was conducted by Andreas Oder in 
the Screening Unit of the FMP. Dr. Peter Schmieder, Brigitte Schlegel and Niels Trieloff 
carried out cyclization determinations via NMR.  
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6.3.4 Peptide stapling via Staudinger-induced thiol addition 
 
In a report from 2012, a BCL9 derived peptide sequence cyclized by ring closing 
methathesis 28, was shown to effectively disrupt the BCL9 and β-Catenin PPI.269 Due to its 
remarkable in vitro behavior it was chosen to be the model system for the establishment of 
the intramolecular macrocyclization of two amino acid side chains using the Staudinger-
induced thiol addition. To probe the intramolecular stapling by the Staudinger induced thiol 
addition, the BCL9-derived peptide sequence was synthesized with azidohomoalanine and 
cysteine 30 replacing the olefinic amino acids used for RCM in the reported peptide 28. By 
choosing those two amino acids as replacements the final linker after Staudinger 
phosphonite reaction with alkyne phosphonite 7 would have the length of eight atoms in 29. 
This is the same length as found for the literature known RCM stapled peptide with the 
double bond only slightly shifted in the linker structure (Scheme 13).  
 
Scheme 13: Synthesis scheme of the macrocyclization of BCL9-derived peptide by the Staudinger induced thiol 
addition reaction. 
 
After the successful SPPS and purification of peptide 30, the initial intramolecular 
Staudinger-phoshphonite reaction was performed by synthesizing alkyne-phosphonite 7 in 
a Grignard reaction from its chloride and adding it to the peptide solubilized in dry DMSO as 
crude at 50°C. It was observed that the reaction did not proceed cleanly and the major 
product was a side product with a mass difference of 28 Da to the desired product 29. We 
hypothesized an intramolecular alkylation reaction of the amine with the ethyl substituent 
could have resulted in the side product formation. The Hackenberger group has previously 
reported alkylation of the N-substituent during a Staudinger-phosphite reaction at elevated 
temperatures.270 Repetitions of the reaction delivered different amounts of the desired 
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product 29 ranging from moderate to low yields, which illustrates the low reproducibility and 
reliability of the Staudinger-induced thiol addition with alkyne-phosphonamidates.  
Nonetheless, these initial tests provided some useful insights into some aspects of the 
reaction. In particular, the solvent was found to have a major influence on the in situ 
cyclization to the desired product. When the reaction was carried out in dry DMSO, no free 
sulfhydryl groups could be identified by Ellman’s test (Figure 27A). If the reaction was 
carried out in dry DMF instead, the Ellman’s test showed 94% free sulfhydryl groups in the 
sample (Figure 27B). Upon basic incubation of this sample at pH 9.0 only disulfide dimers 
were detected by LC-UV/MS and no thiol addition could be observed for the reaction 
carried out in DMF. Following these discoveries, all reactions were performed in dry DMSO 
to facilitate in situ cyclization. 
 
 
Figure 27: UV traces of ellman’s test with 29 for A) the reaction carried out in dry DMSO and B) the reaction 
carried out in dry DMF. From the difference of absorbance at 412 nm for the sample vs. a blank, the 
concentration of free sulfhydryl groups was determined. 
 
All reactions performed to yield 29 (Scheme 13) were either purified by preparative HPLC 
with acidic or basic eluents. Purification with eluents containing 0.1% TFA resulted in a 
better peak separation compared to the purification in 10 mM ammonium acetate buffer at 
pH 9.0, but also promoted methionine oxidation in reactions using DMSO as solvent. To 
prevent methionine oxidation a slightly different peptide was used in the following 
experiments, where methionine was substituted by norleucine (30a/b) (Figure 28).  
Due to the unreliable reaction rates and poor yields with phosphonite 7, the alkene-
phosphonite 31 was tested in the intramolecular reaction. The synthesis and Staudinger 
induced thiol addition of 31 has previously been investigated in intermolecular reactions by 
Marc-André Kasper in the Hackenberger lab on small molecules and for the generation of 
ADCs. Furthermore, he compared reaction speed of alkene- and alkyne-phosphonites, 
which showed a faster conversion in the Staudinger-Phosphonite reaction but a slower thiol 
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addition with the alkene-phosphonite compared to the alkynes. Hence this established 
alkene-derivative could be transferred to the intramolecular approach and observations 
could be embedded with already known small molecule observations. Here, the alkene-
phosphonite 31 synthesis (Figure 28A) was carried out analogously to the alkyne-
phosphonite 7 (Scheme 11C). The temperature for the Staudinger-phosphonite reaction 
with 31 could be loweredfrom 50°C to room temperature due to faster conversion with 31 
towards 32a/32b compared to the reaction with alkyne-phosphonite 7. The azide 
conversion to the phosphonamidate product was fast and no major side products were 
observed (Figure 28B). Thiol addition to the alkene occurred in situ, which was confirmed by 
NMR (see Figure 10.4 and 10.5 in the Appendix) and Ellman’s test.  
 
 
Figure 28: A) Synthesis route for stapling of BCL9 peptides using the Staudinger-Phosphonite induced Thiol 
addition. B) Analytical UPLC-UV trace of crude reaction mixture of 32b. Product is indicated by asterisk and 
appears as double peak due to formed stereoisomers with phosphorous as stereocenter.  
 
From the detailed small molecule studies of the intermolecular Staudinger induced thiol 
addition with alkene-phosphonites carried out by Marc-André Kasper, we expected the thiol 
addition to the alkene to be much slower at room temperature than actually observed during 
our reactions forming 32a/b. Since the cyclization product was gained quantitatively directly 
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after the Staudinger-phosphonite reaction, we wanted to elucidate the factors that 
contribute to the unexpectedly fast thiol addition.  
First, a proximity-based effect was investigated. The cysteine of 30a was alkylated to give 
33, which was reacted with 31 in presence of glutathione (Figure 29A reaction I). Conversion 
to the glutathione addition product 34 was observed after over night incubation via LC-
UV/MS (Figure 29B) comparable to the reaction with 30a, which indicates that a proximity 
based addition reaction is not responsible for unexpectedly fast and quantitative addition to 
the alkene. Another difference to the intermolecular thiol addition was the thiol addition 
reaction being carried out in pure DMSO. Hence the alkene-phosphonamidate peptide 35 
was synthesized (Figure 29A, reaction II) and after hydrolysis the reaction mixture was 
lyophilized and re-dissolved in dry DMSO. After incubating 35 for 24 hours with equimolar 
amounts of glutathione, no thiol addition could be observed via LC-UV/MS (Figure 29C). 
 
 
Figure 29: A) Synthetic plan for the evaluation of in situ thiol addition B) LRMS for crude reaction I. Expected 
[M+3H]3+ for 34: 1164.5976 m/z. C) LRMS for crude reaction of II after glutathione incubation. Expected [M+3H]3+ 
for 35: 1062.2363 m/z D) Comparison of thiol addition in reaction I, with the alkene imidate present and in 
reaction II with only the alkene amidate available for thiol addition.  
 
This experiment led to conclude that the thiol addition is likely to occur at the imidate stage 
during the Staudinger-phosphonite reaction (see Scheme 8 in Chapter 4.3.2.3), because the 
co-occurrence of the imidate and the thiol is the only difference between reaction I and 
reaction II (Figure 29D).  
Next, we studied the stability of the newly generated phosphonamidate linkage in 32a/b 
over a broad range of pH values. Incubation of 32a at pH values from 7.5 to 11.5 showed no 
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significant degradation of the peptide after four days (Figure 30A). However, at acidic pH a 
second peak appeared in the LC-UV/MS trace over time (Figure 30B), with a mass 
difference of about +18 Da, which could correspond to a water addition after P-N bond 
hydrolysis (Figure 30C).  
 
 
Figure 30: A) Stability studies of 32a at different pHs and comparison to 14. B) LC-UV of 32a incubation at 
pH 3.1 over several days. P-N bond cleavage observed with peak *. C) Overview of expected structures after P-
N bond hydrolysis and tryptic digest cleavage sites. D) Tryptic digest of 32a incubated at pH 1.1 for 48 hours. 
 
To provide further evidence for this, 34a was incubated at pH 1.1 for 24 hours, lyophilized, 
re-dissolved in 100 mM ammonium bicarbonate buffer pH 8.0 and digested with trypsin. In 
the analysis of the tryptic digest via LC-UV/MS, all proposed fragments where observed, 
showing that the P-N bond cleavage is indeed the degradation product found at acidic pH 
(Figure 30D). The overall stability at acidic pH was significantly lower compared to the 
previously investigated phosphonamidate linkage with an aromatic substituent at the 
nitrogen atom in molecule 14 (see Chapter 6.2). The rationale behind the lower stability lies 
in the higher basicity of the aliphatic amine in comparison to the aromatic amine, which 
renders it more susceptible to protonation in acidic media and therefore higher degrees of 
P-N hydrolysis. 
In an attempt to further derivatize this macrocyclization method, the third substituent on the 
phosphorous atom was considered as point of derivatization, as it is not directly involved in 
the formation of the linkage. Different substituents can be envisioned at this position, 
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including hydrophobic or hydrophilic moieties to influence peptidic properties or 
chemoselective handles. Because it is literature known that the cellular uptake of stapled 
peptides is heavily influenced by the overall hydrophobicity of the peptide (see 
chapter 4.2.3.), a more hydrophobic staple linker was synthesized. For this purpose, the 
synthesis route of the phosphonite was changed, starting from bis(diisopropylamino) 
chlorophosphine 36 (Scheme 14). Here, the first step is a Grignard reaction with the vinyl 
phosphine followed by an exchange of the diisopropylamine substituents with benzyl 
groups to yield vinylphosphonite 37. The Staudinger-phosphonite reaction with 37 was 
carried out at slightly elevated temperatures than employed with phosphonite 31, because a 
reduced rate of reaction was observed. The reaction progress was monitored by MALDI-
TOF and gave slightly lower yields compared to the reaction employing 31 after HPLC 
purification.  
 
Scheme 14: Synthesis route for stapling of BCL9 peptides using a benzyl substituted linker. 
 
Unlike before, only the D-cysteine peptide 30b was macrocyclized with 37, because the 
ethyl substituted cyclized D-cysteine peptide 32b showed superior activity compared to L-
cysteine variant 32a in first in vitro test (see Chapter 6.3.6). Finally, the secondary structure 
of all cyclized peptides was analyzed by CD spectrometry. Induction of α-helicity in 32a, 
32b and 38 was compared to the non-cyclized peptide 30b and the literature-known 
stapled version of the BCL9 peptide with methionine substituted to norleucine 39, which 
was synthesized as a reference via SPPS (Figure 31B). After the Staudinger induced thiol 
addition, the helicity increased from 20% for the linear peptide 30b to about 50% for 
peptides 32a, 32b and 38 (Figure 31A). Here, the substituent on the phosphorous atom did 
not influence the secondary structure of the peptide. Even though the helicity increase is not 
as strongly pronounced compared to the literature known RCM stapled BCL9 39, 
nevertheless it is significant. It is known that helicity is not the only factor determining the 
effectiveness of a stapled peptide for PPI disruption, but rather the interplay between the 
cellular uptake and the structural stabilization. Hence, we set out to test the peptides’ ability 
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to disrupt the interaction between the BCL9 protein and β-Catenin PPI in an homogenous 
time resolved fluorescence (HTRF) assay and to evaluate their ability to enter cells. 
 
 
Figure 31: A) CD spectra for BCL9 peptides stapled by Staudinger-induced thiol addition or RCM compared to 
the linear peptide. B) Structure of positive control 39. 
 
6.3.5 Protein expression for HTRF assay 
 
In an HTRF assay, a FRET system is created between two fluorescently labeled antibodies 
recognizing a tag on each of the interacting proteins. If the proteins interact a FRET signal is 
generated. If the interaction is disturbed this signal will vanish. In order to perform HTRF 
assays the interacting proteins will therefore have to be expressed with different tags for the 
antibody recognition. β-Catenin was envisioned as GST-tagged protein and BCL9 as His-
tagged protein. The cDNA for GST-tagged β-Catenin was purchased and the protein 
expression was carried out in BL21 cells at 18°C for 18 hours. After expression, harvesting 
and lysis of the cells the pure protein was obtained after a straightforward purification over a 
GST-column (Figure 32).                       
 
Figure 32: A) Purification of GST- β-Catenin. B) Pooled elution fractions rebuffered to PBS. 
 
For the His6-tagged BCL9 protein, the interacting protein domain of BCL9 [243 – 469] was 
ligated into a pET-28a vector exhibiting a N-terminal thrombin cleavage site and a C-
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terminal His6-tag. First attempts using NheI and XhoI restriction sites failed in the ligation. 
After switching restriction sites to BamHI and HindIII, the ligation and transformation 
delivered positive colonies with the expected DNA sequence. Expression was tested in two 
different cell strains at 18°C and 37°C. In these test expressions, an overexpressed protein 
was observed in an SDS gel at the migration height of 35 kDa (Figure 33A). As the expected 
protein has a mass of 27162 Da, the test expression from BL21 cells at 18°C was purified 
over Ni-NTA beads and the pooled elution fractions were analyzed by MALDI-TOF. A single 
peak with the expected mass was observed, confirming the successful cloning and 
expression of the desired protein. On these grounds, a big scale expression of BCL9-His6 
was conducted in BL21 cells at 18°C for 18 hours. After harvesting, cell lysate was purified 
via Ni-NTA beads (Figure 33B) and polished in a size exclusion chromatography (SEC) step 
to yield the pure His6-tagged BCL9 protein (Figure 33C). The pooled fractions were analyzed 
with MALDI-TOF, which confirmed the isolation of pure protein (Figure 33D). With these 
proteins in hand we performed the in vitro assays to determine the inhibitory activity of our 
macrocyclized peptides on the PPI between BCL9 and β-Catenin.  
 
 
Figure 33: A) Test expressions of BCL9-His
6
 in different cell strains and under different conditions. B) Purification 
of BCL9-His
6
 via Ni-NTA beads. C) Further purification via SEC. D) MALDI-TOF spectra of pooled fractions. 
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6.3.6 Functionality assays with cyclized peptides 
 
The HTRF assay was first conducted on the ethyl-substituted peptides 32a and 32b and 
was then compared to literature values. An inhibition of the protein-protein interaction was 
observed at nanomolar IC50 values for both peptides. The D-cysteine peptide 32b however, 
could be identified as the most potent inhibitor with an IC50 of 144 nM, which is comparable 
with the IC50 value determined by GST-pulldown assays and reported in literature for the 
RCM stapled peptide269. Encouraged by these results we also tested a more hydrophobic 
phosphonite in the Staudinger induced thiol addition with the D-cysteine peptide 30b (see 
chapter 6.3.4). For this benzyl substituted cyclized peptide 38 an almost identical IC50 value 
was observed in the HTRF assay, which illustrates that a more bulky substituent does not 
influence the disruption ability of this peptide inhibitor. As negative control a scrambled 
version of the BCL9-peptide (QSEQLERLEHRLQAhaRTLCNleSILRF - 40) was used in the 
assay, which showed no inhibitory activity at all (Figure 34). The literature-known RCM 
stapled peptide 39 served as positive control. Surprisingly, 39 inhibited the protein-protein 
interaction between BCL9 and β-Catenin with a much higher IC50 value compared to 32b 
and 38 and was not in accordance with the reported IC50 value by Takada et al.. Because 
two different assays were used to determine the IC50 values, which limit their comparability, 
we decided to investigate the binding affinity of the peptides to β-Catenin by ITC to gain 
more insight into the binding behavior of the cyclized peptides. Unfortunately, the peptides 
were not soluble at the concentrations needed for well-resolved signals in the ITC set-up. 
Especially peptide 39 was observed to be hardly soluble at concentrations exceeding 
40 µM. Furthermore precipitation was observed during the titration of 39 to β-Catenin 
pointing also towards insolubility of the peptide – protein complex. This insolubility, which 
was much more pronounced for 39 compared to 32b or 38, could also be the reason for the 
surprisingly high IC50 value determined in the HTRF-assay. 
 
Figure 34: Inhibition of BCL9 – β-Catenin in HTRF assay. 
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In order to reach its intracellular target, the stapled peptides need to translocate into cells. 
The cellular uptake of cyclized peptides was to be analyzed by confocal fluorescence 
microscopy with HeLa cells, for which fluorescently labeled peptides were synthesized by 
attachment of fluorescein to the N-terminus of the peptide (Figure 35A/B). Cells were 
incubated with 10 µM peptide in serum free DMEM for two hours and imaged afterwards. 
The peptide fed to the cells consisted of only 10% fluorescein-labeled peptide to ensure 
that self-quenching is not hampering the fluorescence read out during microscopy. At first, 
only bright dots were visible for 38 and 39, suggesting the peptides were trapped in 
endosomes. Upon imaging for longer than 20 seconds using an argon laser at 488 nm, 
bright fluorescence was observed over the whole cell for both peptides. This phenomenon 
could be explained by an endosomal disruption induced by laser irradiation during the 
imaging process. When comparing the fluorescence intensity inside cells, it was apparent 
that peptide 32b did not show any uptake. Compared to that, a significant amount of the 
benzyl substituted linker peptide 38 had been taken up by the cell, comparable to the RCM 
stapled peptide 39 (Figure 35C). However, it should be noted that all the peptides were first 
trapped in endosomes, which makes a quantitative comparison difficult. Nonetheless, this 
shows that a more hydrophobic linker does have a significant influence on the cellular 
uptake, which has also been observed by the Futaki lab recently.271 Using the O-substituent 
for influencing hydrophobicity of the linking molecule seems to be feasible and indeed has 
dramatic effects on the cellular uptake.  
 
 
Figure 35: A) Synthesis of FAM-labeled BCL9 peptides cyclized via Staudinger induced thiol addition. B) 
Synthesis of FAM-labeled BCL9 peptide, which is stapled via RCM. C) Cellular uptake of 10 µM peptide (10% 
FAM-labeled peptide) for 3 h at 37°C 5%CO
2
 in HeLa cells. Pictures show the overlay of FITC fluorescence and 
Hoechst stain after 2/10/20 seconds of imaging with an argon laser (405/488 nm). Scale bar = 20µm. 
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6.3.7 Intramolecular cyclization of R10 peptide.  
 
As second substrate for the intramolecular Staudinger induced thiol addition, the cyclic cell 
penetrating poly-arginine peptide c(R10) was chosen (see chapter 6.2). The linear R10 
peptide 41 with a C-terminal cysteine and an azidohomoalanine N-terminally of the 
polyarginine segment was synthesized by Fmoc-based automated SPPS. After purification 
of peptide 41 via preparative HPLC, the azidohomoalanine was reacted with the crude 
alkene phosphonite 31 analogously as done for the BCL9 peptide 30 (see chapter 6.3.4). 
After over-night reaction and purification, the successful cyclization to 42 was confirmed by 
a negative Ellman’s test and via NMR. To assess the cell-penetrating properties of the 
c(R10), we tested the bioconjugation to eGFP C70M S147C and compared it to GFP 
conjugate 21 in its cellular transduction behavior (see Chapter 6.2). For this purpose, the 
free N-terminus was functionalized with an alkyne phosphonamidate-NHS building block 
(43), which was synthesized by Marc-André Kasper in the Hackenberger group (Figure 36A).  
 
 
Figure 36: A) Synthesis route for Staudinger induced thiol addition cyclized R10 functionalization of eGFP C70M 
S147C B) MALDI-TOF of thiol addition eGFP to 44.  
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After amide bond formation and purification, peptide 44 only differed to peptide 19 in the 
linker used for cyclization. The conjugation towards eGFP C70M S147C was carried out 
under the same reaction conditions as for the lactam cyclized CPPs (see chapter 6.2.), 
yielding 45 in a quantitative fashion according to the MALDI spectra (Figure 36B). The 
biological behavior of peptide – protein conjugate 45 was now directly comparable to 21 in 
cellular uptake studies. The c(R10)-eGFPs were incubated for one hour with HeLa cells at 
37°C in HEPES buffer, afterwards washed with DMEM including 10% FBS and then imaged. 
For quantification purposes the nucleus was stained with Hoechst. In three biological 
replicates no significant differences were observed for the intramolecular Staudinger 
induced thiol addition cyclized cR10-eGFP conjugates compared to the lactam cyclized 
peptide-protein conjugates (Figure 37A). Both conjugates showed mainly diffuse cytosolic 
and nucleolar localization of GFP fluorescence, which accounts for the cytosolic availability 
of the protein (Figure 37B).  
 
 
Figure 37: Cellular uptake of CPP-eGFP conjugates A) Quantification of cellular uptake of three replicates 
B) Confocal images scale bar = 10 µm.
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6.3.8 Conclusion and Outlook 
 
In summary, we applied the Staudinger induced thiol addition as an intramolecular 
macrocyclization tool on two different peptidic targets. The cyclized BCL9 derived peptides 
showed an increased α-helicity upon macrocyclization and were capable of disrupting the 
protein – protein interaction between the BCL9-protein and β-catenin at nanomolar 
concentrations in an HTRF assay. We furthermore demonstrated that the interchangeable 
substituent on the phosphorous could be used to influence the peptides hydrophobicity, 
which facilitated cellular uptake. In a second example, the Staudinger induced thiol addition 
was used for the macrocyclization of a polyarginine peptide, in which the reacting amino 
acid side chains were separated by a longer peptide sequence than in the BCL9 peptide. In 
this case the macrocyclization was also successful and delivered bioactive peptides, whose 
transduction behavior were compared with the lactam-cyclized peptides investigated in 
chapter 6.2. It was shown that the macrocyclization of the cell penetrating peptide via 
Staudinger induced thiol addition facilitates transduction of a covalently conjugated eGFP 
into HeLa cells to the same extend as lactamization does. The use of easily incorporable 
functional groups for the cyclization reaction via SPPS as well as the ability to adjust the 3rd 
substituent on phosphorous of the phosphonite clearly demonstrates the great feasibility of 
this cyclization strategy.  
Future projects will focus on evaluating the influence of different P(III) substituents on the 
structure and biological behavior of cell-penetrating peptides. Furthermore one could 
envision the usage of this substituent as anchoring point for the introduction of other 
functional tags. It is also possible that this reaction could be used for generating highly 
efficient cyclic cell-penetrating peptides in an expressed protein system of interest without 
the need of external peptide synthesis and bioconjugation. Here, we envision the expression 
of a linear CPP-tagged protein, including a spacer, azidohomoalanine, the CPP sequence 
and a cysteine (Figure 38). After expression and purification, the azidohomoalanine could be 
reacted chemoselectively with an alkene-phosphonite and thiol addition to the proximal 
cysteine would generate the c(CPP) tag without the need of peptide synthesis and 
bioconjugation.  
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Figure 38: Concept for the expression of a CPP-tagged protein and its intramolecular cyclization. 
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6.4 Diazo-functionalized CPPs for bioreversible esterification of proteins 
6.4.1 Outline of the Project 
 
In this project we wanted to apply the literature-known bioreversible esterification of 
proteins with diazo compounds152,155 as alternative bioconjugation strategy for the 
generation of cyclic CPP – protein conjugates. To conjugate peptides to proteins, 
esterification via two different routes was envisioned. One route was the N-terminal 
functionalization of the c(R10) peptide 47 with the NHS – diazo building block 46, followed 
by straightforward esterification of eGFP with this diazo-c(CPP) 48 (Figure 39A). The second 
route was the esterification of eGFP with the diazo-compound 50 bearing an alkyne handle, 
followed by post-esterification modification with an azide-functionalized c(CPP) 52 via 
CuAAC (Figure 39B).  
 
 
Figure 39: Bioreversible cCPP conjugation to eGFP by esterification with diazo compounds. A) Route via diazo-
peptide. B) Route via post-esterification functionalization. 
 
After esterification, the cellular uptake of the c(CPP)-protein conjugate should be monitored 
by fluorescence microscopy by exploiting the inherent fluorescence of GFP. Furthermore, 
the bioreversibility of the ester formed in the conjugation was to be analyzed in vitro. The 
c(CPP) – eGFP constructs, which were already described in this thesis (Chapter 6.2 and 
6.3), served as the perfect model system for this purpose, thanks to the c(CPP)’s attraction 
towards the nucleolus of the cell. It has been shown previously that this attraction is strong 
enough to transport covalently bound cargos like eGFPs towards the nucleolus. We 
hypothesized that upon cellular transduction the ester-linked c(CPP) – eGFP conjugate gets 
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cleaved by esterases inside the cell. As the eGFP without the c(CPP) does not exhibit any 
nucleolar attraction it would remain freely inside the cytosol, without nucleolar localization, 
making the cleavage well observable by microscopy. With this setup, the esterification of 
c(CPP)s to eGFP was established with two different diazo building blocks and finally the 
conjugates were envisioned to be tested in their cellular uptake behavior using fluorescence 
microscopy.   
 
6.4.2 Responsibility Assignment 
 
The project was designed and planned by Prof. Dr. Christian P.R. Hackenberger and Prof. 
Dr. Ronald T. Raines. Dr. Kalie Mix synthesized the diazo compounds 46/50 as part of her 
PhD thesis. The author synthesized the peptides, performed the peptide functionalizations 
with the provided diazo compounds and conducted esterification reactions on protein level. 
Kristin Kemnitz-Hassanin expressed and purified the eGFP C70M S147C according to the 
protocol Dominik Schumacher developed in his PhD thesis.262 Initial cellular uptake studies 
were carried out by Henry D. Herce in the group of Prof. Dr. Christina Cardoso and were 
continued by the author.  
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6.4.3 Results and Discussion 
6.4.3.1 Esterification via diazo functionalized peptide (Route A) 
 
We started our investigations with the synthesis of the diazo-functionalized peptide 48. To 
do so, the cyclic R10 peptide 47 was first synthesized by SPPS. After cleavage of the 
peptide from solid support and its purification, the free N-terminus was reacted with the 
NHS-diazo building block 46 to form a stable amide bond (Figure 40A). The reaction was 
complete after four hours and the functionalized peptide could be precipitated from the 
reaction mixture in cold diethylether to provide 48 in purity >90% (Figure 40B). Due to the 
high lability of the diazo group, purification via HPLC was avoided. As the amide bond-
forming step was conducted on a deprotected peptide, the reaction was limited to peptides 
with only one free amine and was therefore compatible with the structure of c(R10), but not 
c(Tat) (see Chapter 6.2). Functionalization of the protected peptide attached to solid support 
was not possible due to the inherent lability of the diazo compound towards acids that 
would be needed for deprotection and cleavage. With 48 in hand, we set out to test the 
esterification on protein level using eGFP C70M S147C as model substrate (Figure 41A).  
 
 
Figure 40: A) Synthesis of diazo-functionalized cR10 and B) LC-UV spectra of 48. 
 
The esterification reaction was carried out in different buffers with or without additional co-
solvent and at pH ranging from 5.8 to 7.4 for 4 to 16 hours. All reactions were carried out at 
37°C with varying equivalents of peptide 48 (Table 3). Our first observation was that the 
reaction did not proceed in PBS at pH 7.4 (Entry 1) and it is indeed known that the targeted 
carboxylic acid needs to be deprotonated in order to react in an esterification. We lowered 
the pH to 5.8, which is roughly the pH that was used in previous protein esterifications with 
diazo compounds.155 We observed that eGFP precipitates at this pH, even when using a 
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buffer with high NaCl content (Entry 3-4). At pH 6.5, the eGFP also precipitated when using 
a buffer without additional NaCl (Entry 2). However, by adding 100 mM NaCl to the buffer, 
the protein remained solubilized and the reaction proceeded to a satisfying result of up to 
two peptides bound to eGFP (Entry 6). As it has been reported before that a buffer-
acetonitrile mixture provides the best conjugation results152,155, the reaction was also probed 
with an additional 20% of acetonitrile, which also led to protein precipitation (Entry 5). 
Finally, 10 mM BisTris buffer with 100 mM NaCl at pH 6.5 was chosen as optimal reaction 
buffer, since the eGFP used showed the highest stability in these conditions. To further 
optimize the reaction, it was conducted with different equivalents of 48, different reaction 
times and purification methods. First of all, we discovered that prolonging the reaction time 
from 4 to 16 hours did not yield significantly more conjugation product (Entry 8/9). When 
comparing different amounts of 48 added to the reaction, it was observed that 10 
equivalents yielded a mixture between 0 – 1 modifications, whereas at 50 equivalents 
yielded 1 – 3 modifications. Another interesting observation was the influence of the 
purification method on the result. When Zeba spin desalting columns (MWCO 7 kDa) were 
used, we could not observe high amounts of eGFP with multiple copies of peptide attached, 
probably due to a tendency of the multiply cR10-tagged GFP to unspecifically bind to the 
column material (Figure 41B, Entry 9).  
 
Table 3: Screening of different conditions for esterification of eGFP. * = including 100 mM NaCl. 
entry buffer time eq. of 48 pH purification result from MALDI 
1 PBS 4 h 50 7.4 ZebaSpin no reaction 
2 10 mM BisTris 4 h  50 6.5 - precipitation 
3 10 mM BisTris* 16 h 10 5.8 - precipitation 
4 10 mM BisTris* 16 h 30 5.8 - precipitation 
5 
10 mM BisTris* 
+ 20% MeCN 
4 h 50 6.5 ZebaSpin 
precipitation after two 
hours 
6 10 mM BisTris*  4 h 50 6.5 ZebaSpin 0 – 2 modifications 
7 10 mM BisTris* 16 h 50 6.5 dialysis 1 – 3 modifications 
8 10 mM BisTris* 4 h 30 6.5 ZebaSpin 0 – 2 modifications 
9 10 mM BisTris* 16 h 30 6.5 ZebaSpin 0 – 2 modifications 
10 10 mM BisTris* 16 h 30 6.5 dialysis 1 – 3 modifications 
11 10 mM BisTris* 16 h 10 6.5 ZebaSpin 0 – 1 modifications 
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In contrast when using dialysis for purification, we observed a distribution of up to three 
modifications (Entry 7 and 10). Taken together all these observations, we synthesized 
different eGFP constructs with either predominantly double (conditions for Entry 10) or 
single c(R10) conjugations (conditions Entry 8), to test whether multiple peptide copies have 
an effect on the cellular uptake rate and if the ester is cleaved inside the cell to release the 
model cargo eGFP from the peptide.  
 
 
Figure 41: A) Esterification of eGFP with 48. B) MALDI-TOF analysis for entry 8 and 10 of table 3. 
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6.4.3.2 Post-esterification peptide functionalization via CuAAC (Route B)  
 
Since the direct site-specific peptide functionalization with the diazo compound 46 is limited 
to peptides with only one free amine in their sequence, we also explored the more flexible 
possibility of esterifying a protein with diazo compound 50 first, before further 
functionalizing the conjugated reactive handle via CuAAC (Figure 39B). The peptides 
employed for the conjugation were azido-functionalized cyclic Tat 52a (Scheme 15A) and 
azido-functionalized Cy3-tagged cR10 52b.  
 
Scheme 15: A) Synthesis of 52a. B) Synthesis of 52b. 
 
The first step of the protein conjugation was the esterification with diazo compound 50. The 
reaction was carried out in a BisTris buffer at pH 5.8 with 1% DMF. The amount of 
carboxylic acid side chains esterified with the alkyne, could be influenced by adjusting the 
reaction time and the number of diazo equivalents (Table 4). The CuAAC with peptide 52a 
was carried out with an alkyne-functionalized eGFP 51 with up to five modifications, 
synthesized using the conditions described in entry 4 (Table 4), because our initial goal was 
to conjugate multiple peptide copies to eGFP (Table 4; Figure 42B, Entry 4). 
 
  Table 4: Screening of different conditions for esterification of eGFP.  
entry eq. of 50 time results according to MALDI 
1 20 2 h 0 – 1 modifications 
2 20 4 h 0 – 2 modifications 
3 20 16 h mainly 3 modifications 
4 30 16 h 2 – 5 modifications 
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Figure 42: A) Synthsis of alkyne tagged eGFP and further functionalization with c(CPP)s. B) MALDI-TOF spectra 
of sterification screen with 50. C) MALDI-TOF of 53a. D) SDS-page of 53b. 
 
In the subsequent CuAAC reaction we reacted 51 with 25 equivalents of 52a. After 
overnight reaction, 51 had only reacted partially to the single modified peptide – protein 
conjugate 53. Due to the already heterogeneous mixture of the starting material 51, the 
analysis of product 53 via MALDI-TOF showed broad peaks, most likely due to the high 
complexity of the final product 51 (Figure 42C). To reduce this complexity, especially when 
synthesizing the FRET-system, we focused on synthesizing lowly functionalized version of 
protein 51. We aimed at a maximum functionalization of two alkynes per protein by using 20 
equivalents diazo compound 50 for four hours during the esterification reaction (Figure 42B, 
Entry 2). The CuAAC with 52b was then carried out with 1.1 equivalents of azido peptide 
52b and was analyzed by SDS-Page (Figure 42D). Purification was carried out via different 
methods, namely dialysis, spin filtration and purification via desalting columns, in order to 
compare their performance. Due to the high hydrophobicity of the Cy3-label, multiply 
tagged eGFPs were prone to stick to both dialysis tubing and spin filters. The best recovery 
was achieved by using desalting columns (MWCO 7 kDa), which yielded 53b in a mixture of 
mainly 0 – 1 peptides attached (Figure 42D).  
 
Results and Discussion 
 88 
6.4.3.3 In vitro application of ester linked cCPP-eGFP  
 
Cellular uptake studies were carried out with HeLa cells in HEPES Buffer with 49 modified 
with mainly one cR10 (Figure 43A, Table 3: Entry 6). The cells were incubated with 10 µM of 
49. In the confocal images, a high cellular uptake into the cytosol as well as the nucleolus 
was observed, hinting towards an insufficient or slow cleavage of the ester bond by 
esterases inside the cell. Furthermore, we observed a very high toxicity in the cells that has 
not been observed for the cCPP-eGFP conjugates discussed previously in this thesis. After 
one hour of incubation, most of the cells that showed high fluorescence were still attached 
to the Ibidi-slide, but were rounding up. Therefore they were found in a different plane in 
confocal microscopy compared to the ones with lower fluorescence. Also they showed a 
completely different Hoechst staining pattern compared to the cells with little or no uptake 
(Figure 43B).   
 
Figure 43: A) MALDI-TOF of 49 used on HeLa cells. B) Confocal images of HeLa cells after incubation with 49. 
Scale bar = 20µm. 
 
Multiple factors could be the cause for the observed toxicity. On one hand, the amount of 
doubly modified protein used in the cellular experiments could lead to a much higher 
toxicity than previously observed for the singly modified c(CPP) – eGFP constructs (Chapter 
6.2 and 6.3). But also when using fewer equivalents in the esterification, resulting in lower 
amounts of doubly esterified 49, cytotoxicity in the cellular uptake study was not reduced. 
Another factor could be the ester linkage itself, because this constitutes the biggest 
difference to 20. Due to this toxicity effect, we did not further test compounds in vitro and 
studies to explain toxicity have not yet been conducted.  
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6.4.4 Conclusion and Outlook 
 
In summary, we showed that the esterification with diazo-compounds could be carried out 
with functional peptides on protein level using two different diazo building blocks. 
Furthermore, we found that the amount of peptidic copies covalently attached to the protein 
can be influenced by the amount of diazo-compound added and by the length of reaction 
time. Unfortunately the in vitro application of final peptide – protein conjugates revealed high 
toxicity of 49 due to an unclear cause.  
This toxicity needs to be further evaluated and pin pointed toward either the conjugation 
method, the multiple attachments of cyclic cell penetrating peptides or a different not yet 
considered source, by testing a more defined system in vitro.  
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7 Summary  
 
Throughout this work the high versatility of peptides could be used to address diverse 
targets. Peptides could be applied as protein – protein and protein – ligand inhibitors as well 
as cellular transduction tags. A special focus was further laid on their bioconjugation to 
protein or polymer scaffolds to either foster their potency or simply transfer their properties 
to a cargo of choice. For these purposes, this work resulted in a bioconjugation method that 
cannot only conjugate a chemically modified peptide to a protein cargo, but which can 
further induce intramolecularly a function within the peptide itself by constraining its 
conformation, which underlies that function.  
 
Project 1: Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus Inhibition.
In nature many tight binding events are built up by multiple low affinity interactions 
happening in close proximity on the same target. This concept is termed multivalency and 
was used in this project for the creation of a virus blocking peptide-polymer-nanoparticle. 
Here presentation of multiple peptidic HA binding ligands on a nanoparticle, which consists 
of polyglycerol was the underlying rational (Figure 44).  
In this thesis it was shown in vitro as well as in vivo that using this concept leads to the 
development of a potent inhibitor for the infection of cells with the influenza virus. The 
hemagglutinin binding peptide sequences PeB and PeBGF have previously been generated 
from the CDR-domain of the HA binding antibody, with higher monovalent binding affinities 
towards HA than its natural ligand sialic acid and was thought to be even more potent in a 
multivalent setting.33 The polymer scaffold offered the opportunity to vary the size as well as 
the density of presented peptidic ligands, which were compared in initial in vitro assays. The 
ligand was conjugated onto differently sized polymers (3a – 6a) that were functionalized 
with azido groups at varying densities throughout CuAAC. 
  
 
Figure 44: Schematic outline of the generation of entry blockers for the influenza – virus. 
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Comparing the different conjugates, we found that the biggest nanoparticles with a ligand 
density of about 1.0 ligand/nm2 (6b and 6d) gave indeed the best results in 
hemagglutination inhibition assays as well as infection inhibition assays. We further carried 
out in vivo tests in mice, which also verified the applicability of multivalent peptide-polymer-
nanoparticles for the inhibition of influenza virus infection. 
 
Project 2: Staudinger-induced thiol addition as cysteine reactive conjugation. 
In this project we applied the Staudinger induced thiol addition for the additive free 
conjugation of biological active peptides to proteins. First this reaction was tested on the 
small cyclic RGDfK peptide272. Here the Staudinger phosphonite reaction was carried out 
between the 4-azido-benzoic acid, incorporated into the peptide by SPPS, with the electron 
rich alkyne phosphonite 7 to yield an electron poor phosphonamidate 12. Thiol addition to 
12 was first tested with glutathione and the conjugation products 14 stability was analyzed. 
Here, it was found that the conjugation product exhibits a high stability between pH 2.3 and 
pH 9 and does not show any signs of thiol exchange, when being incubated with high 
excess of external thiols. This poses an advantage to the often-used maleimide 
bioconjugation. 
The bioconjugation toward proteins was addressed. A quantitative conjugation of alkyne 
peptide 12 to eGFP was achieved. Due to this demonstration of feasible bioconjugation 
between peptides and proteins, the application was expanded to more challenging peptide 
substrates cTat 16 and cR10 17. In all cases the activated electron poor alkyne peptides 
(18/19) were yielded after Staudinger-phosphonite reaction with 7, and could be further 
conjugated quantitatively to eGFP (20/21). In vitro applicability of these cCPP-eGFP 
conjugates was verified by cellular transduction, which was compared to literature121 and 
literature known cysteine bioconjugation reactions, namely maleimides and iodocarbonyl 
linkers. Here it could be shown that the phosphonamidate thiol adduct linked cCPP-eGFPs 
are indeed capable to transduce into cells. Further the transduction behavior is comparable 
to cCPP-eGFP conjugates obtained by other cysteine reactive bioconjugation methods and 
also to previous reports using CuAAC121 for bioconjugation, making the Staudinger induced 
thiol addition an attractive strategy for chemoselective incorporation of a cysteine reactive 
handle into peptides and its further use in bioconjugations. 
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Figure 45: Schematic outline of the Staudinger induced thiol addition for bioconjugation of functional peptides 
with proteins, with an overview of substrate used in the reaction. 
 
Project 3: Intramolecular Staudinger-induced thiol addition as new peptide cyclization 
method. 
Intrigued by the feasible intermolecular bioconjugation via the Staudinger induced thiol 
addition shown in project 2, we set out to also investigate the reaction in an intramolecular 
fashion, as novel peptide macrocyclization strategy. Two different peptide substrates were 
synthesized with an azidohomoalanine as well as a cysteine at strategic points in their 
structure to demonstrate macrocyclization using a phosphonite linker. A literature known 
peptide derived from the BCL9 protein was envisioned to be stabilized in its α-helical 
structure by covalently linking two amino acid side chains in i, i+3 position representing one 
helical turn (Figure 46A). In addition, the R10 peptide discussed previously in project 2, was 
anticipated to be macrocyclized in order to promote its cellular transduction efficiency, 
which it only exhibits upon cyclization as described previously in literature (Figure 46B).118,121 
The intramolecular Staudinger-induced thiol addition on BCL9-peptide 30 was carried out 
using alkene-phosphonites 31 and 36, which reacted successfully with the via SPPS 
incorporated azidohomoalanine, upon which the thiol addition of cysteine to alkene was 
observed in situ. Upon covalent linkage an increase in peptidic helicity was observed via 
CD-spectrometry, indicating the stabilization of the helical structural motif. It is known that 
upon macrocyclizing this peptide sequence via RCM, it is capable to disrupt the BCL9 – β-
catenin interaction. This behavior was also evaluated for the Staudinger cyclized peptides 
and an almost identical IC50 value could be determined for the Staudinger linked peptide 
compared to the literature values for the RCM-linked peptide. Furthermore, the reaction with 
an alkene-phosphonite 36 with a more hydrophobic O-substituent could be carried out 
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successfully. The more hydrophobic linker did not interfere with the stabilization of helical 
conformation or the peptides ability to disrupt interaction of BCL9 and β-Catenin 
(Figure 46A). In cellular uptake assays a higher endosomal uptake could be observed for the 
more hydrophobic peptide, which showed comparable uptake behavior than the RCM 
stapled literature known peptidic inhibitor.  
 
Figure 46: Schematic outline of the literature known peptides and its macrocyclized variants obtained by 
intramolecular Staudinger induced thiol addition for A) the BCL9-peptide and B) the c(R10) peptide. 
 
Furthermore, the intramolecular Staudinger induced thiol addition was used in the 
cyclization of the R10 peptide, which was cyclized by lactamization in project 2. Here 
cysteine was incorporated at the C-terminus and azidohomoalanine N-terminally from the 
arginine sequence by SPPS. Both functionalities were covalently linked by 
alkenephosphonite 31. After cyclization and conjugation to GFP, the cellular transduction 
properties were directly comparable to the lactam-linked peptide – protein conjugate 21. 
Here the applicability of this linker in vitro was confirmed as well as its transduction 
properties, which were similar compared to the ones of lactam-cyclized peptides. Also for 
the cR10 peptide the derivatization of the O-substituent in the phosphonamidate linker 
could be of great interest in future projects. Here a methodological correlation between 
peptidic properties and cellular transduction ability could be established in a feasible 
manner. 
 
Project 4: Diazo-functionalized CPPs for bioreversible esterification of proteins  
The aim of this project was the generation of intracellularly cleavable cCPP-eGFP 
conjugates by esterification of carboxylic acids on GFP with cCPPs throughout diazo 
compounds. The reaction itself was developed in the Raines lab152,155, who also provided the 
diazo building blocks used in this project. Here two different routes of bioconjugation were 
explored. One route was the N-terminal functionalization of the to be conjugated peptide 
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with an NHS-diazo building block 46, followed by the direct esterification with the protein 
(Figure 47, Route A). The cyclic R10 peptide was successfully functionalized with 46 and 
esterification was tested on eGFP. Here it was shown that the amount of conjugated 
peptide could be controlled, by varying peptide equivalents.  
In parallel a second approach for the diazo mediated conjugation was tested. Here the 
protein was first esterified with diazo-alkyne building block 50, followed by a CuAAC with an 
azido-functionalized peptide-tag. Due to the fact that two non-quantitative reactions are 
carried out on protein level, this route was producing diverse conjugation product mixtures 
(Figure 47, route B). Nonetheless, this reaction sequence allowed the conjugation of more 
complex peptides, which cannot be functionalized with diazo compound 46, Conditions 
were found to control the amount of alkyne handles attached in the esterification step and 
the CuAAC with azido-peptides cTat 52a and Cy3-cR10 52b to alkyne tagged GFP was 
successfully carried out.  
Finally cR10-eGFP conjugates, gained throughout route A with mainly one cR10 peptide 
attached to GFP were tested for their transduction capability in HeLa cells. Unfortunately 
the treatment of cells showed high toxicity, which could not be explained in the presented 
set up and should be elucidated further in the future.  
 
 
Figure 47: Schematic outline of bioreversible conjugation of CPPs to eGFP using diazo compounds. 
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8 Experimental Part 
8.1 Materials and Methods 
 
Reagents and solvents, unless stated otherwise, were commercially available and used 
without further purification. Amino acids and resins for SPPS were purchased from 
Novabiochem (Merck) or Iris Biotech GmbH.  
Compound 43 was synthesized and characterized by Marc-Andre Kasper throughout his 
PhD Thesis in the lab of Prof. Dr. Christian Hackenberger.  
Compounds 46 and 50 were synthesized and characterized by Dr. Kalie Mix throughout her 
PhD-Thesis in the lab of Prof. Dr. Ronald Raines.  
Dendritic Polyglycerols were synthesized and characterized by Markus Hellmund during 
his PhD Thesis in the lab of Prof. Dr. Rainer Haag.  
NMR 31P-NMR spectra were recorded on a Bruker AV300. The chemical shifts are reported 
in ppm relative to the residual solvent peak. 1H-NMR spectra were recorded on a Bruker 
300 UltraShield in [D6] DMSO. The chemical shifts are reported in ppm relatively to the 
residual solvent peak 
SPPS was carried out manually or on a Tribute-UV peptide synthesizer (Protein 
technologies, USA) via standard Fmoc-based protocols. 
Preparative HPLC of peptides was carried out on a Gilson PLC 2020 personal Purification 
System (Gilson Inc., Middleton, WI, USA) including either a Nucleodur column (VP250/32 
C18 HTec 5µm) or a Nucleodur column (VP250/21 C18 HTec 5µm) by Macherey-Nagel with 
a flow rate of either 30ml/min or 16ml/min. 
Analytical UPLC-UV/MS was measured at 220 nm on an Aquity UPLC H-Class with a 
quaternary solvent manager, a waters autosampler and an Aquity UPLC-BEH C18 1.7µm, 
2.1 x 50 mm RP column with a flow rate of 0.6 ml/min connected to a waters UV detector 
and a QDaTMdetector. 
The following gradients were used with solvents A = H2O + 0.1%TFA; B = MeCN + 
0.1%TFA:  
Method A (5 min): 0 – 0.5 min (with 5%B in A); from 0.5 – 3 min (5% B to 95% B in A); 3 – 
3.9 min (with 95% B in A); 3.91 – 5 min (with 5% B in A).  
Method B (15 min): 0 – 1.5 min (with 5%B in A); from 1.5 – 13 min (5% B to 95% B in A); 13 
– 13.9 min (with 95% B in A); 13.91 – 15 min (with 5% B in A).  
Method C (50 min): 0 – 2.5 min (with 5%B in A); from 2.5 – 40 min (5% B to 95% B in A); 40 
– 45 min (with 95% B in A); 45 – 50 min (with 5% B in A).  
Analytical HPLC-UV/MS was measured at 220 nm on a Waters system consisting of a 
600S controller, a 616 pump, a 717 plus autosampler and a 2489 UV/Visible detector and a 
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3100 mass detector, with a C18-column (Eclipse, Agilent Technologies, US, 100 Å, 5 μm, 
4.6 mm x 250 mm). 
ESI-MS was measured on an Aquity UPLC H-Class coupled to a Xevo G2-XS Q-Tof. 
MALDI-TOF was measured on a Bruker LT microflex using a 2,5-DHAP matrix. Proteins 
were precipitated in cold acetone and resolved in 10 mM Ammoniumbicarbonate buffer at 
pH 7.4. Protein sample (0.8 µl) was mixed with 2% TFA in water (0.8 µl) and matrix (0.8 µl). 
After addition of matrix the solution (0.8 µl) was transferred a MSP 96 target (polished steel 
BC). 
Protein concentrations were determined by absorption spectroscopy measurements at 
280 nm using the extinction coefficient and molecular weight of the protein with a NanoDrop 
ND-1000. In addition or as alternative method concentrations were determined by BCA 
assay (Thermo Fisher Scientific, USA) according to the manufacturers protocol.  
Protein purification was accomplished either with an ÄKTA purifier FPLC or a BioRad NGC 
system. 
CD-spectroscopy was measured on a Jasco J-720 spectropolarimeter at 20°C and 
parameters set to: measured wavelength range 190 – 260 nm; data pitch of 0.1 nm; 
continuous scanning mode; 100 nm/min scanning speed; 1sec. response; 1.0 nm band 
width; 0.1 cm cell length; 5 accumulations.  
FACS measurements were carried on dual laser BD FACSCalibur. 
Dialysis was performed with regenerated cellulose tubing, MWCO 12000 – 14000 Da 
purchased from Spectrum labs against buffer/MeCN for several days with frequent 
changing of the solvent. 
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8.2 Multivalent Peptide-Polymer Conjugates for Influenza-Virus Inhibition 
8.2.1 Peptide Synthesis 
Both peptides were synthesized on a Rink-Amide-Resin with a loading of 0.74 mmol g-1. 
Single coupling was applied for all standard amino acids (5 eq., 1 h each) on a PTI peptide 
synthesizer. After the peptide sequence was assembled on resin the peptide was capped 
with 4-pentynoic acid N-terminally by treating the resin with 4-Pentynoic acid (5eq), HOBt (5 
eq), HBTU (5 eq.) and DIPEA (5 eq.) in DMF. After two hours of coupling, the resin was 
washed with DMF and DCM. Cleavage from the resin was performed using TFA/TIS/water 
(95/2.5/2.5) for 2 h. Precipitation was carried out in cold and dry ether. The precipitate was 
dissolved in a 1:1 mixture of acetonitrile and water and further lyophilized. The dry crude 
product was then solved in 10 mM ammonium acetate buffer at pH 9.0 and purification was 
accomplished via basic (10 mM ammonium acetate buffer pH 9.0/MeCN) semi-preparative 
HPLC (0-5 min 95/5, Buffer/MeCN; 5-70 min 10/90, Buffer/MeCN).  
PeB-alkyne:  
The final product PeB-alkyne was obtained in a yield of 13.6 % (53 mg, 27.1 µmol) and 
characterized by analytical HPLC-MS (m/z: obs. 1016.9 [M+2]2+, calc. 1016.9254) 
(Method C; rt.: 19.2 min).   
 
 
 
 
 
 
 
 
 
 
Figure 8.1: LC-UV chromatogram of PeB-alkyne.  
 
PeBGF-alkyne 
The final product PeBGF-alkyne was obtained in a yield of 13.6 % (53 mg, 27.1 µmol) and 
characterized by analytical HPLC-MS (m/z: obs. 979.9 [M+2]2+ , calc. 979.9252) (Method C; 
rt.: 20.1 min) 
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Figure 8.2: LC-UV chromatogram of PeBGF-alkyne.  
8.2.2 Polymer synthesis  
 
The polyglycerol sysnthesis was carried out by Markus Hellmund in the group of Prof. Dr. 
Rainer Haag. The synthesis of the hyperbranched polyglycerols was performed according to 
the published procedure.273,274  
Yield: 67%, molecular weight distribution and PDI (see Table 8.1).258  
 
The surface modifications on all polyglycerol cores was performed by Markus Hellmund 
according to the published procedure273 and all experimental details are published258. 
 
Table 8.1. Overview of high molecular weight polymers with number average molar mass (M
n
), mass average 
molar mass (M
w
), molar mass at peak maximum (M
p
), poly dispersity index (PDI) and degree of branching (DB).  
Sample PG100 kDa PG340 kDa 
Mn 66 kDa 117 kDa 
Mw 117 kDa 420 kDa 
Mp 96 kDa 340 kDa 
PDI 1.8 2.0 
DB 56% 59% 
Azide conversion 10% / 30% 10% / 30% 
 
8.2.3 Peptide – Polymer conjugation 
 
The alkyne-functionalized peptide (15.9 µmol, 1.5 eq.) was solubilized in 10 mM ammonium 
bicarbonate buffer and polyglycerol azide (10.6 µmol, 1 eq.) was added. CuSO4 in water 
(20 mM, 177 µl, 20 mol%) and THPTA (100 mM, 177 µl, 100 mol%) in water were premixed 
and added to the reaction mixture. The reducing agent sodium ascorbate (1 eq.) was added 
in two portions at the beginning of the reaction and after 5 h. After the last addition of 
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sodium ascorbate the reaction was stirred overnight. The reaction was quenched by adding 
ethylenediaminetetraacetic acid and further dialyzed for five days against a mixture of 
10 mM ammonium bicarbonate buffer containing 10% acetonitrile. The product was 
lyophilized to yield the crude product. Finally, it was further purified by gel filtration over 
Sephadex 50 fine and fractions with no free peptide visible in MALDI combined. Loading 
was determined by 1H-NMR integration of aromatic tyrosine signals to polymer backbone 
signals (see below). 
The enhancement factor (β) was calculated as followed using the reported IC50 values for 
monovalent PeB and PeBGF.33  
 𝛽𝛽 =  !"!"!"#"$%&'#(
!"!"!"#$%&'#()%
  ; 𝐼𝐼𝐼𝐼!"!"#$%&'#()$ =  𝐼𝐼𝐼𝐼!"!"!#$"%&'()*× 𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛 𝑜𝑜𝑜𝑜 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙  
 
 
Figure 8.3. Determination of dPG loading by 1H-NMR. 
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8.2.4 Dynamic Light Scattering  
 
The dynamic light scattering (DLS) measurements were performed using Malvern Zetasizer 
Nano ZS (Malvern Instruments GmbH, Herrenberg, Germany). All samples were measured 
at a constant scattering angle of 173°, 25°C, and freshly solubilized before measurement in 
10 mM ammonium bicarbonate. All measurements were repeated at least three times. 
 
Figure 8.4. Overview of DLS Data with with its s.e.m. (n≥ 3) 
 
8.2.5 In vivo and in vitro studies 
 
Daniel Lauster conducted the hemagglutination inhibiton assays, the infection inhibiton 
assays and MST measurements according to the details given in the published 
manuscript.258 Mouse experiments performed by Markus Bardua and Ute Hoffmann are also 
described in the manuscript. 258  
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8.3 Staudinger-induced thiol addition as cysteine reactive conjugation 
8.3.1 Peptide synthesis 
Cyclic-(RGDfK)-azide (11) 
 
The cyclic-RGDfK-azido peptide (11) was synthesized manually on a NovaSynTGT alcohol 
resin with a loading of 0.26 mmol/g. First the resin was activated by stirring 480.7 mg resin 
in 2.5 ml toluene and 480 µl acetylchloride at 60°C for three hours. Double coupling of 
Fmoc-Asp(OAll)-OH (123.56 mg, 0.3125 mmol, 2.5 eq) was performed in CH2Cl2 using 
DIPEA (212.6 µl, 1.25 mmol, 10 eq.) as activating base, each for one hour. Further amino 
acid couplings were performed by mixing amino acid (0.25 mmol, 2 eq.), HATU (0.25 mmol, 
2 eq.) and DIPEA (0.5 mmol, 4 eq.) in DMF and coupling once for 30 minutes and once for 
one hour. Fmoc deprotection was accomplished with 20 % piperidine in DMF. After the final 
amino acid coupling the alloc deprotection was achieved by treating the resin with 
Pd(P(Ph3)4) (433 mg, 0.375 mmol, 3 eq.) in a chloroform/acetic acid/NMM (37:2:1;v:v:v) 
mixture for two hours in an argon atmosphere, followed by Fmoc deprotection and 
cyclization with HATU (0.25 mmol, 2 eq.) and DIPEA (0.5 mmol, 4 eq.) in DMF for 16 hours. 
To install the aromatic azide on the lysine residue Fmoc-Lys(dde)-OH was used in the solid 
phase synthesis and was orthogonally deprotected on resin  using 5 ml of a  2% hydrazine 
in DMF solution three times for three minutes, followed by coupling of 4–azidobenzoic acid 
(81.65 mg, 0.5 mmol, 4 eq.) with HATU (190 mg, 0.5 mmol, 4 eq.) and DIPEA (1 mmol, 8 eq.) 
in DMF for two hours. Cleavage from the resin was performed with TFA/CH2Cl2 (75:25;v:v) 
for 2.5 hours. Precipitation was carried out in cold and dry ether. The crude was analyzed 
by UPLC-MS and either used as crude in the following Staudinger reaction or purified by 
preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-
60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 11 was gained as white 
powder (9.4 mg, 12.8 µmol, 10.2 % yield) and was analyzed by analytical UPLC (Method A; 
rt.: 1.72 min).  
LRMS: m/z: 749.66 [M+H]+ (calc. m/z: 749.3485). 
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Figure 8.5: UPLC-UV chromatogram of 11.  
Cyclic-(Tat)-azide (16) 
 
The cyclic-(Tat)-azido peptide (16) was synthesized in a 0.1 mmol scale on a Rink Amide 
Resin with a loading of 0.78 mmol/g. The synthesis was carried out on a PTI synthesizer 
with single couplings of each amino acid (10 eq. amino acid for 40 min) in DMF. After the 
final PEG building block coupling the peptide, still Fmoc protected, was treated with 
Pd(PPh3)4 (24 mg, 20 µmol, 20 mol%) and phenylsilane (308 µl, 2.5 mmol, 2.5 eq.) in 4 ml 
dry CH2Cl2 for one hour in order to cleave the alloc and allyl protecting groups in one step. 
After confirmation of full deprotection by test cleavage, cyclization with 2 eq. HATU 4 eq. 
DIPEA was carried for four hours in DMF.  
The peptide was then Fmoc-deprotected using 20% piperidine in DMF and the 4-
azidobenzoic acid (81.6 mg, 0.5 mmol, 5 eq.) was coupled to the N-terminus with HATU 
(190.1 mg, 0.5 mmol, 5 eq.) and DIPEA (170 µl, 1.0 mmol, 10 eq.) for one hour. Finally, the 
peptide was cleaved from the resin by treatment with 4 ml of a TFA:TIS:H2O (95:2.5:2.5) 
mixture for three hours and precipitated in cold diethylether. The crude peptide was purified 
by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 
5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 16 was gained as white 
powder (30.0 mg as TFA-salt, 11.4 µmol, 11.4% yield) and was analyzed by analytical UPLC 
(Method A; rt: 2.18 min).  
LRMS: m/z: 648.49  [M+3H]3+ (calc. m/z: 648.0569). 
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Figure 8.6: UPLC-UV chromatogram of 16.  
 
Cyclic-(R10)-azide (17) 
 
The cyclic-(R10)-azido peptide (17) was synthesized in a 0.1 mmol scale on a Rink Amide 
Resin with a loading of 0.78mmol/g. The synthesis was carried out on a PTI synthesizer with 
double couplings of each amino acid (5 eq. amino acid for 40 min) in DMF. After the final 
PEG building block coupling the peptide, still Fmoc protected, was treated with Pd(PPh3)4 
(24 mg, 20 µmol, 20 mol%) and phenylsilane (308 µl, 2.5 mmol, 2.5 eq.) in 4 ml dry CH2Cl2 
for one hour in order to cleave the alloc and allyl protecting groups in one step. After 
confirmation of full deprotection by test cleavage, cyclization with 2 eq. HATU 4 eq. DIPEA 
was carried out over night in DMF. The peptide was then Fmoc-deprotected using 20% 
piperidine in DMF and the 4-azidobenzoic acid (81.6 mg, 0.5 mmol, 5 eq.) was coupled to 
the N-terminus with HATU (190.1 mg, 0.5 mmol, 5 eq.) and DIPEA (170 µl, 1.0 mmol, 10 eq.) 
for one hour. Finally the peptide was cleaved from the resin by treatment with 4 ml of a 
TFA:TIS:H2O (95:2.5:2.5) mixture for three hours and precipitated in cold diethylether. The 
crude peptide was purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water 
(0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)) and 
gained as white powder (62 mg as TFA-salt, 18.3 µmol 18.3% yield) and was analyzed by 
analytical UPLC (method A, rt.: 1.93 min). 
LRMS: m/z: 752.35 [M+3H]3+ (calc. m/z: 751.7879).  
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Figure 8.7: UPLC-UV chromatogram of 17.  
 
Cyclic-(Tat)-maleimide (24) 
 
The cyclic-(Tat)-maleimide peptide (23) was synthesized in a 0.05 mmol scale on a Rink 
Amide Resin with a loading of 0.78 mmol/g. The synthesis was carried out on a PTI 
synthesizer with single couplings of each amino acid (10 eq. amino acid for 40 min) in 
DMF. After the final PEG building block coupling the peptide, still Fmoc protected, was 
treated with Pd(PPh3)4 (12 mg, 10 µmol, 20 mol%) and phenylsilane (154 µl, 1.25 mmol, 2.5 
eq.) in 2 ml dry CH2Cl2 for one hour in order to cleave the alloc and allyl protecting groups in 
one step. After confirmation of full deprotection by test cleavage, cyclization with 2 eq. 
HATU 4 eq. DIPEA was carried for four hours in DMF.  
The peptide was then Fmoc-deprotected using 20% piperidine in DMF and then 2-
maleimido acetic acid (15.5 mg, 0.1 mmol, 2 eq.) was coupled to the N-terminus with HATU 
(38.0 mg, 0.1 mmol, 2 eq.) and DIPEA (34 µl, 0.2 mmol, 4 eq.) for four hours. Finally the 
peptide was cleaved from the resin by treatment with 4 ml of a TFA:TIS:H2O (95:2.5:2.5) 
mixture for three hours and precipitated in cold diethylether. The crude peptide was purified 
by preparative reverse phase C18 HPLC. The product 23 was gained as white powder (6 mg 
as TFA-salt, 2.3 µmol, 4.6 % yield) and analyzed by UPLC (method B; rt.: 3.13 min).  
HRMS: m/z: 645.3615 [M+3H]3+ (calc. m/z: 645.3848). 
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Figure 8.8: UPLC-UV chromatogram of 24.  
 
Cyclic-(Tat)-Iodoacetate (25) 
The cyclic-(Tat)-iodoacetate (24) peptide was synthesized in a 0.05 mmol scale on a Rink 
Amide Resin with a loading of 0.78 mmol/g. The synthesis was carried out on a PTI 
synthesizer with single couplings of each amino acid (10 eq. amino acid for 40 min) in 
DMF. After the final PEG building block coupling the peptide, still Fmoc protected, was 
treated with Pd(PPh3)4 (12 mg, 10 µmol, 20 mol%) and phenylsilane (154 µl, 1.25 mmol, 2.5 
eq.) in 2 ml dry CH2Cl2 for one hour in order to cleave the alloc and allyl protecting groups in 
one step. After confirmation of full deprotection by test cleavage, cyclization with 2 eq. 
HATU 4 eq. DIPEA was carried for four hours in DMF.
The peptide was then Fmoc-deprotected using 20% piperidine in DMF and then N-
hydroxysuccinimidyl Iodoacetate (28.3 mg, 0.1 mmol, 2 eq.) was coupled to the N-terminus 
with DIPEA (25 µl, 0.25 mmol, 3 eq.) for four hours. Finally the peptide was cleaved from the 
resin by treatment with 4 ml of a TFA:TIS:H2O (95:2.5:2.5) mixture for three hours and 
precipitated in cold diethylether. The crude peptide was purified by preparative reverse 
phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water 
(0.1%TFA)/MeCN (0.1%TFA)). The product 24 was gained as white powder (8 mg as TFA-
salt, 3.0 µmol, 6.0 % yield) and analyzed by UPLC (method B; rt: 3.17 min). 
HRMS: m/z: [M+3H]3+ 655.6872 (calc. m/z: 655.6834). 
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Figure 8.9: UPLC-UV chromatogram of 25.  
 
TAMRA-c(R10) (22) 
 
The TAMRA labeled cyclic-(R10) (22) peptide was synthesized in a 0.05 mmol scale on a 
Rink Amide Resin with a loading  of 0.78 mmol/g. The synthesis was carried out on a PTI 
synthesizer with double couplings of each amino acid (5 eq. amino acid for 40 min) in 
DMF. After the final PEG building block coupling the peptide, still Fmoc protected, was 
treated with Pd(PPh3)4 (24 mg, 20 µmol, 20 mol%) and phenylsilane (308 µl, 2.5 mmol, 2.5 
eq.) in 4 ml dry CH2Cl2 for one hour in order to cleave the alloc and allyl protecting groups in 
one step. After confirmation of full deprotection by test cleavage, cyclization with 2 eq. 
HATU 4 eq. DIPEA was carried out over night in DMF. The peptide was then Fmoc-
deprotected using 20% piperidine in DMF, followed by coupling of 5-
carboxytetramethylrhodamine (32.3 mg, 0.075 mmol, 1.5 eq.) was coupled to the N-
terminus with HATU (28.5 mg, 0.075 mmol, 1.5 eq.) and DIPEA (25.5 µl, 0.15 mmol, 3 eq.) 
over night. Finally the peptide was cleaved from the resin by treatment with 2 ml of a 
TFA:TIS:H2O (95:2.5:2.5) mixture for three hours and precipitated in cold diethylether. The 
crude peptide was purified by preparative reverse phase C18 HPLC, gained as pink powder 
(22.2 mg as TFA-salt, 6.1 µmol 12.2% yield) and analyzed by UPLC (method B; rt.: 3.90 
min). 
HRMS: m/z: [M+3H]3+ 744.0772 (calc. m/z: 744.4460). 
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Figure 8.10: UPLC-UV chromatogram of 22.  
 
8.3.2 Staudinger phosphonite reaction 
 
Bisethoxyalkyne-phosphonite synthesis (7) 
 
Ethynyl magnesium bromide in THF (0.5 M, 2 ml, 1 mmol, 1 eq.) was cooled to          - 78°C 
in a flame dried schlenk flask and diethylchlorophosphite (0.143 ml, 1 mmol, 1 eq.) was 
added. The solution was stirred for 10 minutes at - 78°C and let warm to room temperature 
and stirred for another 90 minutes. The full consumption of starting material was confirmed 
by 31P-NMR and used as crude in the following Staudinger reaction with azido peptides. 
Due to the inherent lability of bisethoxyalkyne-phosphonite toward water and air the 
compound was not isolated. The correct product formation via this reaction route however 
was previously confirmed, by additionally protecting the P(III)-compound with borane, which 
makes it possible to isolate and characterize the compound as reported by Robert Vallée.231 
 
General procedure P1 for the generation of alkyne – phosphonamidates (8) 
 
Purified azido-peptide was dissolved in DMSO at a 6 mM concentration and dried in a 
flame-dried flask for one hour prior to adding 4 eq. of bisethoxyalkyne-phosphonite (volume 
according to percentage of product determined by NMR). After the reaction mixture was 
stirred over night at room temperature, water was added and the reaction mixture directly 
lyophilized. The crude product was purified by semi-preparative HPLC.  
 
 
Experimental Part 
 108 
 
Cyclic-(RGDfK)-phosphonamidate-alkyne (12) 
 
With peptide 11 (6.9 mg, 9.14 µmol, 1 eq.) the Staudinger-phosphonite synthesis was 
carried out according to the general procedure P1. The crude product was purified by semi-
preparative HPLC (0-5min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60min 10/90, water 
(0.1%TFA)/MeCN (0.1%TFA)), gave the product 12 as a white powder (4.1 mg, 4.89 µmol, 
53.5 % yield) and analyzed by UPLC (method A; rt.: 1.55 min). 
LRMS: m/z:  839.72 [M+H]+ (calc. 839.3606 m/z). 
 
Figure 8.11: UPLC-UV chromatogram of 12.  
 
Cyclic-(Tat)-phosphonamidate-alkyne (18) 
 
Cyclic-(Tat)-azide 16 (20 mg (as TFA-salt), 7.6 µmol, 1 eq.) and bisethoxyalkyne-
phosphonite 7 were reacted in a Staudinger-phosphonite-reaction according to the general 
procedure P1. The product 18 was gained after semi-preparative HPLC (0-5min 95/5, water 
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(0.1%TFA)/MeCN (0.1%TFA); 5-60min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)) as white 
powder (13 mg, 4.8 µmol, 62.9% yield) and analyzed by UPLC (method B; rt.: 3.50 min).  
HRMS: m/z:  678.0569 [M+3H]3+ (calc. m/z: 678.0610). 
Figure 8.12: UPLC-UV chromatogram of 18.  
 
Cyclic-(R10)-phosphonamidate-alkyne (19) 
 
Cyclic-(R10)-azide 17 (35 mg (as TFA-salt), 10.3 µmol, 1 eq.) and bisethoxyalkyne-
phosphonite 7 were reacted in a Staudinger-phosphonite reaction according to the general 
procedure P1. The product 19 was gained after semi-preparative HPLC (0-5min 95/5, water 
(0.1%TFA)/MeCN (0.1%TFA); 5-60min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)) as white 
powder (13 mg, 4.79 µmol, 62.9% yield) and analyzed by UPLC (method B; rt.: 3.70 min). 
HRMS: m/z:  781.7965 [M+3H]3+ (calc. m/z: 781.7920). 
 
Figure 8.13: UPLC-UV chromatogram of 19.  
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8.3.3 Cloning and expression of GFP mutants 
 
eGFP C70M S147C was expressed according to published protocol262 by Kristin Kemnitz-
Hassanin. 
 
Mutagenesis PCR 
 
For mutation of eGFP C70M to eGFP S6C C70M, the cDNA of eGFP C70M was kindly 
provided in a pET28a vector and reported on previously by Dr. Dominik Schumacher262. The 
mutations were carried out by mutagenesis PCR using complementary primer pairs (for 
conditions see table 8.2 and 8.3). 
 
eGFP S6C: GCAGCCATATGGGATGCATTCAGATGG and CCATCTGAATGCATCCC 
ATATGGCTGC 
 
For mutation of hsGFP to hsGFP C71M and hsGFP S3C C71M, the group of Prof. Dr. 
Budisa kindly provided the cDNA of hsGFP in a pET30b vector. The mutations were carried 
out by mutagenesis PCR using complementary primer pairs (for conditions see Table 8.1 
and 8.2). 
 
hsGFP C71M: GTTATGGTGTGCAGATGTTTGCACGTTATCCG and CGGATAACGT 
GCAAACATCTGCACACCATAAC 
hsGFP S3C: GGAGATATACATATGCAGTGCAAAGGCGAAG and CTTCGCCTTTGC 
ACTGCATATGTATATCTCC 
 
Table 8.2: Reaction mix of mutagenesis PCR.  
ddH2O 18.5 µl 
Pfu buffer (10x) (Thermo scientific, USA) 2.5 µl 
template DNA (1 ng/µl) 2 µl 
primer mix (10 µM each)  1 µl 
dNTP mix (10 mM each) (Thermo scientific, USA) 0.5 µl 
Pfu polymerase (Thermo scientific, USA) 0.5 µl 
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Table 8.3: Cycle steps in mutagenesis PCR. 
  eGFP hsGFP 
step cycles temp.[°C] time  temp.[°C] time  
initial denaturation 1 95 30’’ 95 3’ 
denaturation 
22 
95 30’’ 95 30’’ 
annealing 65 1’ 58 1’ 
extension 72 3’ 72 3’ 
final extension 1 72 10’ 72 10’ 
hold  4 ∞ 4 ∞ 
 
DPNI digest 
Digestion of mutated DNA was carried out using DPNI according to Table 8.4 for 4h at 
37°C. 
 
Table 8.4: Reaction mixture of DPNI digest. 
PCR product (not purified) 20 µl 
FastDigestTM Buffer (10x) 4 µl 
DpnI (10 U/µl) (Thermo scientific, USA) 2 µl 
ddH2O 34 µl 
 
Purification of the digestion mixture was carried out using a GeneJETTM Gel extraction kit. 
The digestion mixture was mixed 1:1 with binding buffer and then purified according to the 
manufacturer’s protocol. Final elution was done in 30µl of ddH2O.   
 
Transformation of competent E. coli cells 
 
Cells were transformed by heat shock procedure. Hereby 50 µl cells were thawed on ice 
and 1 µl of purified DNA was added and incubated on ice for 30 minutes. The cells were 
heat shocked at 42°C for 45 seconds followed by the addition of 300 µl prewarmed SOC 
medium. The mixture was then incubated for one hour at 37°C. Everything was plated on LB 
agar plates supplemented with the respective antibiotic and incubated at 37°C over night.  
 
DNA isolation 
Clones were picked and grown in 5 ml of LB medium in presence of the respective 
antibiotic over night at 37°C, 180 rpm. Plasmid-DNA was isolated with a GeneJET Plasmid 
Miniprep Kit (Thermo scientific, USA) according to the manufacturer’s protocol, with the 
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alteration of eluting the DNA in 20 µl ddH2O instead of the included elution buffer. The DNA 
was stored at - 20°C and its concentration was determined by absorption spectrum 
measurement at 260 nm by NanoDrop. Correct DNA sequence was verified by sequencing.  
 
Protein expression 
 
Protein expression was done in E. coli BL21 (DE3) using LB medium containing 100 µg/ml 
Kanamycin. Cells were grown at 37°C, 180 rpm until they reached an OD600 of 
approximately 0.7 and then expression induced by adding 0.5 mM IPTG and further 
incubated at 18°C over night. Cells were harvested by centrifugation at 4000 g for 15 
minutes at 4°C followed by cell lysis, which was carried out in Dulbecco’s PBS with a 
sonicator at 30% for six minutes. Finally debris was centrifugation at 27000 g for 20 
minutes. The His6-tagged-GFP mutant was purified via a 5 ml HisTrapTM FF column on a 
BioRad NGC system and a. Elution was performed in PBS with 500mM Imidazole. The 
fractions containing the wanted protein were combined and dialysis (Slide-A-lyzer, MWCO 
10kDa) against Tris Buffer (TrisHCl 50 mM, 0.5 M NaCl, pH 8.0).  
 
For hsGFP-mutants TEV protease was added to the protein and incubated at 20°C over 
night followed by another purification via HisTrap FF column. The product fractions were 
combined, concentrated and rebuffered to PBS with a Vivaspin 20 filter unit (MWCO 10 
kDa) then shock frozen and stored at - 80°C.    
For eGFP-mutants 1 µl thrombine (1 U/ml) was added to the protein and incubated at 16°C 
over night and purified by size exclusion chromatography using a Superdex 75 10/300 GL 
column. The product fractions were combined and concentrated with a Vivaspin 20 filter 
unit (MWCO 10 kDa) then shock frozen and stored at - 80°C.    
 
Final GFP sequences 
eGFP C70M S147C 
GSIQMVSKGE ELFTGVVPIL VELDGDVNGH KFSVSGEGEG DATYGKLTLK FICTTGKLPV 
PWPTLVTTLT YGVQMFSRYP DHMKQHDFFK SAMPEGYVQE RTIFFKDDGN YKTRAEVKFE 
GDTLVNRIEL KGIDFKEDGN ILGHKLEYNY NCHNVYIMAD KQKNGIKVNF KIRHNIEDGS 
VQLADHYQQN TPIGDGPVLL PDNHYLSTQS ALSKDPNEKR DHMVLLEFVT AAGITLGMDE 
LYK 
 
hsGFP S3C C71M 
MQCKGEELFT GVVPILVELD GDVNGHKFSV RGEGEGDATN GKLTLKFICT TGKLPVPWPT 
LVTTLGYGVQ MFARYPDHIK RHDFFKSALP EGYVQERTIS FKDDGTYKTR AEVKFEGDTL 
VNRIELKGID FKEDGNILGH KLEYNFNSHK VYITADKQKN GIKANFKIRH NVEDGSVQLA 
DHYQQNTPIG DGPVLLPDNH YLSTQSVLLK DPNEKRDHAV LLEFVTAAGI THGKDELYKE 
NLYFQ  
Experimental Part 
 113 
Comparison of both sequences 
 
Figure 8.14: Comparison between hsGFP and eGFP sequences and cysteine mutation. 
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8.3.4 Hydrothiolation of electron-deficient phosphonamidate alkyne 
 
Modelreaction with Glutathion to 14 
 
 
Glutathione (13) (1 mg, 3.25 µmol, 1 eq.) and 12 (1.24 mg, 3.25 µmol, 1 eq.) were mixed in 
135 µl 10 mM ammoniumbicarbonate buffer pH 9.2 and 15 µl acetonitrile (c = 21.6 mM). 
After 10 minutes of shaking at room temperature quantitative conversion to the addition 
product 14 was observed by LC-UV/MS.  
The final product was analyzed by LC-UV: (0-1min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 
1-16.5 min 5/95, water (0.1%TFA)/MeCN (0.1%TFA) on RP-C18 column) rt.: 5.04 min. 
HRMS: m/z: 1146.4451 [M+H]+ (calc. m/z: 1146.4444). 
 
Figure 8.15: UPLC-UV chromatogram of 14.  
 
Stability Studies of 12 
Peptide 12 was dissolved at a concentration of 0.3 mM in different solvents (0.1 M HCl at 
pH 1; water containing 0.1%TFA with a pH of 2; PBS buffer at pH 7.4; ammonium acetate 
buffer at pH 9.0; 0.05 M NaOH at pH 12). As internal standard 0.3 mM tryptophan was 
added. The stability of the starting material was monitored over time via LC-UV. 
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Stability Studies of 14 
 
Conjugate 14 was dissolved at a concentration of 2 mM in different solvents (0.1 M HCl at 
pH 1; water containing 0.1%TFA with a pH of 2.3; PBS buffer at pH 7.4; ammonium acetate 
buffer at pH 9.0; 0.05 M NaOH at pH 12). As internal standard 0.5 mM inosine was added. 
The stability of 14 was monitored over time via LC-UV. 
For the stability studies in presence of a competing thiol, 14 was solved in either PBS or 1M 
Tris HCl pH 9.0 at a concentration of 2 mM and 10 eq. DTT or MesNa were added. The 
mixture was monitored over several days.  
 
General procedure P2 for thiol addition reaction with eGFP C70M S147C 
 
To eGFP C70M S147C buffered in PBS phosphonamidate-alkyne-peptides (20 eq.) were 
added to give the final concentration of 100 µM. The reaction mixture was shaken at 37°C 
and 800 rpm for three hours. The excess peptide was removed by spinfiltration using 
Amicon Spin filters with a 10 kDa MWCO. The sample was filtered five times at 14000 rpm 
for 5 minutes. 
 
Cyclic-(RGDfK)-eGFP (15) 
 
Peptide 12 (0.84 mg, 1.13 µmol, 20 eq.) was reacted with eGFP C70M S147C (56.3 nmol) 
according to general procedure P2.  After removal of excess peptide 12 by spin filtration the 
sample was analyzed by MALDI-TOF after acetone precipitation and re-solvation in 10 mM 
ammonium bicarbonate buffer. Here the quantitative conversion to the product 15 was 
observed. 
MALDI TOF: expected (in Da): 28602.4 (M+H+); found (in Da): 28606.5 (M+H+). 
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Figure 8.16: MALDI-TOF spectrum of 15. 
 
Cyclic-(Tat)-eGFP (20) 
 
Peptide 18 (3.06 mg as TFA-salt, 1.13 µmol, 20 eq.) was reacted with eGFP C70M S147C 
(56.3 nmol) according to general procedure P2.  After removal of excess peptide 18 by spin 
filtration the sample was analyzed by MALDI-TOF after acetone precipitation and re-
solvation in 10 mM ammonium bicarbonate buffer. Here the quantitative conversion to the 
product 20 was observed. 
 
MALDI TOF: expected (in Da): 29795.2 (M+H+); found (in Da): 29851.4 (M+H+) 
 
Figure 8.17: MALDI-TOF spectrum of 20. 
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Cyclic-(R10)-eGFP (21) 
 
Peptide 19 (3.94 mg as TFA-salt, 1.13 µmol, 20 eq.) was reacted with eGFP C70M S147C 
(56.3 nmol) according to general procedure P2. After removal of excess peptide 19 by spin 
filtration the sample was analyzed by MALDI-TOF after acetone precipitation and re-
solvation in 10 mM ammonium bicarbonate buffer. Here the quantitative conversion to the 
product 21 was observed. 
 
MALDI TOF: expected (in Da): 30106.4 (M+H+); found (in Da): 30128.0 (M+Na+). 
 
Figure 8.18: MALDI-TOF spectrum of 21. 
 
General procedure P3 for thiol addition at N-terminal cysteines 
 
N-terminal cysteine GFP (hsGFP S3C C71M or eGFP S6C C70M) buffered in PBS was 
reduced with TCEP for 30 minutes at 37°C prior to the conjugation reaction. After removal 
of TCEP via ZebaSpin filtration, the protein (100 µM) was incubated with cell penetrating 
peptide (20 eq.) for three hours at 37°C. Removal of excess peptide was achieved by 
spinfiltration using Amicon Spin filters with a 10 kDa MWCO. The sample was filtered five 
times at 14000 rpm for 5 minutes. 
 
Cyclic-(Tat)-hsGFP S3C C71M (23)
 
Peptide 18 (1.02 mg as TFA-salt, 0.38 µmol, 20 eq.) was reacted with hsGFP S3C C71M 
according to general protocol P3. After removal of excess peptide 18 by ZebaSpin filtration 
the sample was analyzed by MALDI-TOF after acetone precipitation and re-solvation in 
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10 mM ammonium bicarbonate buffer. Here the quantitative conversion to the product 22 
was observed. 
 
MALDI TOF: expected (in Da): 29698.5 (M+H+); found (in Da) 29698.4 (M+H+) 
 
Figure 8.19: MALDI-TOF spectrum of 23. 
 
Cyclic-(Tat)-eGFP S6C C70M 
 
Cyclic-(Tat)-phosphonamidate-alkyne (1.0 mg as TFA-salt, 0.36 µmol, 6 eq.) was reacted 
with prior reduced eGFP S6C C70M (57.9 nmol, 1eq) (reduction according to procedure P3) 
in PBS for 16 hours at 37°C, 180 rpm. After purification and rebuffering to HEPES by 
ZebaSpin filtration (7 kDa MWCO) the sample was analyzed by MALDI-TOF after acetone 
precipitation and re-solvation in 10 mM ammonium bicarbonate buffer. 
MALDI TOF: expected (in Da): 29794.2 (M+H+); found 29904.6 (in Da): (M+H+) 
 
Figure 8.20: MALDI-TOF spectrum of cyclic-(Tat)-eGFP S6C C70M. 
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Cyclic-(Tat)-maleimide-eGFP (26) 
 
Peptide 23 (0.3 mg as TFA-salt, 0.11 µmol, 5.5 eq.) was reacted with eGFP C70M S147C 
(20.36 nmol, 1eq.) buffered in PBS at a concentration of 50 µM at 16°C. After four hours 
shaking with 800 rpm the excess peptide was removed by ZebaSpin filtration and 
rebuffering to HEPES buffer pH 7.5. The sample was analyzed by MALDI-TOF after acetone 
precipitation and re-solvation in 10 mM ammonium bicarbonate buffer. Quantitative 
conversion to the product 25 was observed. 
MALDI TOF: expected (in Da): 29697.1 (M+H+); found (in Da): 29768.2 (M+K++Na+) 
 
Figure 8.21: MALDI-TOF spectrum of 26. 
 
 
Cyclic-(Tat)-iodoacetate-eGFP (27) 
 
Peptide 24 (0.3 mg as TFA-salt, 0.11 µmol, 5.5 eq.) was reacted with eGFP C70M S147C 
(20.36 nmol, 1eq.) buffered in PBS at a concentration of 50 µM at room temperature. After 
three hours shaking with 800 rpm the excess peptide was removed by ZebaSpin filtration 
and rebuffering to HEPES buffer pH 7.5. The sample was analyzed by MALDI-TOF after 
acetone precipitation and re-solvation in 10 mM ammonium bicarbonate buffer. Here the 
quantitative conversion to the product 26 was observed. 
MALDI TOF: expected (in Da): 29727.0 (M+); found (in Da): 29706.5 (M+)
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Figure 8.22: MALDI-TOF spectrum of 27. 
 
8.3.5 FACS measurements 
 
U87MG cells were cultured in Dulbecco’s MEM medium supplemented with 10% FBS and 
1% Penicillin Streptomycin. 70 000 cells were seeded in an uncoated glass bottom 8-well µ-
slide (Ibidi) 24 hours prior to treatment. Finally cells were incubated with 40 µM cRGD-eGFP 
conjugate in serum free medium at 37°C in a 5% CO2 atmosphere. After four hours cells 
were washed with PBS and treated with acutase to detach cells from the dish. Detached 
cells were transferred into a tube washed with PBS (including 0.5% BSA) three times and 
centrifuged each time at 1200 rpm for 5 minutes. After the final wash the cell pellet was 
solved in 400 µl PBS and measured. 
8.3.6 Cellular uptake experiments 
  
All cell uptake experiments were carried out according to literature122, with HeLa (ATCC 
CCL-2) cells cultured in Dulbecco’s MEM medium supplemented with 10% FBS and 1% 
Penicillin Streptomycin. 70 000 cells were seeded in an uncoated glass bottom 8-well µ-
slide (Ibidi) 24 hours prior to treatment. The cellular uptake was carried out by gently 
washing cells three times with HEPES buffer pH 7.5 (5 mM HEPES, 140 mM NaCl, 2.5 mM 
KCl, 5 mM glycine). The peptide-protein conjugate buffered in the same HEPES buffer was 
added to the cells in 200 µl at respective concentration and incubated for at 37°C in a 5% 
CO2 atmosphere. After one hour cells were gently washed with 25 mM HEPES in 
Dulbecco’s MEM supplemented with 10% FKS and cells were rested for 30 minutes at 
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37°C. The cell nucleus was stained with Hoechst 33342 and cells imaged with a Zeiss 710 
confocal microscope.  
The percentage of cells that took up the GFP conjugate was determined by counting all 
cells showing nucleolar GFP relative to the total number of cells (all Hoechst stained nuclei). 
Each uptake experiment was repeated at least three times.  
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8.4 Intramolecular Staudinger induced thiol addition as new peptide 
cyclization method 
8.4.1 Peptide synthesis 
 
General procedure P4 for peptide synthesis of all BCL9-peptides 
The BCL9 peptide was synthesized in a 0.1 mmol scale on a Rink Amide Resin with a 
loading of 0.78mmol/g. The synthesis was carried out on a PTI synthesizer with a single 
coupling of each standard amino acid (5 eq. amino acid for 40 min). Fmoc-Azidohomoalanin 
(2 eq.) was coupled with HATU (2 eq.) for four hours. Fmoc deprotection was accomplished 
by treating the peptide with 20% piperidine in DMF for 3 minutes two to three times 
according to UV read out. N-terminal acetylation was done by incubation with a mixture of 
lutidine:acetic acid:DMF (6%:5%:89%;v;v;v) for 10 minutes. Final cleavage from solid 
support was carried out by incubating the resin with 4 ml of a TFA:TIS:H2O (95:2.5:2.5) 
mixture for two hours and precipitated in cold diethylether.  
 
BCL9-Nle-wt peptide synthesis 
 
 
The peptide was synthesized according to general procedure P4. The crude peptide was 
purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN 
(0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product was gained as 
white powder (95.2 mg as TFA-salt, 13.2 µmol, 26.4 % yield) and analyzed by UPLC 
(method B; rt.: 6.10 min ). 
HRMS: m/z: 1017.2160 [M+3H]3+ (calc. 1017.2273 m/z). 
 
Figure 8.23: UPLC-UV chromatogram of BCL-Nle-wt.  
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BCL9-Nle-Aha-LCys peptide synthesis (30a) 
 
 
The peptide was synthesized according to general procedure P4. The crude peptide was 
purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN 
(0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 45 was 
gained as white powder (35 mg as TFA-salt, 9.7 µmol, 9.7 % yield) and analyzed by UPLC 
(method B; rt.: 6.95 min).   
HRMS: m/z:  1012.5317 [M+3H]3+ (calc. 1012.5532 m/z).
 
Figure 8.24: UPLC-UV chromatogram of 30a.  
 
Alkylated-BCL9-Nle-Aha-LCys peptide synthesis (33) 
 
Peptide 30a (43.2 mg, 12.0 µmol) was incubated with iodoacetamide (22.2 mg, 120 µmol, 
10eq.) in a mixture of ammoniumbicarbonate buffer and acetonitrile (6:2) with a final pH of 
8.5. After one hour the mixture was purified by preparative HPLC 0-5 min 95/5, water 
(0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The 
product was gained as white powder (25 mg as TFA-salt, 6.8 µmol, 57 % yield) and 
analyzed by UPLC (method A; rt.: 2.34 min). 
HRMS: m/z:  1031.5342 [M+3H]3+ (calc. 1031.5604 m/z). 
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Figure 8.25: UPLC-UV chromatogram of 33. 
 
BCL9-Nle-Aha-DCys peptide synthesis (30b) 
 
The Peptide was synthesized according to general procedure P4. The crude peptide was 
purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN 
(0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product was gained as 
white powder (50.5 mg as TFA-salt, 14.0 µmol, 14 % yield) and analyzed by UPLC 
(method B; rt.: 6.20 min). 
HRMS: m/z: 1012.5383 [M+3H]3+ (calc. 1012.5532 m/z). 
 
 
Figure 8.26: UPLC-UV chromatogram of 30b. 
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Scrambled-BCL9-Nle-Aha-DCys peptide synthesis 
 
The Peptide was synthesized according to general procedure P4.The crude peptide was 
purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN 
(0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product was gained as 
white powder (13 mg as TFA-salt, 3.6 µmol, 3.6 % yield) and analyzed by UPLC (method B; 
rt.: 6.05 min).   
HRMS: m/z: 1012.5481 [M+3H]3+ (calc. 1012.5532 m/z). 
 
Figure 8.27: UPLC-UV chromatogram of scrambled-BCL9-Nle-Aha-DCys. 
 
RCM-BCL9-Nle peptide synthesis (39) 
 
The RCM-BCL9 peptide was synthesized in a 0.05 mmol scale on a Rink Amide Resin with 
a loading of 0.78 mmol/g. Until the first olefinic amino acid the synthesis was carried out on 
a PTI synthesizer with single couplings (5 eq. amino acid for 40 minutes). Olefinic amino 
acids (2 eq.) were coupled manually with HATU (2eq.) and DIPEA (4 eq.) for two hours and 
full conversion was checked by trial cleavage. The three amino acids in between the olefinic 
ones were coupled manually (5 eg. for 40 minutes) all amino acids following the olefinic 
ones were coupled in double coupling steps with five equivalents for 40 minutes. After the 
second olefinic amino acids the synthesis was resumed by automated SPPS on the PTI 
synthesizer. The N-terminus was acetylated by treatment with a lutidine:acetic 
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anhydride:DMF (5:6:89;v:v:v) for 10 minutes. To generate the hydrocarbon staple the resin 
was incubated with a 10 mM solution of bis(tricyclohexylphosphine)-benzylidene ruthenium 
(IV) (1st generation Grubb’s catalyst) in 1,2-dichloroethane for one hour twice. 
The final cleavage from resin was achieved by incubation with a mixture of TFA:TIS:H2O 
(95:2.5:2.5;v:v:v) for two hours followed by precipitation in cold diethylether. The crude 
peptide was purified by preparative reverse phase C18 HPLC, the product was gained as 
white powder (14 mg, 3.9 µmol, 7.8% yield) and analyzed by UPLC (method B; rt.: 
7.34 min). 
HRMS: m/z:  1019.5471 [M+3H]3+ (calc. 1019.5881 m/z). 
 
Figure 8.28: UPLC-UV chromatogram of 39. 
 
FAM-BCL9-Nle-Aha-DCys peptide synthesis (30b-FAM) 
 
The peptide was synthesized according to general procedure P4. After the final regular 
amino acid coupling and Fmoc-deprotection, Fmoc-β-Alanine (5 eq.) was coupled manually 
with HATU (5 eq.) and DIPEA (10 eq.) as activating base for one hour. After Fmoc-
deprotection 5-(6)-carboxyfluorescein succinimidyl ester (2 eq.) was coupled with DIPEA (3 
eq.) as activating base for four hours. Final cleavage from solid support was carried out by 
incubating the resin with 4 ml of a TFA:TIS:H2O (95:2.5:2.5) mixture for two hours and 
precipitated in cold diethylether. The crude peptide was purified by preparative reverse 
phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water 
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(0.1%TFA)/MeCN (0.1%TFA)). The product was gained as yellow powder (42.0 mg as TFA-
salt, 10.2 µmol, 10.2 % yield) and analyzed by UPLC (method B; rt.: 7.20 min). 
HRMS: m/z:  1141.5472 [M+3H]3+ (calc. 1141.5780 m/z); 856.4244 [M+4H]4+ (calc. 856.4355 
m/z). 
 
Figure 8.29: UPLC-UV chromatogram of 30b-FAM.  
 
FAM RCM-BCL9-Nle peptide synthesis (39-FAM) 
 
The FAM-RCM-BCL9 peptide was synthesized in a 0.05 mmol scale on a Rink Amide Resin 
with a loading of 0.78 mmol/g. Until the first olefinic amino acid the synthesis was carried 
out on a PTI synthesizer with single couplings (5 eq. amino acid for 40 minutes). Olefinic 
amino acids (2 eq.) were coupled manually with HATU (2eq.) and DIPEA (4 eq.) for two 
hours and full conversion was checked by trial cleavage. The three amino acids in between 
the olefinic ones were coupled manually (5 eg. for 40 minutes) all amino acids following the 
olefinic ones were coupled in double coupling steps with five equivalents for 40 minutes. 
After the second olefinic amino acids the synthesis was resumed by automated SPPS on 
the PTI synthesizer and Fmoc-β-Ala was coupled N-terminally. To generate the 
hydrocarbon staple the resin was incubated with a 10 mM solution of 
bis(tricyclohexylphosphine)-benzylidene ruthenium (IV) (1st generation Grubb’s catalyst) in 
1,2-dichloroethane for one hour twice. Finally the peptide was fluorescein labeled by 
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coupling 5-(6)-carboxyfluorescein succinimidyl ester (2 eq.) with DIPEA (3 eq.) as activating 
base for two hours. 
The final cleavage from resin was achieved by incubation with a mixture of TFA:TIS:H2O 
(95:2.5:2.5;v:v:v) for two hours followed by precipitation in cold diethylether. The crude 
peptide was purified by preparative reverse phase C18 HPLC, the product was gained as 
yellow powder (16 mg, 4.02 µmol, 8.0% yield) and analyzed by UPLC (method B; rt.: 7.86 & 
7.95 min). 
HRMS: m/z: 1148.5795  [M+3H]3+ (calc. 1148.6129 m/z). 
 
Figure 8.30: UPLC-UV chromatogram of 39-FAM broad double peak due to diastereomer mixture of fluorescein.  
 
Linear-(R10)-Aha-Cys (41) 
 
The cyclic-(R10)-azido peptide was synthesized in a 0.1 mmol scale on a Rink Amide Resin
with a loading of 0.78 mmol/g. The synthesis was carried out on a PTI synthesizer with 
double couplings of each amino acid (5 eq. amino acid for 40 min) in DMF apart from Fmoc-
azidohomoalanin, which (2eq.) was coupled with HATU (2 eq.) for four hours in presence of 
NMM (4 eq.) as activating base.  SPPS was ending with an Fmoc deprotection step to yield 
the free N-terminal amine. Final cleavage from resin was accomplished in two cleavage 
steps. First the peptide was cleaved from resin with a mixture of TFA:TIS:H2O (92:4:4;v:v:v) 
for 2.5 hours, followed by a second cleavage of not fully cleaved protecting groups with 
TFA:TIS:DTT:Thioanisole (88:2:2:8;v:v:v:v) for one hour. The crude peptide was purified by 
preparative reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-
60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 41 was gained as white 
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powder (78 mg as TFA-salt, 24.1 µmol, 24.1 % yield) and analyzed by UPLC (method A; rt.: 
1.51 min). 
HRMS: m/z:  700.0462 [M+3H]3+ (calc. m/z: 700.0908). 
 
Figure 8.31: UPLC-UV chromatogram of 41. 
 
Experimental Part 
 130 
8.4.2 Staudinger Phosphonite Reaction  
 
Bisethoxyalkene-phosphonite synthesis (31) 
 
Vinyl magnesium bromide in THF (1 M, 2 ml, 2 mmol, 1 eq.) was cooled to – 78°C in a flame 
dried schlenk flask and diethylchlorophosphite (0.286 ml, 2 mmol, 1 eq.) was added. The 
solution was stirred for 10 minutes at – 78°C and let warm to room temperature and stirred 
for another 90 minutes. The full consumption of starting material was confirmed by 31P-NMR 
(product at 158.0 ppm; see appendix) and used as crude in the following Staudinger 
reaction with an azido-peptide. Due to the inherent lability of bisethoxyalkene-phosphonite 
toward water and air the unprotected compound was not isolated. The correct product 
formation via this reaction however was previously confirmed by Marc-André Kasper in his 
PhD thesis, by additionally protecting the P(III)-compound with borane, which makes it 
possible to isolate and characterize the compound. 
 
Bisbenzoylalkene-phosphonite synthesis (36) 
 
Bis(diisopropylamino) chlorophosphine (267 mg, 1 mmol, 1 eq.) was given into a flame dried 
schlenk flask and dried under vacuo for 30 minutes. Vinyl magnesium bromide in THF (1 M, 
1.1 ml, 1.1 mmol, 1.1 eq.) was added at – 78°C and the reaction mixture was stirred for 10 
minutes. Then the reaction was let to warm up to room temperature and stirred for another 
30 minutes. First tetrazole in acetonitrile (0.45 M, 5.56 ml, 2.5 mmol, 2.5 eq.) was added to 
the reaction mixture followed by benzylalcohol (0.26 ml, 2.5 mmol, 2.5 eq.). The reaction 
was stirred for 16 hours and used further as crude after confirmation of starting material 
consumption via 31P-NMR (product at 164.2 ppm; see appendix). Due to the inherent lability 
of bisbenzoylalkene-phosphonite toward water and air the unprotected compound was not 
isolated. Marc-André Kasper showed the successful Grignard reaction followed by 
exchange of substituents in exactly this reaction cascade previously for a wide range of 
substituents in his PhD thesis by an additional borane protection step.  
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General procedure P5 for Staudinger-phosphonite reaction with alkyl azides 
 
Purified azido-peptide was dissolved in DMSO at a 3 mM concentration and dried in a 
flame-dried flask for one hour prior to adding five equivalents of bisethoxyalkene-
phosphonite (volume according to percentage of product determined by NMR). After the 
reaction mixture was stirred over night at room temperature and full conversion was 
observed by UPLC-UV/MS, water was added and the reaction mixture directly lyophilized. 
The crude product was purified by semi-preparative HPLC.  
Cyclic-BCL9-Nle-Aha-LCys peptide synthesis (32a) 
 
Peptide 30a (15 mg, 4.16 µmol, 1eq.) was reacted with phosphonite 31 according to the 
general procedure P5. The crude peptide was purified by preparative reverse phase C18 
HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water 
(0.1%TFA)/MeCN (0.1%TFA)). The product 32a was gained as white powder (7 mg as TFA-
salt, 1.89 µmol, 45.4 % yield) and analyzed by UPLC (method A; rt.: 2.93 min). 
HRMS: m/z: 1043.1953 [M+3H]3+ (calc. 1043.2292 m/z). 
Figure 8.32: UPLC-UV chromatogram of 32a. 
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Cyclic-BCL9-Nle-Aha-DCys peptide synthesis (32b) 
 
Peptide 30b (34 mg, 9.43 µmol, 1eq.) was reacted with phosphonite 31 according to the 
general procedure P5. The crude peptide was purified by preparative reverse phase C18 
HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water 
(0.1%TFA)/MeCN (0.1%TFA)). The product 32b was gained as white powder (15 mg as 
TFA-salt, 4.06 µmol, 43.1 % yield) and analyzed by UPLC (method B, rt.: 6.41 min). 
HRMS: m/z: 1043.2085 [M+3H]3+ (calc. 1043.2292 m/z). 
 
Figure 8.33: UPLC-UV chromatogram of 32b.  
 
Cyclic-benzoylphosphonite-BCL9-Nle-Aha-DCys peptide synthesis (38) 
 
Peptide 30b (15 mg, 4.04 µmol, 1eq.) was solubilized in DMSO and reacted with 36 (24.2 
µmol, 6 eq.) in a final concentration of 10 mM. The reaction mixture was stirred for 16 hours 
at 40°C and the crude peptide was purified by preparative reverse phase C18 HPLC (0-5 
min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN 
(0.1%TFA)). The product 38 was gained as white powder (5 mg as TFA-salt, 1.33 µmol, 32.9 
% yield) and analyzed by UPLC (method B; rt.: 6.45 min).   
HRMS: m/z:  1063.8917 [M+3H]3+ (calc. 1063.9010 m/z). 
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Figure 8.34: UPLC-UV chromatogram of 38.  
 
Cyclic scrambled-BCL9-Nle-Aha-DCys peptide synthesis (40) 
 
Scrambled-BCL9-Nle-Aha-DCys (7 mg, 1.90 µmol, 1eq.) was reacted with phosphonite 31 
according to the general procedure P5. The crude peptide was purified by preparative 
reverse phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 
10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The product 40 was gained as white powder 
(3.2 mg as TFA-salt, 0.87 µmol, 45.8% yield) and analyzed by UPLC (method B;                  
rt.: 6.09 min). 
HRMS: m/z: 1043.2217 [M+3H]3+ (calc. 1043.2292 m/z).
 
Figure 8.35: UPLC-UV chromatogram of 40.  
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FAM labeled cyclic-BCL9-Nle-Aha-DCys peptide synthesis (32b-FAM) 
 
Peptide 30b-FAM (21 mg, 5.1 µmol, 1eq.) was reacted with phosphonite 31 according to 
the general procedure P5. The crude peptide was purified by preparative reverse phase C18 
HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water 
(0.1%TFA)/MeCN (0.1%TFA)). The product 32b-FAM was gained as yellow powder (12 mg 
as TFA-salt, 2.9 µmol, 56.9 % yield) and analyzed by UPLC (method B; rt.: 6.70 min).   
HRMS: m/z: 1172.1996 [M+3H]3+ (calc. 1171.9222 m/z). 
 
 
Figure 8.36: UPLC-UV chromatogram of 32b-FAM. 
 
FAM labeled cyclic-benzoylphosphonite-BCL9-Nle-Aha-DCys peptide synthesis (38-
FAM) 
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Peptide 30b-FAM (22 mg, 5.93 µmol, 1eq.) was solubilized in DMSO and reacted with 36 
(35.6 µmol, 6 eq.) in a final concentration of 10 mM. The reaction mixture was stirred for 16 
hours at 40°C and the crude peptide was purified by preparative reverse phase C18 HPLC 
(0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN 
(0.1%TFA)). The product 38-FAM was gained as yellow powder (3.1 mg as TFA-
salt, 0.75 µmol, 12.6 % yield) and analyzed by UPLC (method B; rt.: 6.51 min). 
LRMS: m/z: 1193.11 [M+3H]3+ (calc. 1192.9258 m/z). 
 
Figure 8.37: UPLC-UV chromatogram of 38-FAM broad peak due to diastereomer mixture of FAM. 
 
Cyclic-R10-Staudinger-Macrocycle 42 
 
Peptide 41 was reacted with phosphonite 31 according to general procedure P5 with the 
deviation that the reaction was carried out at 50°C instead of room temperature. The crude 
peptide was purified by preparative reverse phase C18 HPLC (0-5 min 95/5, water 
(0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water (0.1%TFA)/MeCN (0.1%TFA)). The 
product 42 was gained as white powder (10.7 mg as TFA-salt, 3.2 µmol, 26.8 % yield) and 
analyzed by UPLC (method B; rt.: 0.45 & 0.52 min).   
HRMS: m/z: 730.7141 [M+3H]3+ (calc. 730.7668 m/z). 
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Figure 8.38: UPLC-UV chromatogram of 42. 
 
Alkyne-Cyclic-R10-Staudinger-Macrocycle 44 
 
Peptide 42 (20 mg, 6 µmol, 1 eq.) solubilized in DMF (400 µl, c = 15 mM) was incubated with 
NHS-phosphonamidate alkyne 43 (6.3 mg, 18.0 µmol, 3eq.) in presence of DIPEA (4.68 µl, 
26.9 µmol, 4.5 eq.) for one hour. After confirmation of product formation by LC-MS, the 
crude was diluted with water and purified by preparative HPLC. The product was gained as 
white poweder (9.8 mg as TFA salt, 2.8 µmol, 46 %yield) and analyzed by UPLC (method A; 
rt.: 1.64 min). 
LRMS: m/z: 809.0552 [M+3H]3+ (calc. 809.1134 m/z). 
 
Figure 8.39: UPLC-UV chromatogram of 44 after prep. HPLC purification 
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8.4.3 Protein Expression  
 
Protein expression β-Catenin-GST 
 
β-Catenin-GST (pGEX-Bcatfl was a gift from David Rimm (Addgene plasmid #24193)) was 
expressed in E.coli BL21 (DE3) with LB medium including 100 µg/ml Ampillicin. Cells were 
grown at 37°C at 180 rpm until OD600 reached 0.73 followed by induction with 0.2 mM IPTG 
and expression at 18°C at 180 rpm for 16 hours. 
The cells were harvested by centrifugation at 4000 g for 15 minutes at 4°C. Cell lysis was 
carried out in Dulbecco’s PBS with a sonicator at 30% for six minutes. Finally debris was 
centrifugation at 27000 g for 20 minutes. β-Catenin-GST was purified with BioscaleTM Mini 
ProfinityTM GST cartridge (5 ml) on a BioRad NGC system (Binding/Wash buffer: 50 mM Tris 
HCl pH 8.0/ 150 mM NaCl/ 0.1 mM EDTA; elution buffer: 50 mM Tris HCl pH 8.0/ 150 mM 
NaCl/ 0.1 mM EDTA/ 10 mM reduced glutathione). After elution the peak fractions were 
combined and dialysed to Dulbecco’s PBS. The protein was aliquoted at a concentration of 
0.87 mg/ml, shock frozen and stored at - 80°C. 
 
His-BCL9 (243 – 469)  
 
The cDNA for BCL9 was purchased from biocat (Gene ID 607) in a pCR-BluntII-TOPO 
vector.  
PCR 
The Gene region of interest was amplified with BamHI and HindII restriction sites by PCR 
using complementary primer pairs (for conditions see Table 8.5 and 8.6) 
(GTAGTGGATCCAACCAGGACCAGAATTCTTC and ATACGAAGCTTTTAC 
TGCTCGGGAGTCATATGGT) for cloning into the pET28a vector. Two PCRs were done in 
parallel.  
 
Table 8.5: Reaction mix of PCR.   
ddH2O 13.6 µl 
Phu HF buffer (5x) (Thermo scientific, USA) 4 µl 
template DNA (1 ng/µl) 1 µl 
fwd primer mix (10 µM)  0.4 µl 
rev primer mix (10 µM)  0.4 µl 
dNTP mix (10 mM each) (Thermo scientific, USA) 0.4 µl 
Phusion polymerase (Thermo scientific, USA) 0.2 µl 
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Table 8.6: Cycle steps in mutagenesis PCR. 
step cycles temp.[°C] time  
initial denaturation 1 98 30’’ 
denaturation 
30 
98 10’’ 
annealing 58 30’’ 
extension 72 3’ 
final extension 1 72 10’ 
hold  4 ∞ 
 
Digestion with restriction endonucleases 
 
The PCR product as well as the target vector pET28a was digested with the restriction 
endonucleases BamHI and HindII for 70 minutes at 37°C. To the vector digestion, 1 µL of 
FastAP Themosensitive Alkaline Phosphatase (1 U/µl) was added and again incubated at 
37°C for 15 minutes. 
 
Table 8.7: Reaction mix of restriction digestion.   
 PCR product  vector 
DNA 2 x 20 µl 16 µl (1 µg) 
FastDigestTM buffer (10x) 5 µl 2 
BamHI enzyme (10 U/µl) 1 µl 1 
HindII enzyme (10U/µl) 1 µl 1 
ddH2O 3 µl - 
 
DNA purification 
DNA fragments were purified by agarose gel electrophoresis (1% agarose in TAE buffer) at 
120 V in 1x TAE buffer for 20 minutes. The samples were mixed with MidoriGreen Direct 
before loading, for visualization purposes. GeneRuler 1kb Plus DNA Ladder was used as 
size marker. The target DNA bands were excised from the agarose gel with a clean scalpel 
and purified with a GeneJETTM Gel Extraction Kit according to the manufacturer’s protocol, 
but was eluted with 20µl ddH2O contrary to the included elution buffer.  
 
DNA ligation 
The Ligation between vector and PCR product was done with T4 DNA ligase (Thermo 
Scientific USA) and the T4 Buffer (Thermo Scientific USA). The vector to insert ration was 
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either 1:5 or 1:10 and was calculated according to length of both DNA parts and their 
respective concentration. The reation mixture was incubated at 16 °C for 16 hours and 
directly transformed into competent DH5α cells.  
 
Table 8.8: Reaction mix of Ligation.  
vector DNA 50 – 100 ng 
insert DNA variable 
T4 buffer (10x) (Thermo scientific, USA)  2 µl 
T4 DNA ligase (Thermo scientific USA) 1 µl 
ddH2O adjust to 20 µl 
 
Clones were picked and cultured over night in LBKana at 37°C; 180 rpm and DNA was 
isolated with a GeneJET Plasmid Miniprep Kit (Thermo Scientific, USA) according to 
manufacturer’s protocol, but again elution was done in 30 µl ddH2O. DNA concentration 
was determined by Nanodrop and send to sequencing. DNA was stored at -20°C. 
 
Protein expression and purification 
 
Finally His-BCL9 (243 – 469) was expressed in E.coli BL21 (DE3) with LB medium including 
100 µg/ml kanamycin. Cells were grown at 37°C at 180 rpm until OD600 reached 0.7 followed 
by induction with 0.5 mM IPTG and expression at 18°C at 180 rpm for 16 hours. 
The cells were harvested by centrifugation at 4000 g for 15 minutes at 4°C. Cell lysis was 
carried out in Dulbecco’s PBS with a sonicator at 30% for six minutes. Finally debris was 
centrifugation at 27000 g for 20 minutes. His-BCL9 (243 – 469) purified via a nickel affinity 
column. Elution was performed in PBS with 500 mM Imidazole. Elution fractions containing 
the wanted protein were combined and further purified with a Superdex 75 10/300 GL 
column on a ÄKTA FPLC system. The product fractions were combined and concentrated 
with a Vivaspin 20 filter unit (MWCO 10 kDa) then shock frozen and stored at -80°C. 
8.4.4 CD measurement  
 
The peptides were measured in 10% acetonitrile in water at a pH of 7.4 and at a 
concentration of 50 µM. Peptide concentration was determined by BCA assay using a 
PierceTM BCA Protein Assay Kit.  
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8.4.5 Cellular uptake experiments  
 
All cell uptake experiments were carried out with HeLa (ATCC CCL-2) cells cultured in 
Dulbecco’s MEM medium supplemented with 10% FBS and 1% Penicillin Streptomycin. 70 
000 cells were seeded in an uncoated glass bottom 8-well µ-slide (Ibidi) 24 hours prior to 
treatment. The cellular uptake was carried out by gently washing cells three times with 
DMEM without FBS. The FAM labeled peptides which were solved in DMSO (1 mM stock 
solution), were added to the medium after the final wash. The cells were incubated for at 
37°C in a 5% CO2 atmosphere for two hours. Then the cells were gently washed with 25 
mM HEPES in Dulbecco’s MEM supplemented with 10% FKS and cells were rested for 30 
minutes at 37°C. The cell nucleus was stained with Hoechst 33342 and cells imaged with a 
Zeiss 710 confocal microscope. Each uptake experiment was repeated at least three times.  
 
8.4.6 Homogenous time resolved fluorescence assay (HTRF)  
 
The HTRF assay was carried out by Andreas Oder in the FMP screening unit. Betacatenin-
GST (3.75 nM) was first mixed with the peptides at different peptide concentrations in PBS 
with 0.05% Tween 20, followed by addition of BCL9-His (62,5 nM), Anti-GST-Tb (1:200) and 
Streptavidin-XL665 (1:200) in PBS with 0.05% Tween 20. After mixing on a plate shaker for 
15 seconds at 1500 rpm the plate was incubated for one hour at room temperature. The 
plate was read on an Envision plate reader and data plotted using the prism software. 
Positive control wells were a mixture of both proteins and both fluorophores. Negative control 
wells were deprived of betacatenin.  
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8.5 Diazo-functionalized CPPs for bioreversible esterification of proteins 
8.5.1 Peptide synthesis 
 
Synthesis of c(R10)-amine (47) 
 
 
The c(R10) was synthesized in a 0.1 mmol scale on a Rink Amide Resin with a loading of 
0.78mm/g. The synthesis was carried out on a PTI synthesizer with double couplings of 
each amino acid (5 eq. amino acid for 40 min) in DMF. After the final building block coupling 
the peptide, still Fmoc protected, was treated with Pd(PPh3)4 (24 mg, 20 µmol, 20 mol%) 
and phenylsilane ( 308 µl, 2.5 mmol, 2.5 eq.) in 4 ml dry CH2Cl2 for one hour in order to 
cleave the alloc and allyl protecting groups in one step. After confirmation of full 
deprotection by test cleavage, cyclization with 2 eq. HATU 4 eq. DIPEA was carried out over 
night in DMF.  
The peptide was then Fmoc-deprotected using 20% piperidine in DMF and the peptide was 
cleaved from the resin by treatment with 4ml of a TFA:TIS:H2O (95:2.5:2.5) for three hours 
and precipitated in cold diethylether. The crude peptide was purified by preparative reverse 
phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water 
(0.1%TFA)/MeCN (0.1%TFA)).  
The product was gained as white powder (18 mg, 5.5 µmol, 5.5 % yield) and analyzed by 
UPLC (method B; rt.: 3.03 min). 
LRMS: m/z: 704.08 [M+3H]3+ (calcd. m/z: 703.44). 
 
 
Figure 8.40: LC-UV trace of 47. 
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Diazo-c(R10) synthesis (48) 
 
 
The purified c(R10) (9 mg, 2.8 µmol) and the NHS-diazo building block (1.5 eq.) were solved 
in 300µl DMF and DIPEA was added (1.5 eq.). The reaction mixture was shaken for four 
hours and then precipitated in ether.  
The product was gained as white powder (8.2 mg, 2.4 µmol, 85.7 % yield, >90% purity) and 
analyzed by UPLC (method A; rt.: 2.09 min). 
LRMS: m/z: 753.44  [M+3H]3+ (calcd. m/z: 752.79). 
 
Figure 8.41: LC-UV trace of 48. 
 
Synthesis of c(Tat)-azide (52a)
 
 
 
The c(Tat) was synthesized in a 0.1 mmol scale on a Rink Amide Resin with a loading of 
0.78 mm/g. The synthesis was carried out on a PTI synthesizer with single couplings of each 
amino acid (10 eq. amino acid for 40 min) in DMF. After the final building block coupling the 
peptide, still Fmoc protected, was treated with Pd(PPh3)4 (24 mg, 20 µmol, 20 mol%) and 
phenylsilane (308 µl, 2.5 mmol, 2.5 eq.) in 4 ml dry CH2Cl2 for 1 hour in order to cleave the 
alloc and allyl protecting groups in one step. After confirmation of full deprotection by test 
cleavage, cyclization with 2eq. HATU 4 eq. DIPEA was carried out over night in DMF. After 
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Fmoc deprotection with 20% piperidine in DMF, azidobutanoic acid (129 mg, 1mmol, 10eq.) 
was coupled to the N-terminus with HATU (390 mg, 1 mmol, 10 eq.) and DIPEA (170µl, 1 
mmol, 10 eq.) in DMF for two hours. The peptide was finally cleaved with 4ml of a 
TFA:TIS:H2O mixture (95:2.5:2.5) for two hours. After precipitation in ether the crude peptide 
was purified by HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, 
water (0.1%TFA)/MeCN (0.1%TFA)). The product was yielded as white powder (27.2 mg as 
TFA-salt, 10.5 µmol, 10.5% yield) and analyzed by UPLC (method A; rt.: 1.87 min). 
HRMS: m/z: 636.6921 [M+3H]3+ (calc. m/z: 636.7288). 
 
Figure 8.42: UPLC-UV chromatogram of 52a. 
 
Synthesis of c(R10)-Cy3-azide (52b) 
 
 
 
The c(R10) was synthesized in a 0.1 mmol scale on a Rink Amide Resin with a loading of 
0.78 mm/g. The synthesis was carried out on a PTI synthesizer with double couplings of 
each amino acid (5 eq. amino acid for 40 min) in DMF. After the final building block coupling 
the peptide, still Fmoc protected, was treated with Pd(PPh3)4 (24 mg, 20 µmol, 20 mol%) 
and phenylsilane (308 µl, 2.5 mmol, 2.5 eq.) in 4 ml dry CH2Cl2 for 1 hour in order to cleave 
the alloc and allyl protecting groups in one step. After confirmation of full deprotection by 
test cleavage, cyclization with 2eq. HATU 4 eq. DIPEA was carried out over night in DMF.  
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The peptide was then Fmoc-deprotected using 20% piperidine in DMF and Fmoc-Lys(dde)-
OH was coupled to the N-terminus in a standard peptide coupling. After dde removal with 
3% hydrazine in DMF (3 x 3min), the Cy3-COOH (1.5 eq) was coupled with HATU (1.5 eq) 
and DIPEA (3 eq.) for six hours. After final Fmoc deprotection the peptide was finally 
coupled with 4-azidobutanioc acid (5 eq.), HATU (5 eq.) and DIPEA (10 eq.) and afterwards 
cleaved from the resin by treatment with 4ml of a TFA:TIS:H2O (95:2.5:2.5) for 3 hours and 
precipitated in cold diethylether. The crude peptide was purified by preparative reverse 
phase C18 HPLC (0-5 min 95/5, water (0.1%TFA)/MeCN (0.1%TFA); 5-60 min 10/90, water 
(0.1%TFA)/MeCN (0.1%TFA)), product gained as pink powder (20.0 mg as TFA-salt, 
5.1 µmol, 5.1% yield) and analyzed by UPLC (method B; rt.: 6.58 min). 
HRMS: m/z: 929.2254 [M+3H]3+ (calc. m/z: 929.5803). 
 
Figure 8.43: LC-UV trace of 52b. 
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8.5.2 Esterification with eGFP C70M S143C 
General procedure P6 of esterification with diazo-alkyne to generate 51 
 
eGFP C70M S143C was rebuffered to 10 mM BisTris Buffer pH 5.8 at a concentration of 50 
µM and the alkyne-diazo compound (varying amounts se table 4) in 1% DMF to buffer, was 
added. The reaction mixture was shaken at 37°C. After 2 – 16 hours (see table 4), the 
reaction mixture was desalted and rebuffered by a zebaspin column with a MWCO of 7kDa, 
which also could remove the left over diazo-alkyne. Analysis by MALDI-TOF showed 
successful alkyne esterification of differing degrees according to incubation time and 
amount of equivalents (see table 4). 
 
Esterification and CuAAC with 52a to form 53a 
 
Esterification:  
7 nmol eGFP C70M S143C were reacted with 30 equivalents of 50 according to general 
procedure P6 for four hours. Analysis by MALDI showed a 1 – 5 fold esterification on GFP 
51. 
MALDI TOF: 
GFP-alkynen=1 expected Product (in Da): 27948 (M+); found (in Da): 27983 (M+);           
GFP- alkyne n=2 expected Product (in Da): 28133 (M+); found (in Da): 28170 (M+);  
Δ to GFP-alkynen=1: 187 Da (expected 185 Da) 
GFP-alkyne n=3 expected Product (in Da): 28318 (M+); found (in Da): 28359 (M+);      
Δ to to GFP-alkynen=2 189 Da (expected 185 Da);  
GFP-alkyne n=4 expected Product (in Da): 28503 (M+); found (in Da): 28546 (M+);      
Δ to to GFP-alkynen=3 187 Da (expected 185 Da);  
GFP-alkyne n=5 expected Product (in Da): 28688 (M+); found (in Da): 28730 (M+);     
 Δ to to GFP-alkynen=4 184 Da (expected 185 Da). 
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Figure 8.44: MALDI-TOF spectrum of 51 (also found in Figure 42B). 
 
CuAAC: 
To the alkyne-functionalized GFP 51 the azido-c(Tat)  52a (25 eq.) , CuSO4 (10 eq.) and 
THPTA (50 eq.) were added. The reaction was carried out in PBS supplemented with 10mM 
Aminoguanidin hydrochloride and 10 mM Sodium ascorbate. The GFP concentration in PBS 
was 27 µM. The reaction mixture was shaken at 37°C for 16 hours, purified by dialysis and 
analyzed by MALDI-TOF.  
MALDI TOF: mixture of starting material 51 and one times modified 53. 
51: broad peak from 27900 – 28600 Da (from 1 - 5 alkynes) 
53: broad peak from 29800 – 30700 Da (one peptide + free alkynes) 
 
Figure 8.45: MALDI-TOF of 53a (also found in Figure 42C). 
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Esterification and CuAAC with 52b to form 53b 
 
 
16.2 nmol eGFP C70M S143C were reacted with 20 equivalents of 50 according to general 
procedure P6 for four hours. Analysis by MALDI showed mainly a 0 – 2 fold esterification on 
GFP 51. 
MALDI TOF:  
GFP expected Product (in Da): 27764 (M+); found (in Da): 27802.6 (M+);  
GFP-alkynen=1 expected Product (in Da): 27948 (M+); found (in Da): 27987.9 (M+);    
Δ to GFP: 185.3 Da (expected 185 Da) 
GFP- alkyne n=2 expected Product (in Da): 28133 (M+); found (in Da): 28170 (M+);     
Δ to GFP-alkynen=1: 184.4 Da (expected 185 Da) 
 
Figure 8.46: MALDI-TOF spectrum of 51 (also found in Figure 42B). 
 
To the alkyne-functionalized GFP 51 the azido-c(Tat)  52b (1.1 eq.) , CuSO4 (10 eq.) and 
THPTA (50 eq.) were added. The reaction was carried out in PBS supplemented with 10mM 
Aminoguanidin hydrochloride and 10 mM Sodium ascorbate. The reaction mixture was 
shaken at 37°C for 16 hours, purified by size exclusion columns and analyzed by SDS-page. 
Here 53b was shown to be gained as mixture consisting of 51 and mainly one peptide 
modified 53b. 
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Figure 8.47: SDS-Gel of the reaction on formation of 53 (also found in Figure 42D). 
 
Esterification with Diazo-cR10 (48)  
 
eGFP C70M S143C (18 nmol) was rebuffered to 300µl 10 mM BisTrisBuffer pH 6.5 (100 mM 
NaCl) and 48 (30 eq.) was added solved in 60µl of the same buffer. The reaction mixture 
was shaken at 37°C and excess peptide was removed after four hours by desalting with a 
zebaspin column with a MWCO of 7kDa. Analysis by MALDI-TOF showed a 0 – 2 fold 
modification of GFP with the cR10-peptide 53. 
 
MALDI TOF:  
GFP expected Product (in Da): 27764 (M+); found (in Da): 27804.1(M+);  
GFP-cR10n=1 expected Product (in Da): 30001.4 (M+); found (in Da): 30041.4 (M+);    
Δ to GFP: 2237.3 Da (expected 2239.4 Da) 
GFP-cR10n=2 expected Product (in Da): 32240.8 (M+); found (in Da): 32285.9 (M+);     
Δ to GFP-cR10n=1: 2244.5 Da (expected 2239.4 Da) 
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Figure 8.48: MALDI-TOF spectrum of eGFP-ester-cR10. 
 
8.5.3 Cellular uptake experiments  
 
All cell uptake experiments were carried out with HeLa (ATCC CCL-2) cells cultured in 
Dulbecco’s MEM medium supplemented with 10% FBS and 1% Penicillin Streptomycin. 70 
000 cells were seeded in an uncoated glass bottom 8-well µ-slide (Ibidi) 24 hours prior to 
treatment. The cellular uptake was carried out by gently washing cells three times with 
HEPES buffer pH 7.5 (5 mM HEPES, 140 mM NaCl, 2.5 mM KCl, 5 mM glycine). The 
peptide-protein conjugate buffered in the same HEPES buffer was added to the cells in 200 
µl at respective concentration and incubated for at 37°C in a 5% CO2 atmosphere. After one 
hour cells were gently washed with 25 mM HEPES in Dulbecco’s MEM supplemented with 
10% FKS and cells were rested for 30 minutes at 37°C. The cell nucleus was stained with 
Hoechst 33342 and cells imaged with a Zeiss 710 confocal microscope.  
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NMR spectra 
PeB-Series 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.1. 1H-NMR spectra of PG8PeB26 3b. 
 
Figure 10.2. 1H-NMR spectra of PG14PeB19 4b. 
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Figure 10.3. 1H-NMR spectra of PG100PeB8 5b. 
  
Figure 10.4. 1H-NMR spectra of PG100PeB21 5c. 
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Figure 10.5. 1H-NMR spectra of PG340PeB9 6b. 
 
Figure 10.6. 1H-NMR spectra of PG340PeB15 6c. 
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PeBGF-Series 
 
Figure 10.7. 1H-NMR spectra of PG14PeBGF19 4c. 
 
Figure 10.8. 1H-NMR spectra of PG100PeBGF10 5d. 
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Figure 10.9. 1H-NMR spectra of PG100PeBGF29 5e. 
 
 
Figure 10.10. 1H-NMR spectra of PG340PeBGF10 6d. 
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Figure 10.11. 1H-NMR spectra of PG340PeBGF16 6e. 
 
 
 
Figure 10.12: 31P-NMR spectra for crude alkyne phosphonite 7. 
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Figure 10.13: 31P-NMR spectra for crude alkene phosphonite 31. 
 
 
 
Figure 10.14: 31P-NMR spectra for crude alkene phosphonite 36. 
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Cyclic BCL9 peptide 32a 
 
Figure 10.15: HMBC correlating 31P-NMR and 1H-NMR for 32a.
 
Cyclic R10 peptide 42 
 
Figure 10.16: HMBC correlating 31P-NMR and 1H-NMR for 42. 
